2013 Annual Report

Transformations Our vision is nothing less than to revolutionize the treatment of cancer. Introduction MEMORIAL SLOAN KETTERING CANCER CENTER 2 Table of Contents 3

Transforming 04 Message from the Chairman and the President 60 Statistical Profile Biomedical 62 Financial Summary Our goal over the next decade is 64 Boards of Overseers 08 Research and Managers 65 Principal Leadership to integrate molecular and clinical 67 Facilities Update Transforming 69 The Campaign for information to develop therapies Memorial Sloan Kettering that home in on the abnormalities Cancer Center Drug Discovery 71 Donors to the Campaign for driving each patient’s disease. Memorial Sloan Kettering 20 & Development Cancer Center 86 The Society of Memorial Sloan Kettering Cancer Center At Memorial Sloan Kettering, this new era in precision cancer medicine is already becoming a reality for many of our patients. Transforming Capitalizing on our exceptionally powerful combination of clinical and scientific resources, we are delivering on the promise Precision of personalized cancer therapy and are setting the stage for transformational change, both in the immediate future and for 30 Medicine years to come. Join us now on a journey that will span our institution. It begins with the outstanding biomedical research that informs novel Transforming early-stage drug discovery and development, takes us through paradigm-breaking precision medicine and robust clinical research, Clinical and concludes with innovative new approaches that will transform individualized cancer care and extend it to more patients than 40 Research ever before. Transforming Cancer Care 48 & Delivery Cover: (Center, in green scrubs) Surgical oncologist and breast cancer researcher George Plitas; (right) clinical dietitian Tatanisha Peets Inside cover: (Far left) Patient care technician Jasmattie Persaud at a patient’s bedside; (second from right) plastic and reconstructive surgery fellow Adrian Sjarif during an operation; (far right) Valda Gaubiene, Clinical Nurse II, administers chemotherapy to patient Charles Fetter at MSK’s Basking Ridge, New Jersey, outpatient care facility. Back cover: Radiation therapist Michael Guida (left) and patient Renaldo Hill at Memorial Sloan Kettering’s Basking Ridge, New Jersey, outpatient care facility Message from MEMORIAL SLOAN KETTERING CANCER CENTER 4 5 the Chairman and the President

Before going further, we would like to acknowledge that these achievements are made possible by the hard work, generosity of spirit, and creativity of our staff. They are unswerving in their dedication to advancing our knowledge of cancer, discovering more-precise ways to diagnose and treat it, and making the lives of our patients and their families as comfortable as possible. Our staff is the heart, soul, and engine of MSK. The year began with the homecoming of José Baselga, our new Physician-in-Chief and Chief Medical Officer, who did a fellowship here in the 1990s and remained on the faculty for several years before returning to his native Spain. An internationally renowned physician-scientist and breast cancer expert, he joined us from Massachusetts General Hospital (MGH), where he was Chief of the Division of Hematology/Oncology and Associate Director of the MGH Cancer Center. Dr. Baselga began his tenure with two key appointments. First, medical oncologist Paul Sabbatini was named Deputy Physician-in-Chief for Clinical Research and has led an extraordinary team in streamlining and accelerating MSK’s clinical trials process. We now have two Institutional Review Boards, doubling our capacity to do clinical trial reviews. We’ve seen remarkable decreases in the time between the review and approval of trials and are seeing a significant increase in trials, with more patients participating. Later in the year, Dr. Baselga named gynecologic surgeon and Chief of the Gynecology Service Richard R. Barakat Deputy Physician-in-Chief for the Regional Care Network and MSK Cancer Alliance. The Memorial Sloan Kettering Cancer Alliance, a unique initiative established to improve the quality of cancer care and the lives of cancer patients, was announced in 2013. Simultaneously, we introduced the Alliance’s first member, Hartford HealthCare, a five-hospital system in Connecticut. The MSK Cancer Alliance will allow more patients access to our clinical trials. It will also offer them the benefit of precision medicine as we translate molecular insights into innovations ranging from the latest diagnostic tests to targeted therapies. Clinical and administrative teams led by Dr. Barakat are now focusing on preparations to fully implement the program later this year. DOUGLAS WARNER III CRAIG THOMPSON Chairman, Boards of Overseers and Managers President and Chief Executive Officer Dr. Baselga brought energy and innovation to other important areas, including molecular oncology, and participated in MSK’s partnership with IBM in developing a powerful cancer resource. Built on the IBM Watson cognitive computing platform, it will provide medical professionals with improved access to current, comprehensive cancer data and practices. In collaboration with Executive Vice President and Chief Hospital Operating Officer Kathryn Martin, he also guided us through the Joint Commission accreditation review of both our hospital and clinical laboratories, for which we received outstanding marks. In 2013 we implemented strategic programs The year concluded with the appointment of Joan Massagué as the Director of the Sloan Kettering Institute. An exemplary scientist whose research has produced and long-term approaches that can harness the results central to the understanding of cancer, Dr. Massagué has led SKI’s Cancer Biology and Genetics Program since 2003 and has been part of the SKI community power of big and innovative ideas — ideas that since 1989, when he joined us as the Alfred P. Sloan Chair of SKI’s Cell Biology Program. His scientific acumen and invaluable expertise coupled with his ability to are revolutionizing how we understand and unite people will keep MSK at the forefront of cancer research. During the national and international search for a new SKI director, we received treat cancer. strong interim leadership from Molecular Biology Program Chair Kenneth J. Marians and Molecular Pharmacology and Chemistry Program Chair David A. Scheinberg. Dr. Marians helped shepherd us through the National Cancer Institute’s review of our cancer research, also known as the Core Grant. It is a tribute to our entire community that we received a rating of “exceptional” and were awarded a full five- year renewal. Many people contributed to the success of our programs — and the grant submission itself. We thank them all. Message from MEMORIAL SLOAN KETTERING CANCER CENTER 6 7 the Chairman and the President

Dr. Scheinberg led the effort to establish the Tri-Institutional Therapeutics Discovery in oncology with the potential to be applied to many types of cancer. (To learn more Institute (Tri-I TDI), a unique partnership between MSK, Weill Cornell Medical about CAR therapy and these researchers, see Cell-Based Therapies on page 26.) College, and The Rockefeller University. The Tri-I TDI has entered into an initial In addition to the new approaches to therapy taken by our scientists, MSK infectious partnership with Takeda Pharmaceuticals International, Japan’s largest pharmaceutical disease specialist Kent Sepkowitz has been appointed Deputy Physician-in-Chief company, to assist investigators at the three institutions in developing small-molecule for Quality and Safety. This newly created position highlights MSK’s commitment therapeutic agents and molecular probes for the treatment and diagnosis of cancer to continuing to lead in the development and implementation of a comprehensive and other human diseases. (To read more about the Tri-I TDI, see Transforming Drug quality of care program as well as increased dedication to a center-wide promotion Discovery & Development beginning on page 20 of this report.) of a culture of safety. Dr. Sepkowitz, who joined MSK in 1988 as a fellow in the In recent years, scientists have shown that the mutations that give rise to cancer JOHN R. GUNN Infectious Disease Service, has led the Hospital Infection Control program for the Chief Operating Officer vary among people, even those with the same type of cancer. The identification past 15 years and earned the trust and respect of staff members in every part of the of genetic and molecular targets in individual cancers can be used to help select institution. He will bring to this new role an ability to unite people in pursuit of an effective therapies and create new ones. In 2013, MSK established several new environment continually focused on quality. centers to capture a tumor’s genetic information and exploit it to its full potential. Members of the Boards of Overseers and Managers have recently accepted new A transformative $100 million gift from the Marie-Josée and Henry R. Kravis roles as well. Scott M. Stuart has been elected Chair of the Board of Managers of Foundation allowed us to create the Marie-Josée and Henry R. Kravis Center for Memorial Hospital, and Louis V. Gerstner, Jr., formerly Vice Chair of the Boards Molecular Oncology (CMO). This new center will make it possible to realize the of Overseers and Managers, has become Honorary Chair of the Sloan Kettering promise of precision oncology and support the development of new, individualized Institute and remains Chair of the Board of Gerstner Sloan Kettering Graduate cancer therapies and diagnostic tools. Among the aims of the CMO will be to analyze School of Biomedical Sciences. We are deeply grateful for the extraordinary and more than 10,000 patient tumors in the first year alone, with an eye toward offering JOSÉ BASELGA steadfast guidance Mr. Gerstner has provided to MSK in his many leadership roles molecular analysis for every type of cancer and for all MSK patients. Mrs. Kravis Physician-in-Chief and since joining the board in 1977. has been a member of MSK’s Boards of Overseers and Managers since 2000 and is Chief Medical Officer, Richard I. Beattie, formerly Vice Chair of the Boards and Chair of the Board of Chair of the Board of the Sloan Kettering Institute. (To learn more about the CMO, Memorial Hospital Managers of Memorial Hospital, has become Honorary Chair of the Memorial see Transforming Precision Medicine beginning on page 30.) Hospital Board. Mr. Beattie has our profound thanks for offering his acute With an initial commitment of $10 million, MSK Board member David M. Rubenstein intelligence and leadership as we carried out our mission at a time of significant paved the way for another ambitious initiative. Called the David M. Rubenstein Center change in the healthcare landscape. for Pancreatic Cancer Research (CPCR), it brings together MSK’s outstanding physicians MSK’s network of regional sites continues to develop, beginning with our new and an expanding group of scientists in an intensive program designed to speed ambulatory care facility in Harrison, New York, slated to open this fall. Construction progress in understanding and treating one of the deadliest types of cancer — and one on the Josie Robertson Surgery Center on York Avenue is ongoing, and work will soon that has been relatively understudied. (To learn more about the CPCR, see page 38.) begin at the East 74th Street complex we are jointly developing with Hunter College Also among MSK’s many accomplishments in 2013 were the development of of the City University of New York. important new treatments for prostate cancer and improved ways to diagnose JOAN MASSAGUÉ We are pleased with our 2013 financial results. Our investment and philanthropic leukemia, endometrial cancer, and salivary gland cancer, and the determination of Director, Sloan Kettering Institute revenues were strong, allowing us to invest in MSK’s future. the structure of a complex protein (mTOR) that plays a role in many forms of cancer. The title of this report — Transformations — perfectly characterizes and captures the While it is impossible to list all of MSK’s scientific achievements, one in particular past year. Indeed, “transformational” is the word we heard, time and again, on the deserves special mention. This year, Science magazine identified the development lips of our clinicians, scientists, and other staff as they described their feelings about of immunotherapy for the treatment of cancer as the most important scientific the progress we’ve made and what they know is to come. advance of 2013 — in all fields. The magazine cited the efforts of two groups of MSK investigators as exceptional. We stand on the brink of opportunities in cancer research that are leading to discoveries inconceivable a mere decade ago. And today, the gifted men and women of Memorial Singled out by Science was the collaborative preclinical and clinical work of Sloan Kettering are translating these discoveries into treatment realities. On the Jedd D. Wolchok, Chief of our Melanoma and Immunotherapeutics Service, and pages that follow, we invite you to join us on an inspiring journey into the future. immunologist James P. Allison (formerly at MSK, now at MD Anderson Cancer Center in Houston) in their development of a drug called ipilimumab (Yervoy™), JAMES D. ROBINSON III approved by the FDA in 2011 for the treatment of metastatic melanoma. The other Honorary Chairman, Boards of Overseers and work came from Michel Sadelain, Director of the Center for Cell Engineering, Managers and his colleagues Renier J. Brentjens, Director of Cellular Therapeutics, and Isabelle Rivière, Director of the Cell Therapy and Cell Engineering Facility. These investigators played a seminal role in the development of a major area of research highlighted by the magazine: a cell-based targeted immunotherapy called chimeric Douglas A. Warner III Craig B. Thompson antigen receptor (CAR) therapy. Chimeric antigen receptors are a new class of drugs Chairman, Boards of Overseers and Managers President and Chief Executive Officer Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 8 9 PrecisionBiomedical MedicineResearch

A detail from the laboratory of chemical biologist Gabriela Chiosis, whose drug development research is featured in A Long and Winding Road: PU-H71 on page 28 Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 10 11 BiomedicalPrecision ResearchMedicine

“What was inconceivable in cancer science even a decade ago is within reach today. And at the end of the next ten years, oncology will not be as we now know it,” says cancer biologist Joan Massagué, the new Director of the Sloan Kettering Institute.

“My ambition for the Institute is to look back a decade from now and say, ‘We have been at the center of the most transformative period in the quest to put our arms around cancer and to change our perception of, and power over, the disease.’ ” Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 12 13 Biomedical Research

Dr. Massagué, an interna- Q: What does this new appointment Q: Can you give an example? tional leader in the study of mean to you personally? cancer metastasis and the A: Certainly. Take immunity and growth factors that regulate A: Well, it’s a fantastic thing, and an cancer. The immune system has both cell behavior, joined opportunity to serve. It comes at a tumor-inhibiting and tumor-promoting Memorial Sloan Kettering moment when I feel prepared. Having functions. MSK is positioned with produced a significant body of scientific cutting-edge strength both in elucidating 01 in 1989 as Chair of the Sloan Srinivas Malladi is Kettering Institute’s Cell work, which remains robust, I am now the intricacies of the immune system and a research scholar increasingly motivated to look beyond my in developing new ways to exploit it for the in the laboratory of Biology Program. In 2003, he Joan Massagué. was named inaugural Chair own science. I’m eager to work to enhance benefit of patients. of SKI’s Cancer Biology our extremely vibrant programs in ways There are three big examples in this and Genetics Program. that will be most productive for the field, and I’m proud to say we’re leading 02 many people who make up our research in all three of them. The first chapter Lan He works as Dr. Massagué was a a senior research Howard Hughes Medical community. of the story is based on the presence technician in Investigator for 24 years and And of course, Memorial Sloan of great basic immunology research Dr. Massagué’s lab. is the incumbent of the Alfred Kettering is a wonderful institution. and laboratories that are studying the 01 02 It’s never crossed my mind to go biology of immune cells in the tumor P. Sloan Chair at Memorial 03 Sloan Kettering. He succeeds anywhere else! microenvironment. Current work is Research scholar pointing at novel ways to leverage special Jie Su is a member Thomas J. Kelly, who served of Dr. Massagué’s as SKI director for more kinds of immune cells, called tumor- laboratory team. than ten years. Q: Why have you spent 25 years at associated macrophages, in order to turn MSK? What’s so special about them against the tumor. [See Reeducating Here, Dr. Massagué talks this place? Macrophages to “Eat” Cancer on page 19.] about his new role, his The other two chapters are linked. expectations for the SKI A: For me, there has never been a Each year, Science magazine announces research enterprise, and what question of where I should be. For one pivotal scientific achievement as excites him most in cancer example, I would not have started on my the “Breakthrough of the Year.” The research today. metastasis project had I not been at the magazine identified the development Sloan Kettering Institute. Were there of immunotherapy for the treatment of other places like it? Not really. Some that cancer as the most important scientific came close? Yes, but not many. You could advance of 2013 and singled out two count them on the fingers of one maimed modalities of immunotherapy in the hand! Not many places at all. hands of MSK researchers that have If I put a word on it, it would be played leading roles in pioneering “togetherness.” It’s being surrounded by this work. scientists and physicians who know both One of the key milestones cited by the fundamental mechanisms of biology Science is the work of immunologists to and the processes of cancer intimately, explain how a protein receptor on the and who know the right questions to ask. surface of T cells, called CTLA-4, puts And this is applicable to any aspect of the brakes on the T cells and prevents cancer: genetic origins, tumor spread and them from carrying out immune attacks. metastasis, drug resistance, cancer stem Immunologist James Allison [now at cells — you name it. We have both the MD Anderson Cancer Center in Houston] intellectual firepower and the technology identified an antibody that blocks CTLA-4 necessary to unravel the mysteries of the and showed that turning off those brakes disease and find its weak flanks. MSK is allows T cells to destroy cancer. Anti- unrivaled as a place to do research at the CTLA-4 eventually became ipilimumab highest levels.

03 Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 14 15 Biomedical Research

[Yervoy™], a drug that was approved Q: Could you elaborate on the Q: How does one make choices? Q: Tell us more about this in 2011 for the treatment of metastatic opportunities in cancer research “golden era.” melanoma. While he was at MSK, today, and also some of the A: You think carefully about why to study Dr. Allison, along with [MSK physician- challenges? a particular problem — a fundamental A: A major goal of cancer research in scientist] Jedd D. Wolchok, helped guide cellular process, a particular form of the years ahead will be to join molecular the development of ipilimumab from A: Let’s start with the challenges: funding cancer, whatever. Then you decide how and clinical information to develop the first laboratory studies through the resources. They’re always limited. And and when to apply your effort in this vast treatments individualized to each late-stage clinical trials that led to paradoxically, they are more limited than landscape of cancer-related and basic patient’s cancer. And on this score, we its approval. ever right now, when we are in a golden biology questions. have entered a new revolution. Today, The final example, also cited in the era of opportunity in cancer research. The skill at a premium now more genomic-scale molecular oncology Science article, is the development of On the positive side, the opportunities, than ever is understanding how and applied to the clinic is possible, and soon chimeric antigen receptor [CAR] therapy. and our capabilities, are tremendous. why to choose your research problem. it will be routine. This is based on the idea that a patient’s Philanthropy is a wonderful resource This is what I try to teach my students For instance, we are now able to own T cells can be collected from the that is having a huge impact on our and postdocs: Choose a problem that’s interrogate the genetic profiles of tumors blood, engineered to recognize cancer ability to move basic and translational important, that’s feasible, that has value from patients who have had an unusually cells and acquire stronger antitumor research forward. And so, with limited in as many areas as possible. And that good response to a drug that most other 01 properties, and then reinfused to resources and great scientific and goes for every investigator and every patients did not respond to and ask why A detail from the laboratory of circulate through the bloodstream and medical opportunities, the big challenge program here. With the wealth of choice those patients responded. Tumors are Joan Massagué attack those cancerous cells. MSK has is the challenge of choice: Individually comes the responsibility of choosing well. giving us answers, as revealed in their been a leading center in developing as investigators and collectively as an genetic analysis. We can then go on to this technology. One of the first great institution, we must choose well what use what we learn to make the drug in 02 Research technician successes in the field has come in the to investigate. question effective in a broader population Ruzeen Patwa in treatment of leukemia. [To learn more of patients, while shedding new light on Dr. Massagué’s lab about this work, see Cell-Based Therapies the fundamental mechanisms that drive on page 26.] normal cells as well as cancer.

01

We have entered a new revolution. Today, genomic-scale molecular oncology applied to the clinic is possible, and soon it will be routine.”

02 Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 16 17 Biomedical Research

To this end, we’ve recently created research. I would actually say that a the Marie-Josée and Henry R. Kravis growing portion of the most impactful Center for Molecular Oncology [CMO]. No research being done here, both in terms other medical center has yet put together of quality and relevance, is work that such a program, and it’s a transformative involves both clinical and experimental initiative. The CMO will cut across scientists. And of course, this is our community, from the clinic to the surrounded by brilliant basic science as investigators who focus on the more well as superb clinical research. 01 basic aspects of our research endeavors. We are also looking at a refreshment A detail from the laboratory of Joan [To learn more about the CMO, see of our workplaces. I recently appointed Massagué Transforming Precision Medicine on a task force to propose improvements page 30.] that will ensure our classic Rockefeller We are truly at an inflection point, Research Laboratory building remains as 02 Pipetting a reagent in a moment in history when mankind is vibrant and cutting-edge for the next 20 Dr. Massagué’s lab turning cancer from what we’ve known years as the newer Zuckerman Research

01 it to be — the way we’ve related to it Center building. in the 20th century as an impossible, It’s also important to me to keep obscure disease — into a “normalized” developing our training activities. disease. Our relationship with it will With our educational leaders, we will be much more like the one we have with cultivate our teaching and professional infectious diseases, for which we have developmental tools for graduate students antibiotics and other treatments to cure and research fellows across all programs or control them. and departments. Expanding our training in biostatistics and bioinformatics is a must, too. There is more and more Q: What is your vision for the Sloan research that is generating large amounts Kettering Institute over the next of extremely complex data, so all of us several years? depend heavily on these disciplines to navigate this information and understand A: There will be changes, of course, and I its biological or clinical relevance. intend to engage my colleagues from SKI And, naturally, I want to lead by and Memorial Hospital to help craft and continuing robust research, both basic implement them. and translational, in my own laboratory I’ll work closely with [Memorial and inspiring others to join in our efforts. Hospital Physician-in-Chief and Chief The level of confidence we have in what is Medical Officer] José Baselga to further achievable in cancer is higher now than it integrate the research in SKI with ever has been. that done in the hospital. We would like to see a fluidity in how we appoint and connect our investigators within departments, programs, and centers. Some of our investigators may be based within SKI, and some may be centered in the hospital, but that distinction won’t matter all that much. As laboratory and clinical sciences are becoming one, we’re erasing the conceptual barriers between basic, translational, and applied cancer

02 Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 18 19 Biomedical Research

01 02 Johanna Joyce Dr. Joyce and talks with graduate research fellow students (from left) Daniela Quail Ryan Smith and Robert Bowman.

Reeducating 01 02 Macrophages to “Eat” Cancer

Researchers have tried for decades to fight Dr. Joyce and her colleagues set out to test a drug that cancers by killing cancer cells. But cancer inhibits a protein called CSF-1R, known to be essential for biologist Johanna Joyce, a member of the macrophage survival. They used mouse models of a subtype of Sloan Kettering Institute’s Cancer Biology brain cancer called proneural glioblastoma. and Genetics Program, proposes a promising The results were both striking and surprising. First, the new approach: targeting the noncancerous drug stopped newly formed tumors from progressing, caused white blood cells known as macrophages that more-established tumors to shrink, and allowed the mice to surround and infiltrate tumors. live significantly longer. The next result was no less surprising, although initially “There is a crucial confounding. “We thought CSF-1R would wipe out the need for better Macrophages patrol virtually every tissue of the body, macrophages in the tumors,” Dr. Joyce explains. “But when strategies to control gobbling up bacteria, dead cells, and other waste. Indeed, some we looked at the tumors of mice we had treated, we found that [glioblastomas], biologists have referred to them as “garbage trucks.” However, the macrophages in the tumors were still there, even though and our findings Dr. Joyce and other scientists had an idea that these cells may the drug had killed macrophages in the surrounding normal suggest macrophages not be so innocent. And they were correct. brain tissue.” About 20 percent of the cells in brain tumors are What the investigators ultimately discovered was that the represent a potent macrophages. A 2013 study led by Dr. Joyce and published in drug had actually changed the behavior of the macrophages — therapeutic target.” the journal Nature Medicine revealed that macrophages can in effect reeducating them, blunting their tumor-promoting support the growth and progression of glioblastoma brain functions while making them more apt to elicit an antitumor tumors — the commonest and most deadly form of primary response. For example, macrophages exposed to the brain tumor — and that it might be possible to control the reeducating effects of CSF-1R were induced to attack tumors by disease by manipulating these cells with a drug. “eating” glioblastoma cells, a process known as phagocytosis. Less than 5 percent of people with glioblastoma survive CSF-1R inhibitors are currently being tested in early- longer than five years after they are diagnosed, even if they stage clinical trials in glioblastoma patients and could be undergo treatment with surgery, chemotherapy, radiation, applicable to other diseases as well. “Studies have shown that or a combination of these. “There is a crucial need for in several cancer types, including breast, ovarian, thyroid, better strategies to control these tumors,” Dr. Joyce says, and pancreatic neuroendocrine tumors, increased numbers of “and our findings suggest macrophages represent a potent tumor-associated macrophages correlate with poor prognoses, JOHANNA JOYCE therapeutic target.” so it would be logical to test the drug in these diseases as well,” Cancer Biologist Dr. Joyce notes. Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 20 Research technician 21 PrecisionDrug Discovery Smit Shah works in the laboratory of &Medicine Development chemical biologist Gabriela Chiosis. Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 22 23 Drug Discovery & Development

Taking an idea out of the laboratory and into the clinic: Easier said than done. Sometimes called the “valley of death,” this no-man’s-land is where great ideas developed at academic institutions may languish for years for lack of funding or support from drug companies. Bringing together academic and pharmaceutical scientists to speed the development of new drugs and diagnostics underlies the 2013 establishment of the Tri-Institutional Therapeutics

Discovery Institute (Tri-I TDI). MICHAEL FOLEY DAVID SCHEINBERG Director, Tri-Institutional Therapeutics Discovery Institute Chair, Experimental Therapeutics Center Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 24 25 Drug Discovery & Development

Why do so many good ideas born in academia die in their infancy? The answer, according to chemist and entrepreneur Michael A. Foley, inaugural Director of the Tri-I TDI, is simple: a lack of the right kind of research funding. Many high-value projects have advanced too far to qualify for funding from the National Institutes of Health but are still too early to interest partners or venture capitalists.

“The investment required to move research through the traditional pathway of drug development is so great that the economics become prohibitive,” says Dr. Foley. “The courage of the leaders of the three Tri-I TDI institutions in publicly declaring that they are going to try to advance beyond where academia can typically take research is what attracted me to join them.” Launched in October 2013, the Tri-I TDI is a pioneering partnership between Memorial Sloan Kettering, The Rockefeller University, and Weill Cornell Medical College. 01 02 The aim — to accelerate biomedical research findings into innovative treatments for people with various diseases, including cancer — will leverage the talent and resources on the three campuses, including MSK’s Experimental “The partnership is spectacular,” says Dr. Foley, who brings The new program will also allow scientists to develop drugs 01 A detail from the Therapeutics Center and Technology Development Fund, the 25 years of industry and academic experience to the Tri-I TDI for neglected diseases, sometimes referred to as “orphans.” laboratory of Abby and Howard P. Milstein Program in Medicinal Chemistry and who has placed 12 drugs into clinical development. “Many diseases don’t involve that many patients,” says Dr. chemical biologist at Weill Cornell Medical College, and the High-Throughput “Takeda appreciates how special the setting here is. They chose Scheinberg. “As a consequence, pharmaceutical companies Gabriela Chiosis Screening Resource Center at The Rockefeller University. The to do this with us for a reason — because it’s an extraordinary and sometimes even funding agencies are not interested.

Tri-I TDI has also formed an initial partnership with Takeda environment for biomedical research.” But the resources of this new partnership will let us focus on 02 Pharmaceuticals International, Japan’s largest pharmaceutical Takeda’s medicinal chemists will bring their expertise some of these very important and lethal diseases and get early Research fellow Liza Shrestha is company, to develop small-molecule drugs. to bear on the projects of Tri-I TDI scientists, but “our pharmaceutical company involvement to develop drugs to a member of This first-of-its-kind institute was founded with a researchers will get all the benefit of Takeda’s expertise treat them.” Dr. Chiosis’ lab team. $15 million gift from Lewis and Ali Sanders (Mr. Sanders is a without losing control,” says Dr. Foley. “When you license your “I want to empower investigators at all three institutions,” member of the MSK, Rockefeller, and Weill Cornell boards). project or drug target to a pharmaceutical company, it’s gone. says Dr. Foley. “They’re brilliant. Let them dream big dreams. “The Tri-I TDI is unique because for the first time it They might call you once in a while to ask your advice, but it’s And let the Tri-I TDI facilitate certain aspects of the drug joins three academic institutions with different expertise not your project anymore. In the Tri-I TDI, we will be working development process while they concentrate on advancing our and resources — all of which complement each other — to shoulder-to-shoulder with Takeda.” understanding of important biological processes.” advance a myriad of therapeutic and diagnostic ideas toward The initial goal for the Tri-I TDI will be to develop “Given our scientists’ deep understanding of the biology the clinic,” explains physician-scientist David A. Scheinberg. small-molecule therapeutics for the treatment of cancer, of human disease — which is essential to making a drug — it As Chair of the Experimental Therapeutics Center and the as well as infectious diseases, diabetes, cardiovascular almost borders on tragedy that economics do not allow them to Molecular Pharmacology and Chemistry Program at the Sloan disease, and neurodegenerative disorders. Longer-term, says push their ideas forward,” he adds. “It is incumbent upon the Kettering Institute, Dr. Scheinberg led the effort to establish Dr. Scheinberg, “We will expand our work to include biological academic community to find ways to rework the traditional the Tri-I TDI at MSK. “This is not licensing our ideas to a agents such as monoclonal antibodies, which are increasingly process for answering the key question, ‘Will this impact pharmaceutical company that will then take them and develop being used to treat cancer, as well as other diseases. In human health and be useful?’ I believe it can be done. My them elsewhere. This is actually bringing academia and addition, we expect to begin to try to make a new generation colleagues — the leaders of MSK, Weill Cornell, Rockefeller, industrial groups together on our campuses to work as a team.” of molecular imaging agents to improve diagnosis.” Takeda, along with Lew Sanders and Howard Milstein — believe it can be done. And we all believe absolutely that it can be done right here.” Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 26 27 Drug Discovery & Development

from patients and introducing a synthetic gene into the cells using an engineered viral vector. Viral vectors are disabled viruses that cannot replicate but are capable of delivering their genetic cargo into a host cell. The genetically altered T cells are then infused back into the patient, where they multiply, seeking out and destroying cancer cells. Cell-Based Therapies: “Chimeric antigen receptors are a new class of drugs in oncology,” says Dr. Sadelain. “What makes CAR technology so attractive is the potential to apply it to many cancers. The A Radical engineered cells must persist in the patient long enough to induce substantial tumor regression and eventually a complete Departure remission, acting like a ‘living drug’ and patrolling the body in search of tumor cells to eliminate.” Paves the The majority of the 14 treated patients who responded to CAR therapy either already had or will eventually undergo stem cell transplants. However, some patients are not able to Way for the undergo transplants because they are not well enough, and others choose not to have additional treatment. Future “As more patients get CAR therapy, and not all of them are able to go on to get a transplant, we’re getting an increasing number of patients we can follow over time who we hope will remain in remission for the long term without a transplant,” Every year, Science magazine spotlights says Dr. Brentjens. He adds that cell-based immune therapy a pivotal scientific achievement as the could eventually become the new standard of care, allowing “Breakthrough of the Year.” The 2013 winner patients to avoid transplants altogether. was cancer immunotherapy, an approach “An important feature that distinguishes MSK from most that aims to instruct the immune system to other academic centers is our ability to translate conceptual recognize and attack tumor cells in much the innovations and preclinical modeling and bring them to the same way that it targets infectious agents. first-in-human clinical trials, as was the case with the ALL And MSK investigators played a seminal role study,” says Dr. Rivière. in a major area of research highlighted by the “In a broad context, the significance of CAR therapy is the magazine: the development of a cell-based fact that it utilizes cells, not molecules, as drugs,” concludes targeted immunotherapy called chimeric Dr. Sadelain. “We see it as a potential sea change in medicine, antigen receptor (CAR) therapy. paving the way for the immunotherapies, stem cell therapies, and regenerative medicine of the future. We created the “CAR therapy is at the same time cell therapy, gene therapy, Center for Cell Engineering to spearhead this research, then and immunotherapy,” explains Michel Sadelain, Director of established the Cell Therapy and Cell Engineering Facility MSK’s Center for Cell Engineering. “It represents a radical to support the clinical research and, more recently, the departure from all forms of medicine in existence until now.” Cell Therapy Center to deliver this new form of medicine to In 2013, Dr. Sadelain, along with Renier J. Brentjens, more patients.” Director of Cellular Therapeutics, reported that genetically MSK currently has trials under way evaluating cell-based modified immune cells (T cells) showed great promise in killing immune therapies in the adult and pediatric forms of ALL as cancer cells in patients with relapsed B cell acute lymphoblastic well as chronic lymphocytic leukemia, B cell non-Hodgkin leukemia (ALL). The study, reported in Science Translational lymphoma, and prostate cancer. Medicine, included five patients. A more recent study reported In late 2013, Drs. Sadelain, Brentjens, and Rivière in the same journal in February 2014 included an additional were among the founders of a biotechnology company called 11 patients. The researchers found that 14 of 16 total treated Juno Therapeutics. (All three researchers will continue in patients, all presenting with chemotherapy-resistant disease, their roles at MSK.) Juno is pioneering efforts to speed the showed a complete response after receiving the T cells. development of novel immunotherapies for cancer and is Over the past decade, Drs. Sadelain and Brentjens; based on groundbreaking discoveries by scientists at MSK, RENIER BRENTJENS ISABELLE RIVIÈRE MICHEL SADELAIN Isabelle Rivière, Director of the Cell Therapy and Cell Fred Hutchinson Cancer Center, and the Seattle Children’s Director, Director, Director, Engineering Facility; and other MSK researchers have Research Institute. Cellular Therapeutics Cell Therapy and Cell Engineering Facility Center for Cell Engineering investigated this approach, which involves removing T cells Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 28 29 Drug Discovery & Development

01 02 Liza Shrestha is a Research fellow research fellow in Alexander Bolaender Gabriela Chiosis’ lab. is a member of Dr. Chiosis’ laboratory.

A Long and Winding Road:

01 PU-H71

GABRIELA CHIOSIS Chemical Biologist Drug discovery is “a long, complex effort,” that would be most sensitive to therapy with PU-H71. says chemical biologist Gabriela Chiosis, a The investigators needed a way to select patients who had member of the Sloan Kettering Institute’s cancers with increased reliance on Hsp90. It became clear Molecular Pharmacology and Chemistry that attaching a radioactive label to PU-H71 could allow Program. She should know. The journey to them to identify Hsp90-avid tumors. Working with MSK’s the discovery in her laboratory of how a small Departments of Radiochemistry and Radiology, Dr. Chiosis’ molecule can be used to block the activity of laboratory developed a radioactively labeled version of PU-H71. a cancer-promoting protein began more than “Now we can see the real-time distribution of PU-H71 a decade ago. everywhere in the body,” she says. “When you give a patient a drug, you don’t really know where it goes. But with radiolabeled PU-H71, a patient is like an open book.” Dr. Chiosis’ laboratory brings together experts in biology, In early investigational clinical studies now ongoing at chemistry, and medicine to investigate proteins called MSK, patients are given PU-H71 labeled with a very small “We’re not just giving chaperones, which help maintain a cell’s function by assisting amount of radioactive iodine, enabling doctors to perform PET a drug and crossing other proteins to fold properly. In some diseases, however, the scans to visualize how the drug is taken up in cancer cells. our fingers hoping protective function of chaperones has the paradoxical effect of “Tumors with active Hsp90 light up — and the more that something will stabilizing a variety of proteins required for tumor growth and sensitive a tumor, the more it lights up,” explains Dr. Chiosis. happen. We have a progression. One such chaperone protein is called heat shock “We can see not only where the agent is but also how long way of monitoring protein 90 (Hsp90). As its name suggests, heat shock proteins it stays there. And we can also see how much of the agent is what we are doing protect cells when they are stressed by high temperatures, but actually in a tumor itself, so we know the concentration of the in every tumor. It is Hsp90 is also known to play a role in cancer, as well as in some drug at any given time. This is a feat I don’t think has yet been neurodegenerative diseases. achieved in any targeted therapy in oncology.” patient specific.” “Hsp90 is a very promising target for cancer therapy,” Dr. Having not only the therapeutic agent but also the Chiosis says. In 2005, she and her colleagues discovered a small companion diagnostic provides investigators and clinicians molecule called PU-H71 that blocks the activity of Hsp90. with a rational way to deliver PU-H71. “We’re not just giving “It was recognized at the time as an important finding,” she a drug and crossing our fingers hoping that something will 02 recalls. Next, she and her collaborators began exploring the happen,” she says. “We have a way of monitoring what we are biology of PU-H71 and how best to develop the compound into doing in every tumor. It is patient specific.” an agent that could be used clinically. In their early studies, Dr. Chiosis and her colleagues are What they knew was that certain cancers are “addicted” focusing on the use of PU-H71 in several cancers, determined to the activity of Hsp90, and that it would be these tumors by the presence of Hsp90 activity. TransformingTransforming MEMORIAL SLOAN KETTERING CANCER CENTER 30 Integrated Genomics 31 PrecisionPrecision Operation and Center for Molecular MedicineMedicine Oncology group leader Daoqi You and Center for Molecular Oncology Associate Director Agnès Viale work with an Ion Proton Sequencer. Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 32 33 Precision Medicine

Let’s now look for genetic needles in cancer’s haystack. It is not a simple quest. But against the backdrop of an explosion in the discovery of biologically and therapeutically significant aberrations in human tumor genomes, that’s exactly what scientists and clinicians at Memorial MICHAEL BERGER AGNÈS VIALE DAVID SOLIT Sloan Kettering are doing — with MICHAELAssociate Director, BERGER Associate Director,AGNES VIALE Director, DAVID SOLIT Marie-JoséeTitle and to Henry go here R. Kravis Marie-Josée and HenryTitle R. to Kravis go here Marie-Josée and Henry R. KravisTitle to go here remarkable success. Center for Molecular Oncology Center for Molecular Oncology Center for Molecular Oncology Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 34 01 35 Precision (From left) CMBT Co-Chair Neal Rosen, CMO Director Medicine David Solit, and Memorial Hospital Physician-in-Chief and CMBT Co-Chair José Baselga attend a weekly meeting of the CMBT.

Until about 1980, most research on cancer treatment decisions. For example, MSK was the first academic therapy was directed at tumor cells that were center to perform large-scale tumor profiling when Marc rapidly dividing, not “targeted” in the sense Ladanyi, the William J. Ruane Chair in Molecular Oncology that the word is used today. The aim was to and Chief of the Molecular Diagnostics Service, developed discover universal cancer drugs that would methods to genotype lung cancer patients for genetic mutations stop tumor cells from growing in all patients in their tumors that predict for response to targeted drugs. with a certain cancer type. Another approach, developed by CMO Associate Director Michael F. Berger — who also holds an appointment in the Department of Pathology — Dr. Ladanyi, and colleagues in the More recently, scientists have shown that cancers are highly Department of Pathology including Maria Arcila and Donavan genetically variable. Identification of genetic and molecular Cheng, is a cancer genomic assay called MSK-IMPACT, which targets in individual tumors can be used to help select effective uses next-generation sequencing to capture and analyze therapies and create new ones. And with the development 341 select genes. of newer technologies, identification of these genetic and During this time, Memorial Sloan Kettering researchers molecular targets has accelerated exponentially over the past drew upon a range of resources. Of special importance to few years. MSK established several new centers in 2013 to studies of the molecular underpinnings of cancer is the allow our researchers to harness a tumor’s genetic information institution’s extensive collection of tumor samples, taken and exploit it to its full clinical potential. from virtually all patients whose tumors have been removed at The new Marie-Josée and Henry R. Kravis Center for Memorial Hospital in the past ten to 15 years. No institution in Molecular Oncology (CMO), made possible by a transformative the world has a comparable resource. $100 million gift from the Marie-Josée and Henry R. Kravis “We have collected tens of thousands of tumors that NEAL ROSEN Foundation, is undertaking a wide-ranging effort to correlate can be used by MSK scientists to determine the spectrum Co-Chair, Center for Mechanism-Based Therapies tumor molecular profiles with clinical outcomes and responses of molecular changes that underpin the development of to therapy. CMO investigators will aim to identify the specific cancer types,” explains Dr. Solit. “Among many other functional significance of genetic alterations in tumors and the initiatives, Marie-Josée and Henry Kravis’s gift will allow for opportunities they offer for treating cancer patients in a more a more comprehensive collection of tumor samples and the 01 individualized manner. associated clinical histories of the patients treated by MSK “In an era of personalized cancer therapy, the CMO brings physicians. For example, it will allow for the creation of a together the diverse expertise and advanced technology comprehensive centralized database linking the tumor archive required to perform molecular profiling of tumors,” says with the relevant information associated with each sample, Next-generation sequencing is a term that describes MSK physician-scientist David B. Solit, inaugural Director of including molecular and pathological characterization of the Next-Generation a number of modern sequencing technologies that the CMO. “This multidisciplinary team includes clinicians, tumor and the clinical course of the disease of the patient from Sequencing have revolutionized the study of genomics and pathologists, cancer biologists, and bioinformaticians. By whom the tumor was removed.” molecular biology. using next-generation sequencing [one of the methods by One of the challenges investigators face is making as Compared to traditional DNA sequencing which scientists extract genetic information from tumors], many of these tissue samples available for DNA sequencing methods — the process by which the precise we are able to rapidly decode tumor genomes. Our goal is to as possible. Dr. Berger will work to accomplish this. “We are order of nucleotides is determined within a DNA perform genomic profiling for all patients at Memorial Sloan optimizing our protocols and computational methods to be molecule — next-generation sequencing scales up the Kettering. The CMO provides the infrastructure and expertise able to analyze the vast majority of clinical samples, many process considerably, producing millions or billions to accomplish this goal. It also brings physicians together with of which may contain very small amounts of cancer cells or of sequences at the same time. Scientists can analyze scientists who are working to discover new molecular changes may have been stored using preservatives that can reduce the more samples simultaneously, look at more genes that promote tumor formation, which may represent new drug quality of the DNA,” he says. at once, and identify different classes of mutations targets.” (To learn more about next-generation sequencing, see MSK-IMPACT sequences genes that previously have been — as well as look deeper into a tumor sample. If a the sidebar at right.) implicated in the development or behavior of tumors, and many mutation is present in only a tiny percentage of cells Over the past decade, MSK has compiled a remarkable can be targeted with existing drugs or with newer therapies in a sample, next-generation sequencing allows record of achievement focused on understanding cancer at its now being tested in clinical trials at MSK. researchers to detect that mutation more easily. most fundamental levels and using that knowledge to guide Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 36 37 Precision Medicine

01 02 03 IGO and CMO group IGO and CMO An RNA chip for the leader Juan Li research assistant 2100 Bioanalyzer in works with a HiSeq Tony Deblasio talks Dr. Viale’s lab, used to Sequencer. with Agnès Viale in measure the quality her laboratory. and quantity of RNA

“Targeted sequencing makes genomic research on needle When mutations are discovered that may be targets for biopsy samples or low-quality tissue more feasible,” Dr. Berger drug treatment — whether with currently available targeted explains. “And in some cases we have a better chance of making drugs or new therapies — novel trials are needed to test clinically relevant discoveries if we focus on deep sequencing these hypotheses. One such trial is called a “basket” study. these previously characterized genes in many specimens, Traditional clinical trials focus on a particular cancer type. rather than broadly analyzing the genome.” Basket studies, however, are not tumor type specific but gene He and his colleagues are also working to develop new or mutation specific. “We enroll patients in basket trials based assays to detect mutations that the MSK-IMPACT assay on a specific mutation found in their tumor and not on the basis may miss. of where their cancer originated,” explains Dr. Solit. “We have Another challenge MSK researchers face is the rapid patients in these studies with different cancer types, such as development of new technologies. To help make certain that ovarian, colorectal, and lung cancers, all being treated with the institution remains ahead of the curve, Agnès Viale was the same drug because their tumors carry a similar molecular recruited as Associate Director of the CMO and head of the signature. What we’re trying to figure out is whether patients MSK Integrated Genomics Operation (IGO). Dr. Viale, who with a specific mutation all respond to a particular targeted created and has directed the MSK Genomics Core Laboratory drug.” (To learn more about basket studies, see Transforming for the past ten years, says, “My role is to ensure that our Clinical Research beginning on page 40.) investigators have access to the technologies they need to “We predict that the work performed within the Center conduct cutting-edge research. Our goals are not just to foster for Molecular Oncology will eventually impact the care of all this crucial research but also to enable clinicians to use these patients at Memorial Sloan Kettering,” he says. “Our vision is genomics technologies as new, precise diagnostic tools that can nothing less than to revolutionize the treatment of cancer, and guide cancer treatment decision-making. We want to develop I do not believe that there is another institution in the world as new tests that will help our patients get the best treatments for well-equipped to perform this work on such a large scale.” their individual cancer.” The CMBT, the next chapter in this story, involves the “This is a very exciting time,” she continues. “Sequencing is patient as a partner in both research and care. Co-chaired changing the way we study cancer in the laboratory and provide by physician-scientist Neal Rosen and Memorial Hospital cancer care to patients. During the next ten years, I expect Physician-in-Chief and Chief Medical Officer José Baselga, 01 that we will move beyond the classification and treatment of the CMBT’s patient focus represents a paradigm shift in cancer cancers based upon the ‘geographic’ location of the tumor — for medicine that illuminates, on a molecular level and over time, example, breast, lung, or brain cancers — but instead will tailor a tumor’s adaptation to therapy. therapy to the genetic landscape of the tumor. That’s where It remains an unfortunate fact of treatment that even we’re headed: We’re going to sequence each individual’s cancer with the use of the latest targeted drugs, eventually most to identify the therapy mostly likely to beat it.” cancers will develop resistance. Yet the mechanics by which Researchers at the CMO will also work closely with MSK’s this happens are still largely unexplored. CMBT investigators Center for Mechanism-Based Therapies (CMBT) to bring aim to discover the mechanisms of tumor adaptation and the new findings into the clinic. “There are two aspects to what predominant molecular targets for halting this process. we’re doing,” says Dr. Solit. “First, find the mutations that are “Our investigations will lay a foundation for developing new important and figure out which ones predict for a response combination therapies that strike a primary tumor target as to treatment, treatment resistance, early onset of cancer, well as key secondary targets that underlie tumor adaptation,” or prognosis. Second, after we have identified the relevant says Dr. Rosen. “The goal is to eradicate the tumor while mutations, we need to develop therapies that directly target preempting its ability to adapt and develop drug resistance.” the mutant proteins or the pathways activated as a result. Research at the CMBT will begin with targeted therapies The CMBT will be the ‘effector’ arm of the CMO and will help involving close collaborations with the CMO and MSK’s translate our findings into clinical trials.”

02 03 Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 38 39 Precision Medicine

Human Oncology and Pathogenesis Program, among other divisions. The genetics-based research of these groups focuses on primary cancer-driving pathways and novel drugs that specifically inhibit them. “The CMBT takes the next step, emphasizing an integrated approach and looking at the physiology of the cell as a unified system,” Dr. Rosen explains. “We’ll study how a drug hits its target, how it shrinks a tumor and causes toxicity as a result of how often it’s given, and how the cell adapts when the drug inhibits a targeted pathway. We’ll then investigate ways to prevent this adaptation.” Finally, CMBT researchers will translate findings into clinical trials. As part of this work, they will closely monitor patients to determine the molecular course of their disease One of the initiatives she pioneered — which will be as well as the most effective mechanism-based therapy and deployed by the CPCR — is a rapid medical donation program. schedule of therapy to increase their chances for a cure. In such In the program, patients with end-stage disease consent to We want to devote all studies, they will use many of the novel technologies developed have a rapid autopsy, in which living tumor cells can be taken our energies to making by scientists in the CMO. from both the primary tumor and metastatic disease in other STEVEN LEACH this the best center in As part of a robust new effort to address some of the organs. “By engaging these patients, Dr. Iacobuzio-Donahue Director, the David M. Rubenstein Center most “difficult” cancers — those that have proved especially has been able to understand — in ways that nobody else has for Pancreatic Cancer Research the world for pancreatic treatment-resistant — MSK has established the David M. before — how different mutations are linked to the spread of cancer research.” Rubenstein Center for Pancreatic Cancer Research (CPCR), the disease and how different subpopulations of cancer cells directed by surgeon, developmental biologist, and pancreas undergo evolutionary selection and growth,” says Dr. Leach. cancer expert Steven D. Leach. Dr. Leach is a recent recruit Working with biologist Scott W. Lowe, Chair of the Geoffrey from Johns Hopkins, where he was the Paul K. Neumann Beene Cancer Research Center at MSK, CPCR scientists will Professor in Pancreatic Cancer. The CPCR will be co-directed also support the distribution of innovative mouse research by medical oncologist Eileen M. O’Reilly, surgical oncologist technologies that Dr. Lowe has created. These methods 01 (Clockwise from left) Peter J. Allen, and pathologist Christine Iacobuzio-Donahue. can rapidly and inexpensively create mice with pancreatic Peter Allen, Steven Leach, “The resources provided by Mr. Rubenstein [a cancers that biologically are very similar to those in their Christine Iacobuzio-Donahue, and Eileen O’Reilly member of MSK’s Boards of Overseers and Managers] are human counterparts. “These mouse models will be made transformative,” says Dr. Leach. “They allow us to assemble available to the MSK community so that they can be readily a truly multidisciplinary team of physicians and scientists. used in preclinical studies, allowing us to rapidly screen new 02 There has never been a gift like this, focused completely on therapeutic strategies for pancreatic cancer,” Dr. Leach says. Pathologist Christine Iacobuzio-Donahue, pancreatic cancer. This cancer has historically been under- Beyond mice, Dr. Leach adds that “we will create an Co-Director of studied and funding is woefully deficient, even as the vast infrastructure that fosters increased investigation related to the CPCR majority of patients still die of their disease. There is an urgent pancreatic cancer throughout MSK. We want to make sure that need for much more study and better results, which this gift clinicians and scientists interested in the study of pancreatic 03 will accelerate.” cancer tissue have ready access to tumor material, tumor 01 Surgeon Peter Allen, Partnering with MSK clinicians and scientists, researchers microarrays, and tumor DNA and RNA.” Co-Director of the CPCR at the CPCR will attack pancreatic cancer in a number of ways, An expanded program of clinical trials will also be launched including uncovering alterations in the genome responsible under the umbrella of the CPCR. And, says Dr. Leach, “there for the onset, growth, and spread of the disease. Dr. Iacobuzio- are aspects of the biology of this cancer that make it an often- 04 Donahue, another recent recruit from Johns Hopkins, has fatal disease, even when diagnosed early, so we’ll also be Medical oncologist Eileen O’Reilly, done seminal work in showing how pancreatic cancer cells exploring ways for ever-earlier diagnosis.” Co-Director of with a series of mutations evolve into ever-more-complex “The CPCR’s mission statement is ‘To improve the lives the CPCR lineage trees, and has started to look at the disease from an of patients with pancreatic malignancies through bold, evolutionary biology perspective. innovative, multidisciplinary research,’ and we want to devote all our energies to making this the best center in the world for pancreatic cancer research,” he concludes. “We want to do 02 03 04 the highest-impact research and rapidly apply our findings to benefit patients.” Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 40 41 Clinical Research

Clinical Research Nurse IV Jennifer Winkelmann Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 42 43 Clinical Research

Paul Sabbatini, Deputy Physician-in-Chief for Clinical Research, has been leading the endeavor. A physician-scientist who cares for women with ovarian cancer, Dr. Sabbatini “[MSK clinical trials] are a real Smarter, smaller, faster: From cars to computers, was appointed in 2013 to support a partnership among coordinated effort to expand and streamline patients, physicians, it’s the future. It’s also the new paradigm of clinical MSK’s clinical research program. and our entire clinical research at Memorial Sloan Kettering, where research team.” we’ve taken transformative steps to bring novel “Most of the approaches that doctors use to treat cancer – Richard Carvajal today are the direct result of successful clinical trials in the Director, Developmental Therapeutics Program therapies to more patients more quickly. past,” he says. But the times — and our understanding of the biology of cancer — are changing radically. With that, clinical research is also evolving. “The historical way to develop cancer treatments was built on an inflexible sequence of clinical trials,” Dr. Sabbatini says. “This methodical progression from phase I to phase III trials advanced the field, but progress has been slower than we The Center for Mechanism-Based Therapies (CMBT) would have liked, and in many instances there have been only provides a venue in which investigators and doctors can begin incremental improvements.” And while clinical trials remain to align patients that have particular targets with specific the best way to improve treatments, the rigid trial paradigm drugs. (To read more about the CMBT, see Transforming has become outmoded in many contexts. “What we need to Precision Medicine beginning on page 30.) rethink is the large clinical trial with long follow-up looking for “In the CMBT we are now able to bring developmental small improvements,” he explains. therapeutics [led by physician-scientist Richard D. Carvajal], In a new era of precision medicine, increasing numbers immunotherapeutics [led by physician-scientist Jedd D. of patients can be enrolled in trials of therapeutic agents Wolchok], and cellular therapeutics [led by physician-scientist targeting specific mutations or pathways present in their Renier J. Brentjens] under one roof,” Dr. Sabbatini explains. individual tumors, independent of the type of cancer with “Quite literally, the CMBT gathers a large group of people which they were diagnosed. This means that new cancer drugs in one room — we meet every Thursday — and provides a venue can be tested in smaller trials with fewer patients. for discussion for investigators who have phase I trial ideas “The key to these trials is that we have become much more or concepts, or for pharmaceutical companies that want to nimble in confirming responses early on. In a phase I trial partner with us in developing concepts or trials,” he says. “It’s we’re able not only to evaluate safety and get the correct dose been very successful both in improving efficiencies of trial but also to get a real hint of efficacy,” says Dr. Sabbatini. “You conduct and in getting our scientists and clinicians involved in get answers and you get them quickly.” early drug development, which is where we think we can have To bring these novel therapies to patients more efficiently, the most impact.” (To learn about more of MSK’s efforts in this Dr. Sabbatini and his colleagues doubled the capacity of the regard, see Transforming Drug Discovery & Development on Research Council, which is responsible for the scientific review page 20.) of trials, and created a second Institutional Review Board The hub of operations of MSK’s clinical research program (IRB). The IRBs are responsible for approving, monitoring, and is the Office of Clinical Research, led by Executive Director PAUL SABBATINI COLLETTE HOUSTON reviewing all biomedical research involving human subjects. Collette Houston. Her staff is responsible for managing all Deputy Physician-in-Chief for Clinical Research Executive Director, Office of Clinical Research “We’ve also created a system in which we can track where aspects of clinical trial protocols. “This means the development protocols are in the approval pipeline,” says Dr. Sabbatini. “We of protocols from initiation through completion, quality have someone dedicated to reviewing that and intervening assurance, and everything in between,” Ms. Houston says. when protocols fall off track. And in selected protocols, we’ve The “in between” includes informatics, education, training of seen the time-to-activation numbers [which measure how long the staff that conduct the research, and committee reviews. it takes to get a drug or therapy into a clinical trial] fall. We still have work to do, but that’s our focus as we go forward.” Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 44 45 Clinical Research

Traditional Clinical Trials versus Basket Trials DRUG A

The standard approach for developing many cancer treatments has been built upon a Tumor Type 1 Tumor Type 2 series of clinical trials to establish the effectiveness of drugs in specific cancers — for (for example, (for example, breast cancer) colon cancer) example, in breast or colon cancer. (See the infographic below.) A novel approach to clinical trial design called a “basket” trial starts with one trial, the basket, and one or more “targets” and allows patients with different diseases to enroll in a group or cohort. (See the infographic on the opposite page.) This allows for exploration of a treatment’s effectiveness across many diseases early, quickly, and in one trial. The goals of such trials are to accelerate the translation of scientific discoveries into new therapies and to increase the number of patients who can benefit from innovative mechanistic approaches with molecularly targeted therapies.

Traditional Clinical Basket Clinical Patients with cancers of different Trial Design Trial Design organs — such as the breast and colon — but whose tumors all share the same genetic mutation or pathway.

Patients whose tumors Patients whose After responses are seen did not respond to Drug A tumors have responded in a group of patients, move on to other treatment well to Drug A. additional patients (called options. an expansion cohort) can be added to see if the responses Phase I Phase II Phase III Phase IV are seen in a larger group.

A treatment is tested to A treatment is evaluated The same treatment is If the new drug is approved establish a dose (often the typically in about 35 tested in a randomized by the FDA, phase IV trials maximum tolerated dose) patients with the same type trial with a large number may be continued to learn and to establish safety and of cancer and with the dose of patients organized more about how best to use learn about side effects. established in the phase I into groups to assess the it, as well as its long-term Traditional phase I trials study. The goal is to observe effectiveness of the new benefits and side effects. are generally small. tumor shrinkage over a agent often compared to a period of time. standard of care treatment.

Researchers analyze the responses of patients with each type of cancer. This information can inform the next steps and accelerate the time it takes for new and effective therapeutic agents to reach patients. Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 46 47 Clinical Research

01 Jennifer Winkelmann, Clinical Research Nurse IV, and Richard Carvajal, Director of the Developmental In addition, her office is responsible for contracting, research Therapeutics Program, talk with a patient. billing, multicenter trial management, and research support services to help clinical departments manage their activities.

Dr. Carvajal, Director of the Developmental Therapeutics 02 Program, explains that the program is primarily the small- Ms. Winkelmann and Dr. Carvajal molecule arm of MSK’s drug development efforts, looking at what have come to be called targeted therapies. Dr. Wolchok’s program studies novel agents that modulate the immune system’s response to cancer. And Dr. Brentjens’ program works on a form of gene therapy in which patients’ own immune cells are genetically manipulated to directly attack tumors. of starting with multiple clinical trials in different diseases, 01 02 (To learn more about Dr. Brentjens’ research, see Cell-Based investigators begin with one trial — the basket — and one or Therapies on page 26.) more targets, and allow patients with different cancers to Dr. Carvajal, a member of the Melanoma and enroll. If one group shows a good response, physicians can Immunotherapeutics Service in the Department of Medicine, expand the group to immediately assess whether other patients is charged with developing and increasing early-phase clinical would also benefit. trials at MSK. He says that historically, patients would be On the flip side, if a group is not showing evidence of referred to phase I trials only when their oncologists had run effectiveness, the trial can be closed and patients can move out of standard options. But not anymore. on to consider other therapies. This can happen quickly, so “Because of molecular profiling and having more-precise patients do not lose valuable time receiving a treatment that understandings about the unique biology of individual isn’t working. “We can make decisions much, much sooner than tumors, we are now able to identify patients with tumors if we used the traditional trial model,” explains Dr. Sabbatini. harboring alterations in gene X, to understand the effects of “More and more, we’re going to see that drugs will go from these alterations on tumor growth, and then to match patients phase I directly to phase III clinical trials in terms of the directly to trials studying agents that address each specific developmental path,” Dr. Carvajal says. “Because we’re now molecular event,” he says. not only looking at toxicity and dosage in these contemporary As researchers are better able to assemble these genetic phase I studies, but also assessing efficacy. We are going to profiles — correlating the biology of tumors to treatments — see a decrease in the number of phase II trials conducted. It’s they are seeing dramatic responses in patients who previously no longer enough just to show we can give a drug at a certain have experienced disease growth after a number of prior dose safely; we have to show that it does something to help therapies and who have opted to join an early-stage trial. “So our patients.” even if there are standard options available,” says Dr. Carvajal, Both men speak movingly of the patients who participate. “sometimes we’ll recommend to patients that perhaps we “It’s truly humbling for us to look at our patients, who are should consider this particular clinical trial.” dealing with a serious illness, with many choices to make with Twelve physicians with disease-specific and specialized regard to therapy, and see how many are willing to enroll in drug development expertise ­­— along with specially trained these trials,” says Dr. Sabbatini. phase I clinical and treatment research nurses, technicians, “This is a real partnership among patients, physicians, and and research and administrative staff — make up the our entire clinical research team,” says Dr. Carvajal. “Patients Developmental Therapeutics Program. Each physician has a are very selfless. We do this, of course, in the hope that we’re particular drug development focus, such as cancer metabolics, going to help them — and often we do. And patients do it in the epigenetics, stem cell targeting, cell cycle targeting, cell hope that they will be helped. But they also do it because they signaling pathways, novel chemotherapeutics, resistance know they’ll help people in the future.” mechanisms, or DNA damage repair. (To learn more about how MSK’s clinical research program Another significant area in the evolving clinical research is expanding at our network sites and as part of the new MSK RICHARD CARVAJAL landscape at MSK is basket trials. These trials study a drug Cancer Alliance, see Transforming Cancer Care & Delivery Director, Developmental Therapeutics Program with a specific mechanism of action that may potentially beginning on page 48.) work regardless of the type of cancer a patient has. So instead 48 49

Patient Renaldo Hill (left) and radiation therapist Michael Guida at Memorial Sloan Kettering’s Basking Ridge, New Jersey, outpatient care facility Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 50 51 Cancer Care & Delivery

An internationally recognized physician-scientist, José Baselga joined Memorial Sloan Kettering in 2013 from Massachusetts General Hospital (MGH), where he was Chief of the Division of Hematology/ Oncology and Associate Director of the MGH Cancer Center.

It was a homecoming of sorts: He did his medical oncology fellowship at Memorial Hospital and was a faculty member on the Breast/Gynecology Service from 1994 through 1996, after which he returned to his native Spain. Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 52 53 Cancer Care & Delivery

His laboratory research deal of time thinking about how to achieve as Deputy Physician-in-Chief for includes the development of even better clinical integration across Clinical Research, and he’s been doing novel molecularly targeted all our locations, and I include in this a tremendous job of streamlining and cancer therapies, with a not only our network campuses on Long accelerating our clinical trial process. special focus on breast cancer Island and in New Jersey and Westchester We now have two Institutional Review and therapeutic approaches County, but also our Manhattan facilities. Boards, doubling our capacity to do to targeting a pathway Central to realizing these plans has clinical trial reviews. As a result, we’ve called PI3K. His work in the been the appointment of [Chief of the seen remarkable decreases in the time preclinical and early clinical Gynecology Service] Richard R. Barakat between the review and the approval development of therapies has to the newly created position of Deputy of clinical trial protocols — down from helped introduce a number of Physician-in-Chief for the Regional 200 to 90 days. And we are also seeing new targeted agents. Care Network and MSK Cancer Alliance. an increase in clinical trials with more Dr. Barakat will lead the network, patients participating. Dr. Baselga talked to us about expanding its presence throughout the I’m deeply grateful to Dr. Sabbatini several of the highlights New York metropolitan area and building and to everyone who has contributed so of 2013 and the future of relationships with medical institutions much to these efforts, including Collette Memorial Sloan Kettering’s outside the region. He’ll also lead the Houston [Executive Director, Office of clinical enterprise. effort to fully implement and expand Clinical Research] and her colleagues. the recently announced Memorial Sloan [To learn more about the clinical research Kettering Cancer Alliance. enterprise at MSK, see Transforming Clinical Research on page 40.] Q: You’ve just marked your first year as Physician-in-Chief. What was it like? Q: The MSK Cancer Alliance, whose first partnership is with Q: During your first year at MSK A: This was a year of getting acquainted Hartford HealthCare (HHC), a number of new centers were — or reacquainted — with MSK. Over is an unprecedented undertaking established to foster collaborations the course of the past 12 months, I met a and represents a sea change in among clinical investigators and tremendous number of people from every MSK’s clinical enterprise. scientists, with the aim of bringing part of the institution and learned about more novel therapies to patients. the workings of its clinical operations. I A: Yes, it does. Let me put it into an Can you talk about this? spent a lot of time with our department important and all-encompassing context, 01 chairs and visited virtually all our which is clinical research: During 2013, A: My “big” answer is that I believe treatment facilities, both in Manhattan we embarked on a major restructuring MSK is becoming a real engine of 01 and in our regional network. It was a of our clinical research operations, and execution of new ideas that will transform Jessica Uporsky, Clinical Nurse II, chats wonderful experience, and my most Hartford HealthCare — and, eventually, patients’ lives. with patient Eric indelible impression is that you have to other Alliance members — will play a More specifically, the new centers R. Nahm at MSK’s Basking Ridge facility. live in this place to see how great it is. key role in this. In order to continue our are part of a larger vision to develop and clinical research mission and make it bring treatments to patients that were

even more robust, we need larger patient not available before — indeed, that didn’t 02 Q: You mentioned our patient-care populations. Almost every important exist before. Patient Charles Fetter is prepared facilities, so let’s begin there. advance in cancer treatment has come First, with the participation of our for his chemotherapy about as a result of clinical trials — and to gifted pathologists, we have massively treatment by Valda Gaubiene, Clinical A: A good place to start! conduct effective trials, you need many expanded our tumor sequencing program. Nurse II, also at MSK This was the year in which we laid out patients to participate. In the past year, we have sequenced Basking Ridge. the vision and strategic planning for our Early in my tenure, I appointed more than 10,000 patient tumors. That’s sites. My colleagues and I spent a great [medical oncologist] Paul Sabbatini

02 Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 54 55 Cancer Care & Delivery

an incredible tour de force. In order to Q: Improving patient access to MSK Q: Broader picture, how do you see design tumor-specific treatments, we has also been one of your priorities. the state of cancer research and must know what is happening within treatment now and as we move into individual cancers, and tumor profiling is A: It has. And we’ve made great progress the future? fundamental to this. over the past year. As everyone knows, A landmark $100 million gift from the these are challenging times for the A: I can tell you that I’ve been doing Marie-Josée and Henry R. Kravis medical community generally. But at this for many years and I’ve never Foundation has allowed us to create the MSK, despite these challenges — which seen the acceleration of progress that Marie-Josée and Henry R. Kravis Center include space constraints — we’ve been I see today. While it’s difficult to make for Molecular Oncology [CMO]. Its able to improve patient access. Several predictions — and cancer is anything inaugural leader will be [physician-scientist] initiatives spanning the entire institution but simple — I will point to just a few David B. Solit; we have also appointed have resulted in shortening the time major advances that have deepened our [physician-scientist] Richard D. Carvajal between a call from a patient or caregiver understanding of cancer biology and are as Director of the Developmental seeking an appointment and when that changing the way we think about treating Therapeutics Program. The major goal of patient can see one of our physicians. these diseases. cancer research in the years ahead will For the first time, we have the capacity be to integrate molecular and clinical to sequence tumors in real time and information in order to develop precision Q: Looking ahead to your second year, identify actionable mutations [which can treatments, and the CMO will be the first what will be on your mind? be targeted with drugs or help doctors 01 (From left) program in the country to span the full diagnose or make predictions about a Gynecologic range of activities required to translate A: Interestingly, I think this next year person’s disease]. For the first time, we oncologist and head of the Gynecology molecular insights into clinical innovations. will partly be one of turning my attention have the ability to investigate the complex Research Laboratory The Center for Mechanism-Based back to some of MSK’s core values. Of patterns of feedback in cellular signaling Douglas Levine, hematologist 01 02 Therapies [CMBT], co-led by me and course, I will continue to focus on clinical pathways that drive the growth of cancer, and Chief of the [physician-scientist] Neal Rosen, is excellence — we are who we are because and this has opened the gates for us to Leukemia Service Martin Tallman, and another important virtual center. In 2013 we have the best people anywhere: the explore new combination therapies. medical oncologist we reinvigorated the CMBT, and it has best physicians, nurses, and support staff. For the first time, we have proof that David Hyman attend a weekly meeting become the forum in which ideas from the They are all superb professionals. harnessing a person’s immune system to of the Center for lab are being brought into the clinic. We’ve But we should never get so focused fight cancer actually works. Mechanism-Based Therapies (CMBT). launched a weekly CMBT conference, on our research mission that we forget On top of that, there are extraordinary for example, where clinical investigators that in the end, patients are our main and continuing developments in surgery, are coming together with scientists and mission, the reason we are here. And in radiation oncology, in molecular 02 biotechnology companies to discuss how during 2014 I want to work with my imaging and nanotechnology. And this is Computational biologist Nikolaus to develop and advance new therapies. colleagues to make certain we deliver the only the tip of the iceberg. Schultz speaks at a And with generous support from [MSK best, most compassionate patient-care Let me put it another way: If someone meeting of the CMBT. Board member] David Rubenstein, we’ve experience possible. went away to a desert island at the start established the Center for Pancreatic of 2013 and came back now, they would 03 Cancer Research, headed by [surgeon and be amazed. And it would take them more (From left) CMBT cell biologist] Steven D. Leach, an expert than a year to catch up. Co-Chair Neal Rosen, CMO Director in pancreas cancer and a recent recruit As I begin my second year here, I David Solit, and from Johns Hopkins. This is part of a personally couldn’t be more enthusiastic Physician-in-Chief and CMBT Co-Chair transformative effort at MSK to rigorously about the future. MSK is an energizing José Baselga listen address the more “difficult” cancers — the and inspiring institution, and I feel both to a presentation at a CMBT weekly cancers that have proved most treatment- excited and privileged to play a part in our meeting. resistant. [To learn more about these communal efforts to conquer cancer. new centers, see Transforming Precision Medicine on page 30.] 03 Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 56 57 Cancer Care & Delivery

01 “Our mission is to improve the lives of (From left) Richard Barakat people with cancer, and to do that we need talks with radiation to be a force in the community, to have a oncologist Preeti Parhar, radiation presence, an influence, and to make certain oncologist Karen our innovations get to patients,” Dr. Baselga Borofsky, and network administrator continues. Miriam Balsamo.

For Richard R. Barakat, Deputy Physician-in-Chief for the Regional Care Network and MSK Cancer Alliance, his recent appointment brings him back to a familiar place: He was the first MSK surgeon to work at one of Memorial Sloan Kettering’s regional campuses — at Mercy Hospital in Rockville Centre on Long Island. Today, MSK campuses also include freestanding ambulatory care facilities in Basking Ridge, New Jersey, and in Commack, Long Island; a skin cancer center in Hauppauge, also on Long Island; and a facility in Sleepy Hollow, New York. A new 114,000-square-foot freestanding outpatient site will open in Harrison, New York, in the fall of 2014. (To learn more about MSK Harrison, see Facilities Update on page 67.) “I’ve always thought our network campuses were a great idea,” says Dr. Barakat, who has been Chief of MSK’s Gynecology Service for 13 years. “I’ve also had a real personal fondness and attachment to them because of my earlier association.” Dr. Barakat makes a special point of mentioning that he 01 uses the word “campuses” very deliberately when he talks RICHARD BARAKAT about the facilities in MSK’s network. “We are all colleagues,” we came up with a model that can be extended to all our Deputy Physician-in-Chief for the Regional Care Network and MSK Cancer Alliance he says. “I like to think of Memorial Sloan Kettering as one campuses,” says Dr. Barakat. “We’re speaking to our surgeons institution where we all have one shared mission, and our who have been at MSK — in some cases for many years — and network campuses are where we are able to achieve the goals even chiefs of services, all of whom live in the community, and of that mission. One of the most important aspects of my job asking them to work at Harrison one day a week. [Surgical will be to fully integrate the campuses and make sure that the consultations, often the first point of patient contact with MSK, physicians, nurses, and support staff who practice at them feel will be offered at Harrison.] This will allow us to infuse the empowered and part of this great institution.” MSK multidisciplinary culture across all our campuses with “If you want to extend the best patient care in the world — For many new patients, MSK’s regional facilities offer an a blend of senior clinicians and new clinicians so everyone easier point of access to MSK’s care. “We provide care for can learn from one another. And we want to look at this for all the best protocols, the best surgical procedures, and so patients that is both convenient and outstanding — whether models of care, including nursing.” on — you can’t do it from an ivory tower in Manhattan,” that’s surgical consultations, chemotherapy, radiation therapy, And so people who spend a portion of their time at MSK’s or psychosocial or other support services,” Dr. Barakat says. Manhattan campus but live near the regional facilities will asserts Memorial Hospital Physician-in-Chief and Chief In an effort to make that care even better, there are also be serving their own communities. “That’s a very powerful several new strategies that Drs. Barakat and Baselga and their message,” Dr. Barakat says. “MSK doctors and nurses and Medical Officer José Baselga. So let’s leave the tower and colleagues will be implementing over the coming months and social workers will be seeing patients — as well as clinicians go into the streets. ... years. The Harrison facility offers a template for these changes, who have practices in the community — not only professionally, including a reevaluation of how the campuses are staffed. but as part of their daily lives. They’ll be running into these “When we began thinking about clinicians who might want to work in Harrison, rather than thinking only about hiring new people who may not be familiar with the MSK culture, Transforming MEMORIAL SLOAN KETTERING CANCER CENTER 58 59 Cancer Care & Delivery

same people in their churches, their synagogues, at the HHC, a multihospital healthcare system in Connecticut, grocery, at social events. It’s a great way to become part of the is responsible for the care of approximately 18 percent of community. And I think we have to do more of that. We don’t all cancer patients in the state. “The MSK Cancer Alliance want to be viewed as interlopers but as people who are there to is an opportunity to further our mission by working with help their community.” top-quality institutions in the community,” says Dr. Barakat. “I also want to integrate the clinicians who work full-time “HHC was identified as our first partner because it shares our at our network campuses more fully with our Manhattan commitment to excellence in patient care and has one of the campus,” Dr. Barakat emphasizes. “I want them to spend highest-quality cancer programs in the region.” some time in the city, participate in videoconferencing, and in Dr. Barakat makes it clear that the Alliance is a two- every way have opportunities to interact and collaborate with way street. “We truly look at this as a bidirectional flow of clinicians in Manhattan.” information and learning,” he says. “HHC has outstanding Memorial Sloan Kettering is also seeking to transform clinicians, and we’ll be learning from them because they are cancer care delivery beyond its own network of campuses. pros at delivering community-centered cancer care. At the A transformative new initiative announced in 2013 called same time, they will learn from us.” However, he says, “We are the Memorial Sloan Kettering Cancer Alliance will expand not asking them to do everything exactly as we do it. We’re not the institution’s ability to offer a range of services as well as saying, ‘Do this, then that.’ It’s not an algorithm. It’s really just the clinical trials that reflect MSK’s mission to develop new allowing clinicians at HHC to look at what they’re doing that’s therapies and deliver them to patients as rapidly as possible. different from us and consider incorporating our practices (To learn more about MSK’s clinical research programs, see into theirs.” Transforming Clinical Research on page 40.) As the collaboration evolves, certain HHC cancer clinicians “About 80 percent of cancer care in the United States is will participate in observerships and will be integrated into delivered in community settings, and cancer advances can take MSK’s disease management teams. The two institutions years to reach patients,” explains Dr. Baselga. “Many of these will also jointly recruit a physician-in-chief for the Hartford patients also lack access to sophisticated genetic tests and HealthCare Cancer Institute who will be on staff at both HHC clinical trials. The MSK Cancer Alliance — of which Hartford and MSK. In addition, a dedicated research manager will be HealthCare [HHC] is the first member — is creating a new employed by MSK but based in Hartford to assist with the model to address the challenges of providing high-quality clinical trials mechanisms. 2013 Year in Review cancer care to many more patients, including cutting-edge, “We are really linking care across the institutions,” says state-of-the-art trials. HHC will include our first clinical trials Dr. Baselga, “but it’s important to note that HHC patients will site established through the MSK Cancer Alliance, and it will remain patients of HHC Cancer Institute and will continue to be an extraordinary resource for these patients.” receive their treatment locally.” Dr. Barakat concludes by explaining that while HHC is the first member of the MSK Cancer Alliance, it won’t be the last. “At MSK, we are all committed to advancing our goal of bringing leading-edge cancer care into the community,” he says. “Our immediate focus is on ensuring that the alliance with Hartford works, and works well. But ultimately we want to create a network of providers so that we can reach more patients in even more communities.”

01 Patient Janet A. Klikier (left) and radiation therapist Marisa Losco

01 Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 60 61

Statistical Profile

09 10 11 12 13 09 10 11 12 13

PATIENT CARE STAFF

Patient Admissions: Adults 21,932 22,852 22,983 23,139 20,773 Sloan Kettering Institute Members 140 142 143 149 143 Patient Admissions: Children 1,537 1,494 1,503 1,459 1,553 Hospital Attending Staff 768 804 834 876 935 Total Admissions 23,469 24,346 24,486 24,598 22,326 Registered Nurses 1,845 1,945 2,018 2,133 2,221 Support Staff 8,321 8,613 8,989 9,244 9,707 Total Patient Days 140,224 143,532 140,990 149,368 144,345 Average Patient Stay (days) 6.0 5.9 5.8 6.1 6.5 Total Staff* 11,039 11,469 11,950 12,402 12,975 Bed Occupancy Rate Volunteers 917 942 1,058 1,018 1,004 (based on adjusted bed count) 88.5% 83.7% 82.2% 87.0% 83.0%

Outpatient MD Visits: Manhattan 406,024 418,415 432,802 436,510 463,724 EDUCATION Outpatient MD Visits: Regional Network 94,293 97,658 103,098 104,964 108,198 Total Outpatient Visits 500,317 516,073 535,900 541,474 571,922 Residents and Clinical Fellows — Positions 436 447 440 445 464 Screening Visits 27,369 23,373 20,518 15,519 12,826 Residents and Clinical Fellows — Annual Total 1,651 1,625 1,676 1,682 1,691 Surgical Cases 19,233 19,362 19,374 19,691 20,465 Research Fellows 303 295 321 320 323 Research Scholars 121 132 131 124 133 Research Associates 90 94 82 89 91 Radiation Treatments and Implants: Manhattan 57,856 59,223 60,393 60,289 61,335 Graduate Research Assistants — 23 29 39 41 Radiation Treatments and Implants: Network 47,987 47,926 51,615 50,476 53,660 PhD Candidates 227 231 225 222 227 Total Radiation Treatments and Implants 105,843 107,149 112,008 110,765 114,995 MD/PhD Candidates 28 26 21 21 19 Registrants in CME Programs 2,395 2,554 2,533 3,968 3,681 Diagnostic and Interventional Radiology Procedures 358,052 362,609 377,360 391,187 416,360 Medical Observers 572 541 526 566 630 Clinical Investigation Protocols (open to accrual) 507 552 552 657 735 Medical Students 399 391 429 431 392 Nursing Students 109 105 142 178 179 Social Work Students 6 6 6 6 7 Radiation Oncology Technology Students 15 14 14 13 15 Physical Therapy Students 3 3 4 7 2 Occupational Therapy Students 4 3 3 4 2

*In 2013, 31 staff members held appointments in both the Institute and the Hospital. Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 62 63

Financial Summary

(in thousands)

09 10 11 12 13

OPERATING REVENUES (in thousands)

2013 TOTAL 2013 TOTAL Patient Care Revenue $ 1,723,313 1,854,776 2,141,421 2,201,941 2,367,731 OPERATING REVENUE OPERATING EXPENSES Grants and Contracts 167,495 186,327 190,948 185,160 202,061 Contributions Allocated to Operations 126,250 117,323 130,791 144,497 164,943 $3,025,466 $2,847,103 Royalty Income 62,232 68,663 77,510 78,350 94,058 Other Income 43,144 44,874 48,351 51,167 57,150 $2,367,731 Investment Return Allocated to Operations 103,998 100,389 104,699 75,877 82,028 Patient Care Revenue $1,689,501 Transfer of Board-Designated Compensation and Fringe Benefits Annual Royalty Annuitization 37,158 41,578 46,417 51,709 57,495

Total Operating Revenues $ 2,263,590 2,413,930 2,740,137 2,788,701 3,025,466

OPERATING EXPENSES (in thousands)

Compensation and Fringe Benefits $ 1,286,536 1,361,032 1,466,667 1,582,212 1,689,501 Purchased Supplies and Services 757,863 772,968 835,621 879,219 924,691 Provision for Bad Debts and Assessments 10,881 11,046 18,285 17,541 19,969 Depreciation and Amortization 171,806 175,494 195,461 210,810 210,373 Interest Expense 64,997 47,931 57,098 54,894 55,039 Less Fund-Raising Expenses Transferred to Non-Operating Income (Expenses) (40,320) (43,926) (44,665) (47,305) (52,470)

$924,691 Total Operating Expenses $ 2,251,763 2,324,545 2,528,467 2,697,371 2,847,103 Purchased Supplies and Services Income from Operations $ 11,827 89,385 211,670 91,330 178,363 $202,061 Grants and Contracts PHILANTHROPY (in thousands) $164,943 Contributions Allocated to Operations Philanthropy $ 166,247 237,666 301,374 231,159 380,500

$94,058 Royalty Income $210,373 CAPITAL SPENDING (in thousands) $82,028 Depreciation and Amortization Capital Spending $ 226,049 262,371 223,251 258,613 315,282 Investment Return Allocated $55,039 to Operations Interest Expense

$57,495 $19,969 BALANCE SHEET SUMMARY (in thousands) Transfer of Board-Designated Provision for Bad Debts Annual Royalty Annuitization and Assessments Assets $ 6,068,707 6,448,415 6,790,005 7,795,606 8,481,418 Liabilities 2,467,135 2,550,889 2,848,843 3,562,546 3,337,444 $57,150 ($52,470) Other Income Less Fund-Raising Expenses Transferred to Non-Operating Net Assets $ 3,601,572 3,897,526 3,941,162 4,233,060 5,143,974 Income (Expenses) Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 64 65

Boards of Overseers and Managers Principal Leadership as of March 26, 2014 Memorial Sloan Kettering Cancer Center as of March 26, 2014

Douglas A. Warner III James D. Robinson III Craig B. Thompson, MD John R. Gunn Chairman Honorary Chairman President and Chief Executive Officer Chief Operating Officer

Marie-Josée Kravis Louis V. Gerstner, Jr. Vice Chair of Boards Honorary Chair of the Board, José Baselga, MD, PhD Joan Massagué, PhD Chair, Board of Managers, Sloan Kettering Institute Physician-in-Chief and Director, Sloan Kettering Institute Sloan Kettering Institute Chief Medical Officer, Memorial Hospital

Scott M. Stuart Richard I. Beattie Vice Chair of Boards Honorary Chair of the Board, Paul Sabbatini, MD Richard R. Barakat, MD Kent Sepkowitz, MD Chair, Board of Managers, Memorial Hospital Deputy Physician-in-Chief Deputy Physician-in-Chief, Deputy Physician-in-Chief Memorial Hospital for Clinical Research Regional Care Network and MSK Cancer Alliance for Quality and Safety

Clifton S. Robbins Norman C. Selby Craig B. Thompson, MD Treasurer Secretary President and Chief Executive Officer Kerry Bessey Edward J. Mahoney Roger N. Parker, Esq. Senior Vice President and Senior Vice President, Executive Vice President and Chief Human Resources Officer Facilities Management and Construction General Counsel Frederick R. Adler Ellen V. Futter Paul A. Marks, MD Norman C. Selby Richard I. Beattie Philip H. Geier, Jr. Donald B. Marron Stephen C. Sherrill Eric Cottington, PhD Kathryn Martin Patricia C. Skarulis Mrs. Edwin M. Burke Louis V. Gerstner, Jr. Jamie C. Nicholls Peter J. Solomon Senior Vice President, Research and Executive Vice President and Senior Vice President and Mrs. John J. Byrne +Martha V. Glass James G. Niven William C. Steere, Jr. Technology Management Chief Hospital Operating Officer Chief Information Officer Mrs. Joseph A. Califano, Jr. Laurie H. Glimcher, MD Hutham S. Olayan Scott M. Stuart Ian M. Cook Jonathan N. Grayer Bruce C. Ratner Craig B. Thompson, MD Stanley F. Druckenmiller John R. Gunn Clifton S. Robbins Lucy R. Waletzky, MD Michael P. Gutnick Avice A. Meehan Edwin Taliaferro Anthony B. Evnin Bette-Ann Gwathmey Alexander T. Robertson Douglas A. Warner III Executive Vice President and Senior Vice President and Vice President, Roger W. Ferguson, Jr. William B. Harrison, Jr. James D. Robinson III Peter Weinberg Chief Financial Officer Chief Communications Officer Internal Audit and Compliance and Steve Forbes Jane D. Hartley Virginia M. Rometty Jon Winkelried Chief Compliance Officer William E. Ford Benjamin W. Heineman, Jr. Benjamin M. Rosen Deborah C. Wright Jason Klein Richard K. Naum Richard N. Foster David H. Koch David M. Rubenstein Jeff Zucker Senior Vice President and Senior Vice President, Development Carolyn B. Levine, Esq. Stephen Friedman Marie-Josée Kravis Lewis A. Sanders Mortimer B. Zuckerman Chief Investment Officer Deputy General Counsel and Corporate Secretary

+ ex officio

Board of Overseers Emeriti Mrs. Elmer H. Bobst James W. Kinnear Jack Rudin Mrs. Arnold Schwartz Paul A. Marks, MD Peter O. Crisp Elizabeth J. McCormack, PhD Fayez S. Sarofim J. McLain Stewart President Emeritus Richard M. Furlaud

Board of Scientific Consultants Frederick R. Appelbaum, MD Titia de Lange, PhD Gregory Hannon, PhD James E. Rothman, PhD Richard Axel, MD James R. Downing, MD Caryn Lerman, PhD Gregory L. Verdine, PhD Philip A. Cole, MD, PhD Levi A. Garraway, MD, PhD Arthur Levinson, PhD Ralph Weissleder, MD, PhD Nancy E. Davidson, MD Maura Gillison, MD, PhD Sir Paul Nurse, FRS Irving L. Weissman, MD Joseph L. Goldstein, MD Stanley R. Riddell, MD

For a listing of the members of the professional staff of Memorial Hospital and the Sloan Kettering Institute, please visit www.mskcc.org/annualreport. Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 66 67

01 (Left) An exterior Facilities Update view of MSK Harrison; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences (right, top and bottom) Many interior Memorial Sloan Kettering Cancer Center spaces at MSK as of March 26, 2014 Harrison are flooded with natural light. 2014 Louis V. Gerstner, Jr. Craig B. Thompson, MD Memorial Sloan Kettering Chairman of the Board President continues to expand to Joan Massagué, PhD Kenneth J. Marians, PhD Linda D. Burnley meet the growing needs Provost Dean Associate Dean of its clinical and research

John R. Gunn Michael P. Gutnick Carolyn B. Levine, Esq. enterprises. Building new Treasurer Assistant Treasurer Secretary facilities and extending MSK’s reach ensures that we are able to bring our expert, Trustees Richard I. Beattie Jonathan N. Grayer Benjamin M. Rosen multidisciplinary cancer care Richard N. Foster David H. Koch Norman C. Selby to as many communities and Stephen Friedman Marie-Josée Kravis Craig B. Thompson, MD Ellen V. Futter Hutham S. Olayan Douglas A. Warner III patients as possible while 01 Louis V. Gerstner, Jr. simultaneously advancing our pioneering research Memorial Sloan Kettering’s new 60th Street In October 2014, Memorial Sloan Kettering programs. Outpatient Center at 16 East 60th Street, Harrison will join MSK’s growing network scheduled to open in September 2014, will of regional ambulatory care facilities, Sloan Kettering Division offer care from MSK experts in dermatology providing the multidisciplinary cancer Weill Cornell Graduate School of Medical Sciences (including Mohs surgery), general internal care of MSK clinicians to residents of medicine, geriatrics, head and neck surgery, Westchester and Fairfield Counties and as of March 26, 2014 interventional and general radiology, the Hudson Valley. Patients will have ophthalmic oncology, orthopaedics, plastic access to personalized medicine and and reconstructive surgery, male sexual leading-edge clinical trials all under one Joan Massagué, PhD Kenneth J. Marians, PhD health and reproduction, and presurgical roof. Among the services offered will be Director Director, Graduate Studies testing. The location will also provide medical oncology, radiation oncology, space for two innovative new clinics: a neuro-oncology, chemotherapy, diagnostic Graduate Program Co-Chairs Melanoma High-Risk Surveillance Clinic for and interventional radiology, surgical Nikola P. Pavletich, PhD Alan Hall, PhD Alexander Y. Rudensky, PhD patients with a personal or family history consultations, dermatology, social work, and Biochemistry and Cell and Developmental Immunology and Microbial of melanoma, and a multidisciplinary survivorship and other support services. Structural Biology Unit Biology Unit Pathogenesis Unit Advanced Skin Cancer Program for patients We will also offer a range of sophisticated Stewart Shuman, MD, PhD David A. Scheinberg, MD, PhD with nonmelanoma skin cancers who may imaging technologies, including MRI, Molecular Biology Unit Pharmacology Unit require specialized follow-up care. CT, PET scans, PET/CT, ultrasound, and mammography, as well as a robust radiation treatment planning system. Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 68 69

The Campaign for 01 02 (Left) The Josie Memorial Sloan Robertson Surgical Kettering’s 74th Memorial Sloan Kettering Center; (right, top Street complex will and bottom) the overlook the East interior spaces of the River and offer surgical center will be state-of-the-art serene and inviting cancer care. for patients and 2015 caregivers. 2018 Memorial Sloan Kettering benefited enormously from the generosity of thousands of donors who

made contributions large and Douglas A. Warner III Louis V. Gerstner, Jr. Craig B. Thompson small to the Campaign for Memorial Sloan Kettering.

01 02

The Memorial Sloan Kettering Josie to be ready to receive patients in Fall 2016. Playing a critically important role in MSK’s Campaign Co-Chairs Douglas A. The spirit of giving exhibited by MSK’s Robertson Surgery Center, made Located in Middletown, the clinical portion overall cancer care delivery system will Warner III, Chairman of MSK’s benefactors at all levels was also evident possible by a generous commitment from of the site will occupy approximately half be our new Memorial Sloan Kettering Boards of Overseers and Managers, in the increasing number of donors who the Robertson Foundation, is slated to the building and will offer comprehensive Ambulatory Care Center at 74th Street, and Louis V. Gerstner, Jr., Honorary made their gifts online. According to the be completed in 2015. This 16-story, ambulatory oncology services delivered by expected to be completed in 2018. Located Chair of the Boards, continued to Chronicle of Philanthropy’s annual report 179,000-square-foot building on York MSK clinicians. A portion of the remaining between East 73rd and 74th Streets along lead the historic Campaign, working on online giving, Memorial Sloan Kettering Avenue between East 61st and 62nd Streets space will house a new MSK data center, the FDR Drive, the property was purchased with their fellow Board members ranked first in online fund-raising will feature 12 operating rooms equipped providing a second active production site in by MSK from the New York Economic and President Craig B. Thompson among all hospitals, medical centers, and to provide technologically sophisticated New Jersey to enhance data security. Development Corporation in collaboration to share news about the Campaign’s universities. surgical care on an outpatient basis. The with Hunter College of The City University vital priorities to a wide group of Laboratory testing is particularly important Thousands of volunteers participated Robertson Foundation was established by of New York, and the two institutions are potential donors. in cancer treatment, and as MSK has grown, on behalf of MSK in a range of athletic investor Julian Robertson and his wife, the jointly developing it. The complex will so has our need for laboratory services. As of December 31, 2013, the Campaign fund-raising initiatives, spotlighting our late Josephine “Josie” Robertson, along house an MSK outpatient facility along with Last year more than 6.5 million lab tests had recorded a total of $3.128 billion lifesaving mission while raising vital funds with their family. Mrs. Robertson, who was Hunter College’s new Science and Health were performed by our Department of in gifts and pledges; it is now closing for research and patient care. elected to MSK’s Boards of Overseers and Professions building. Current plans for the Laboratory Medicine — more than double in on its $3.5 billion goal. Under the Managers in 2004, worked with her husband MSK portion of the site are to provide care Cycle for Survival, MSK’s indoor team the annual volume of just a decade ago. leadership of Anne M. McSweeney to support a range of causes in education, for patients with lung, head and neck, and cycling fund-raiser to benefit research A new Laboratory Medicine Building and Richard K. Naum, the MSK Office medical research, and other areas. hematologic cancers. The facility will also into rare cancers, drew nearly being constructed on East 64th Street will of Development had an especially include a state-of-the-art outpatient bone 17,000 participants and generated More than six percent of MSK’s patients consolidate all our laboratory medicine successful year, generating marrow transplantation program as well as a record $20 million for the cause. live in the Jersey Shore area — a region programs and allow us to meet our growing $382.1 million in gifts and pledges — sophisticated radiation oncology, diagnostic that will be served by our Memorial Sloan clinical demands. It is slated to be completed an all-time high for the institution imaging, and interventional radiolology. Kettering Monmouth facility, expected in the second quarter of 2017. by a wide margin. Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 70 71

Donors to the Campaign for Memorial Sloan Kettering

$100,000,000 or more The Donald B. and Catherine C. Marron Lewis A. Sanders The Estate of Geoffrey Beene Foundation Estate of Joseph J. Santry The Starr Foundation Mr. and Mrs. Milton Petrie Allan H. Selig Mortimer B. Zuckerman Laurance S. Rockefeller The Peter Jay Sharp Foundation Laurance S. Rockefeller Fund Mr. and Mrs. Richard Siegal Donna and Benjamin Rosen The Society Boutique — MSK Thrift Shop David M. Rubenstein Estate of Margaret McCormack Sokol $50,000,000 — $99,999,999 Robert F. X. Sillerman and Laura Baudo Stand Up To Cancer Mr. and Mrs. William H. Goodwin, Jr., Sillerman through their Tomorrow Swim Across America, Inc. and the Commonwealth Foundation Foundation The William and Lynda Steere Foundation for Cancer Research The Simons Foundation UBS David H. Koch The Society of MSK Special Projects Sue and Edgar Wachenheim III The Leonard and Evelyn Lauder Foundation Committee The Weinberg Family Foundations Stop & Shop Supermarket Company, Inc. Michael A. and Zena Wiener 01 02 Virginia and D. K. Ludwig Fund for Cancer Research Mr. and Mrs. Douglas A. Warner III Kathryn D. Wriston Robertson Foundation

03 04 $5,000,000 — $9,999,999 $2,500,000 — $4,999,999 $25,000,000 — $49,999,999 Anonymous Anonymous Together with Equinox, the event’s Fred’s Team brought together its largest 01 A Cycle for Survival The Atlantic Philanthropies Bristol-Myers Squibb Company Mr. and Mrs. Bruce Adam founding partner, Cycle for Survival is group ever — 877 members — to raise event in Bethesda, Mr. and Mrs. Jack Byrne The Carson Family Charitable Trust The Allbritton Foundation now the fastest-growing athletic fund- funds for MSK in the ING New York City Maryland Stanley F. and Fiona Druckenmiller The Steven A. and Alexandra M. Cohen Bethany Allen raising event in the country. It kicked Marathon. Fred’s Team members also The Louis V. Gerstner, Jr. Foundation, Inc. Estate of Eleanor Backer off the season in September 2013 with participated in the NYC Half-Marathon, Foundation, Inc. Trust of Richard J. Eisemann Band of Parents Foundation 02 The Sidney Kimmel Foundation Charlotte and Bill Ford III The Arthur & Rochelle Belfer Foundation outdoor events in Times Square and went Boston Marathon, and various other Evelyn Konrad and The Tow Foundation Mr. and Mrs. Frederic B. Garonzik Estate of Mary Ann Benjamin on to hold a total of 41 rides in 13 cities events of their choice, raising $4.4 million Mark Rubin, best all- Mr. and Mrs. Philip H. Geier, Jr. Estate of Lillian R. Berkman around athletes at the nationwide in February and March 2014. in contributions through their efforts. 2013 RBC Decathlon Estate of Sherlock Hibbs Mr. and Mrs. Melvin R. Berlin Family ICAP The James E. and Diane W. Burke The RBC Decathlon, which brings together As the Campaign for Memorial Sloan $20,000,000 — $24,999,999 The Robert J. Kleberg, Jr., and Foundation, Inc. members of the financial community Kettering advances toward its $3.5 billion Helen C. Kleberg Foundation Estate of Nizza Burstyn 03 Anonymous to compete in traditional track-and- goal, it will continue to rely on the Members of Fred’s The Breast Cancer Research Foundation Trust of L. H. P. Klotz Mrs. D. Wayne Calloway field events, is now in its third year. In generosity of donors whose dedication Team in Times Square Prostate Cancer Foundation John W. Kluge Iris and B. Gerald Cantor Foundation before the 2013 New The Society of MSK Trust of Evelyn Lauder The Kristen Ann Carr Fund combination with another new event, the and support make a crucial impact on York City Marathon The Lebensfeld Foundation Estate of Marion B. Carstairs Wall Street Mile race, the Decathlon raised every aspect of MSK’s mission in the fight Estate of Tse Kyung Lee James D. Carter approximately $1.4 million to benefit against cancer in all its forms. The Leon Lowenstein Foundation, Inc., and Estate of Franklin Chenenky research leading to new therapies for 04 $10,000,000 — $19,999,999 Robert and John Bendheim Pei-Yuan Chia and the Chia Family Rob Simmelkjaer, a pediatric cancers. Fred’s Team member, Anonymous Martin S. and Sheila Major and Family Foundation running the New York Trust of Burton Abrams Melanoma Research Alliance The Irma L. and Abram S. Croll City Marathon The Elmer and Mamdouha Bobst Estate of Samuel U. Mitchell Charitable Trust Foundation Jamie Nicholls and Fran Biondi The Doris Duke Charitable Foundation Mr. and Mrs. Raymond T. Dalio Charitable Trust The Mitzi and Warren Eisenberg The Stephen and Barbara Friedman The Robert and Kate Niehaus Foundation Foundation/The Susan and Foundation Peserga International Foundation Leonard Feinstein Foundation Alan and Sandra Gerry Frederick Henry Prince Memorial Fund Anthony B. and Judith W. Evnin The Arnold and Arlene Goldstein Family Mr. and Mrs. John S. Reed Estate of Elizabeth M. Frelinghuysen Foundation Dorothy Rose and Dr. Milton Rose Estate of Jeanette R. Fulham Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 72 Transformations 73

Donors to the Campaign for Memorial Sloan Kettering

Estate of Francis Gonzalez The Thompson Family Foundation Mr. and Mrs. Peter O. Crisp The Gordon Fund Margaux’s Miracle Foundation Mr. and Mrs. Herbert J. Siegel Mr. and Mrs. Jonathan N. Grayer Estate of Richmond E. Thompson Cure Breast Cancer Foundation, Inc. Trust of Jane H. Gordon Mrs. Joseph L. Martino M. Steven and S. David Silbermann Lita Annenberg Hazen Charitable Trust Trust of Jane Toplitt Estate of Helen M. Curry Grass Family Foundation The G. Harold & Leila Mathers Foundation The Rosanne H. Silbermann Foundation William Randolph Hearst Foundations TOSA Foundation Trust of Margaret E. Dahm The Marion and Louis Grossman Mrs. William L. Matheson Mary Ann and Arthur M. Siskind through Estate of Irma A. Howard Dennis D. Dammerman Foundation Merrill Lynch & Co.Foundation, Inc. the Siskind Family Sarcoma Fund W. M. Keck Foundation The Dana Foundation Mr. and Mrs. Robert Grossman Fred and Marie-Noelle Meyer The Skirball Foundation Estate of Martin C. Kessler Trust of Myra Davis Trust of Helen Guerin Estate of Wilma S. Mills Trust of William Kirkland Smith F. M. Kirby Foundation, Inc. $1,000,000 — $2,499,999 Estate of Charles E. Dillman Hackers for Hope Estate of Robert C. Mitchell Trust of Emily V. Smyth Susan G. Komen for the Cure Allen & Company, Inc. Gloria DiPietro-Cooper Mr. and Mrs. James J. Hagan Trust of Douglas C. Mohl Trust of Clemance and Edwin Snyder Henry and Marie-Josée Kravis Mr. and Mrs. Andrew B. Abramson Trust of Nancy K. Dunn Estate of Joseph M. Hand The Ambrose Monell Foundation Ira Sohn Conference Foundation, Inc. Myra Nelson Larrison Mr. and Mrs. Frederick R. Adler The Ellison Medical Foundation Mr. and Mrs. John J. Hannan Estate of Warren A. Montel Susan and Peter Solomon Family LIVESTRONG Foundation Alex’s Lemonade Stand Entertainment Industry Foundation Estate of Margaret H. Hanson Morgan Stanley Foundation The Lustgarten Foundation for Mr. and Mrs. Fred M. Alger III Estate of Selma Ettenberg Stephen P. Hanson The William T. Morris Foundation The Sontag Foundation Pancreatic Research Alliance for Cancer Gene Therapy The Eunice Foundation Jamie and Jeffrey Harris Trust of Anna V. Muller Sportsmen for Charity The Lymphoma Foundation Stephen and Madeline Anbinder Estate of Harry Fagen The Heckscher Foundation for Children Mushett Family Foundation, Inc. St. Baldrick’s Foundation Trust of Philip R. Mallory John M. Angelo and Judy Hart Angelo Farmer Family Foundation Mr. and Mrs. Benjamin W. Heineman, Jr. Trust of Saul Nathonsohn John R. & Inge P. Stafford Foundation Trust of Estelle A. Manning Anonymous Trust of Harold Farrington Marie B. Hilliard Nonna’s Garden Foundation Estate of Stanley R. Stones The T. J. Martell Foundation for Leukemia, Estate of Roone P. Arledge The John K. Figge Family The Charles and Marjorie Holloway The Olayan Group Mr. and Mrs. David K. Storrs Cancer and AIDS Research The Award of Courage Corporation Estate of Barbara D. Finberg Foundation, Inc. Pediatric Cancer Foundation The Margaret Dorrance Strawbridge Estate of Charles J. Mauro Roger and Lori Bahnik The Jerome and Anne C. Fisher Estate of Harriet Huber Estate of Frederick Pelda Foundation of PA The Abby R. Mauzé Charitable Trust The Batishwa Fellowship Charitable Foundation William Lawrence & Blanche Hughes John and Francie Pepper The Sussman Family Fund Florence Miner Trust of Edgar D. Baumgartner Flight Attendant Medical Research Institute Foundation Trust of Elizabeth L. Perkins Trust of M. Allen Swift Gloria Miner Mr. and Mrs. Daniel C. Benton The Stephanie and Lawrence Flinn, Jr. Estate of Doris Hutchison Perry Capital LLC Tarnopol Family Foundation The Naddisy Foundation Allen and Joan Bildner Charitable Trust Leslie Hutchison and Virginia Shaw Estate of Jeanne Poli Terry Fox Run for Cancer Research (NYC) The New York Community Trust The Anita and Leonard Boxer Family Estate of Harry N. Forman IBM Corporation Laura and Christopher A. Pucillo Trust of Irving Tirkfield The Samuel I. Newhouse Foundation Foundation Lorraine Friedman Inspire 2 Live Foundation Sara and Iser Rabinovitz Estate of Lillian Tomek Stavros S. Niarchos Foundation Breast Cancer Alliance, Inc. Trust of Oscar H. Friedman Trust of Harry C. Jaecker, Jr. Mrs. Katharine J. Rayner The Beth C. Tortolani Foundation Ronald O. Perelman Mr. and Mrs. Viatcheslav I. Brecht Friezo Family Foundation The Jewish Communal Fund Charles H. Revson Foundation Anthony and Carole Trapani Estate of Catherine R. Price The Andrea and Charles Bronfman Fund for Ophthalmic Knowledge Estate of Clarence W. Johnson RJR Oncodermatology Fund The Trump Group Bruce C. Ratner Philanthropies, Inc. Estate of Frank H. Gabriel Estate of Wilda Johnson Estate of Edith Roberts Mr. and Mrs. Thomas Tuttle RBC Decathlon Estate of Helen Brown Gabrielle’s Angel Foundation Trust of Marion Kahn Estate of Josephine T. Robertson Universal Network Television The Robbins Family Foundation Trust of Emil A. Buelens Sara Gadd Estate of Mary B. Ketcham Estate of Anne Morales Rodgers The V Foundation for Cancer Research The Jim and Linda Robinson Foundation Estate of Diane B. Burkhart Estate of Thomas Gardiner Kids Walk for Kids with Cancer Mary Jo and Brian Rogers Trust of Virginia and Edward Van Dalson Jack Rudin The Burnett Foundation Trust of Virginia L. Garrison Estate of John W. Knox The Felix and Elizabeth Rohatyn John L. Vogelstein The Louis & Rachel Rudin Foundation Cancer Research Institute Trust of Florence K. Geffen Mr. and Mrs. Matania Kochavi Foundation Trust of Edward W. Vollintine The May & Samuel Rudin Family Robert B. Catell The Lawrence M. Gelb Foundation, Inc. Estate of Rosemarie Krulish The Laura Rosenberg Foundation, Inc. Lucy R. Waletzky, MD Foundation John and Michael Chandris Richard L. Gelb The Thomas G. Labrecque Foundation Estate of Lillian E. Rosenmerkel Joan and Sanford I. Weill Damon Runyon Cancer Research The Laura Chang and Arnold Chavkin Genentech Trust of Grace Fay Lamb Juliet Rosenthal Foundation, Inc. Louis and Jane Weinstock Foundation Charitable Fund General Electric Company Philippe Laub The Peter M. Sacerdote Foundation The Lillian S. Wells Foundation, Inc. Estate of Marilyn L. Schaefer Trust of Charles P. Ciaffone Eileen Genet Fund for Ovarian Cancer Estate of Wilhelmina LeJeune Lewis A. Sanders Mr. and Mrs. Clay T. Whitehead Estate of Grace A. Shapro Trust of George Clegg Research and Prevention Estate of Ada Leventhal Fayez Sarofim & Co. Estate of Carolyn H. Wilson Mr. and Mrs. H. Virgil Sherrill Simon & Eve Colin Foundation, Inc. Trust of Josephine A. Gilmore Estate of Harold F. Levinson Estate of Margaret W. Schafer Winterburn Foundation The Joachim Silbermann Family The Comer Science and Education Estate of Thelma Gish Leon Levy Foundation Estate of Catherine M. Schooley Diana S. Wister Paul E. Singer Foundation GIST Cancer Awareness Foundation The LisaBeth Foundation The Beatrice & Samuel A. Seaver Foundation The Meryl and Charles Witmer Charitable Joan and Joel Smilow The Connecticut Sports Foundation GIST Cancer Research Fund The Litwin Foundation Mr. and Mrs. Norman C. Selby Foundation George Strawbridge, Jr. Ian and Patricia Cook Estate of Anna H. Gleason Robert S. Ludwig and Gwenyth E. Rankin Dr. David E. and Beth Kobliner Shaw The Wolfensohn Family Foundation Mr. and Mrs. Scott Stuart Trust of James J. Corbalis, Jr. Miriam and Alan Goldberg Lymphoma Research Foundation Trust of Henry H. Shepard Mr. and Mrs. Robert Wright The Joseph and Arlene Taub Foundation Trust of Caroline S. Coulton Goldman Sachs & Company Mr. and Mrs. J. Randall MacDonald Mr. and Mrs. Stephen C. Sherrill Zev’s Fund Inc. Margaretta J. Taylor Countess Moira Foundation Golfers Against Cancer Foundation Mr. and Mrs. Joel Mallah Alfred J. and Stephanie Shuman through Ziff Brothers Investment, LLC The Maloris Foundation the Windmill Lane Foundation Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 74 Transformations 75

Donors to the Campaign for Memorial Sloan Kettering

$500,000 — $999,999 Constant Convocation Center The Horace W. Goldsmith Foundation Trust of Anthony J. Masard The Raymond & Beverly Sackler Fund for $250,000 — $499,999 Estate of Marguerite Abrams Cookies for Kids’ Cancer Alfred G. & Hope P. Goldstein Fund Max Cure Foundation the Arts and Sciences Trust of George Aaron The Rita Allen Foundation The Elaine Terner Cooper Foundation Estate of Helen M. Golen Mr. and Mrs. Louis V. Mazzella Dr. Nathan E. Saint-Amand Accelerate Brain Cancer Cure (ABC2) American Brain Tumor Association Trust of Faye Copeland Mr. and Mrs. Alan I. Greene Trust of John C. McCormick Estate of George W. Schneider III Foundation The American Italian Cancer Foundation Estate of Leonard Corso Trust of Richard M. Greifer The James S. McDonnell Foundation Estate of Alana M. Schuster Estate of John D. Adams, Jr. American Skin Association Sharon Levine Corzine Peter M. Guggenheimer Estate of Donald G. McKeon The Seraph Foundation The Louis & Bessie Adler Foundation Anonymous Chandler Cox Foundation The Marc Haas Foundation Estate of Ralph Melson The Shen Family Foundation The Alliance Against ASPS Foundation Roland Arthur Estate of Helen M. Cramer Mr. and Mrs. William W. Haerther, Jr. Estate of Ruth Vitow Messias Trust of William and Isabelle Sherlock Trust of Eileen Alpert Aventis Pharmaceuticals, Inc. CureSearch for Children’s Cancer Estate of Ethel V. Haldeman Trust of Russell A. Meyer Evelyn R. Simmers Charitable Trust Alzheimer’s Association Mr. and Mrs. Robert C. Baker Family John and Georgia DallePezze Evelyn A. J. Hall Charitable Trust J. P. Morgan Chase Trust of Barbara K. Snader American Health Assistance Foundation Foundation Mr. and Mrs. Marvin H. Davidson Mr. and Mrs. Stephen L. Hammerman The Norman M. Morris Foundation The Society of MSK Associates The American Ireland Fund Estate of Eileen W. Bamberger Davis Charitable Foundation Estate of Olga V. Hargis Trust of Paula Moss Committee The Ametek Foundation, Inc. Trust of Barbara G. Bargar Estate of Sandra Newman Dawson Mr. and Mrs. William B. Harrison, Jr. Mr. and Mrs. Charles H. Mott Estate of Katherine R. Sonneman Dorothy A. Anderson Estate of Doris A. Baumann The Thompson Dean Family Foundation Estate of Judith B. Helfant Muscular Dystrophy Association Spin4Survival Anonymous Richard I. Beattie Estate of Carol T. Decker Estate of Ruth H. Hewlett The National Brain Tumor Society Estate of Helen E. Steadman Estate of Anita S. Appel The Arnold and Mabel Beckman Foundation The DeGroot Family Foundation Marie B. Hilliard National Childhood Cancer Foundation Bonnie and Steven E. Stern Mr. and Mrs. Frank W. Appleton, Jr. Trust of William T. Benitt Annette and Oscar de la Renta Trust of Benjamin Holmes Carole and Raymond Neag The Mel Stottlemyre Myeloma Foundation Arms Wide Open Childhood Cancer The Besen Family Deutsche Bank Securities Inc. Trust of Karla Homburger News Corporation Mr. and Mrs. Paul A. Street Foundation The Bie Family Foundation Trust of James Douglas The Patricia M. Hynes and Roy L. Reardon The New York Yankees Foundation Trust of James Strobridge Joyce Ashley Estate of Dan Biele The Walter S. and Lucienne B. Driskill Foundation Occidental Petroleum Corporation Mrs. Laure Sudreau-Rippe Estate of Rose Ashton-Irvine Jane and Bill Bird Foundation Deanne and Arthur Indursky Trust of Melba M. O’Connell The Michael Sweig Foundation Avon Foundation Trust of Susan E. Black Estate of Louis Duenweg Invest for Children, a Foundation of The Sylvan and Ann Oestreicher Foundation Ping Y. Tai Foundation Estate of William C. Bahn, Jr. Betty, James, and Thomas Blake Trust of Phyllis K. Dunn Investindustrial Trust of Jo Anne H. Olmsted The Craig D. Tifford Foundation, Inc. The Banbury Fund (The Thomas Blake, Sr. Memorial Fund) The Emerald Foundation Mrs. H. Anthony Ittelson E. Stanley O’Neal Barbara Davies Troisi Foundation Estate of Florence Barrack The Blue Dot Foundation Mr. and Mrs. David Epstein The Rona Jaffe Foundation Estate of Beatrice P. K. Palestin Estate of Stanley F. Tucker Estate of Marcia Batten Trust of Ethelvida Boehme Arthur Falcone Johnson & Johnson Elsa U. Pardee Foundation Tudor Investment Corporation Betsy L. Battle Estate of William Boehme Estate of Katie Fasal Estate of Horace A. Jones The Perelman Family Foundation Daniel P. and Grace I. Tully Foundation Trust of Gertrude E. Beck Mr. and Mrs. David Boies Estate of Beatrice Feinstein Fritz and Adelaide Kauffmann Foundation The Perkin Fund Turner Construction Company Estate of Grace Becker Estate of Marcel S. Bollag The Fibrolamellar Cancer Foundation Kinetics Foundation Estate of Philip W. Pfeifer Twenty-First Century Fox, Inc. Estate of Ethel A. Bell Trust of Frederick W. Bonacker, Jr. Estate of Alice H. Ficht Estate of Joan E. Kinley Pfizer Inc. United Way of Tri-State Trust of Virginia Poole Benjamin The Bondi Foundation Trust of Alice D. Fiedler Estate of Hazel V. Knapp Estate of Lucie Picard Uniting Against Lung Cancer Corinne Berezuk and Michael Stieber Estate of Adele Bozio Trust of Marie Finch Estate of Ruth Koch Estate of Marion M. Pincus Trust of Ward M. Vanderpool Estate of Irma Berg Trust of Nancy J. Bradford Estate of Susan L. Fischer The Koodish Family Charitable Trust Josephine K. Poling Vanguard Charitable Endowment Fund Bergstein Family Foundation Mr. and Mrs. Peter Bren The Michael J. Fox Foundation The Kronthal Family Mr. Bernard Posner Variety – The Children’s Charity Estate of Gertrude G. Bernstein Terri Brodeur Breast Cancer Foundation Trust of Ira S. French The Jacob & Valeria Langeloth Foundation Margot Rosenberg Pulitzer Foundation Richard C. Vergobbi The Lisa E. Bilotti Foundation Trust of Dorothy Fielder Brown Trust of Dr. Benjamin T. Friedman Trust of Charles T. Larus Mrs. Jenice Pulver Estate of Christine Villano The Nancy and Robert S. Blank Foundation Mrs. Edwin M. Burke Trust of Edith West Friedmann Lazard Capital Markets PVH Corp. The Warner Foundation, Inc. Trust of Ronald M. Blau Hilary and Joseph A. Califano, Jr. Estate of Maud Gallagher The Lerner Foundation The Mitchell P. Rales Family Foundation Estate of Ingeborg K. Watson Estate of Ida Bloom The Cancer Research Foundation The Gateway for Cancer Research Estate of Anne Leventon John Bradbury Reed Trust of Thomas J. Watson, Jr. Albert and Betty Bodian of America Estate of Joseph G. Gaumont Dr. Nancy Alpern Levin Trust of Irene Dorothy Reel Trust of Bessie Weintraub Estate of Marthe Bonneau The Richard E. Capri Foundation on Estate of Selma Geller Life Raft Group Estate of Muriel G. Reich Estate of Ruth C. Weismann Trust of Lillian Borchardt behalf of the Wolf Family Joe Gellert Trust of Martin C. and Margaret V. Lohsen Estate of Agnes Rezler Mr. and Mrs. Harold S. Wertheimer The Louis L. Borick Foundation Estate of Richard B. Carman Estate of Lillian B. George Trust of Louis J. Lombardi Estate of Richard A. Riecker Trust of Reamer W. Wigle The Albert C. Bostwick Foundation The Tina and Richard V. Carolan The Gerber Foundation Harry J. Lloyd Charitable Trust Drs. Helena and David Rodbard Trust of Richard A. Yudkin Mr. and Mrs. Kevin A. Bousquette Foundation The Aaron and Betty Gilman Family Mr. and Mrs. Edward Lundy Alexander J. Roepers Estate of Anna M. Zavatt Trust of Alice M. Branch James & Patricia Cayne Charitable Trust Foundation Estate of Evelyn P. Lyon Shafi Roepers Ronald Zung The Braver Foundation The Y. C. Ho/Helen and Michael Chiang Estate of William J. Glasgow Earle I. Mack Foundation Trust of William C. Rogers Bridgemill Foundation Foundation Estate of Robert E. Gleason Estate of Lucille Knowles Freedman Mann Juliet Rosenthal Foundation Estate of Paul P. Brieloff Trust of Betty R. Ciaffone Mr. and Mrs. Robert S. Goldberg The Lois H. Mann Charitable Foundation Mr. and Mrs. Stephen J. Rosenthal Citigroup The Joyce & Irving Goldman Family March of Dimes Foundation The Arthur Ross Foundation, Inc. Estate of Harry J. Colish Foundation Estate of Anne Markowitz Trust of Edward G. Ryder Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 76 Transformations 77

Donors to the Campaign for Memorial Sloan Kettering

Bright Focus Eli Lilly & Co. Estate of Eldridge A. Greenlee Pamela and Dwaine Kimmet Estate of Harry H. Maus Robert Pufahl Estate of Madalyn B. Bryant Rita H. Schaefer Elliott Grinberg Family Foundation Trust of Estelle Knapp The Mayday Fund Purdue Pharma LP The Bugas Fund Empire Blue Cross & Blue Shield Virginia and Howard Groombridge Trust of Paul and Fran Knight MBNA America Bank Patricia A. Quick Charitable Trust Tory Burch The Charles Engelhard Foundation Mr. and Mrs. Martin D. Gross Joel Koschitzky The MBNA Education Foundation Trust of Harriet C. Rath Estate of Marian Butler Mr. and Mrs. Israel Englander Trust of William Gross The Gwen L. Kosinski Foundation Mary Jane McCarthy James N. Rentas 5K Run/Walk Cancer Support Services, Inc. Trust of June K. Evans Shoshanna and Josh Gruss Mr. and Mrs. Marvin H. Koslow The Michael W. McCarthy Foundation Trust of Anne Ressner The Paul Robert Carey Foundation Trust of Lillian Evans Robert C. Halboth The Fred W. Kramer Charitable Trust Mr. and Mrs. Thomas R. McCullough Estate of Walter E. Rex III Mr. and Mrs. Kenneth Carmel Lord Evans of Watford Mrs. Melville W. Hall Cheryl Gordon Krongard Mr. and Mrs. Jay H. McDowell The Rice Family Foundation Mr. and Mrs. Michael Carr Trust of Sarah W. Ewing Trust of Florence M. Hammer Trust of Walter C. Kronke Estate of Charles McGreevy Louise & Frank Ring Estate of Georgia M. Catrini Mr. and Mrs. Barton Faber Mr. and Mrs. Jose Kuri Harfush Estate of Harriette H. Kussin Mr. and Mrs. Thomas E. McInerney Irene Ritter Foundation Trust of Ruth C. Celarek Estate of Giuliana Fantini Gladys and Roland Harriman Foundation Estate of Sidney Lacher Estate of Alan McMaster The Andréa Rizzo Dance Therapy Fund Estate of Burdette G. Chamberlin Trust of Mary E. Farrell Susanne and Shelley Harrison The Lakeside Foundation MeadWestvaco Corporation Trust of Lillian Robbins Joan Chorney Estate of Ralph R. Feigelson Mr. and Mrs. Robert L. Harteveldt Mr. and Mrs. Joseph M. La Motta The Merck Company Foundation Mr. and Mrs. Stephen Robert Florence Chu, MD The Feinstein Family Foundation Trust of Abraham Hases Estate of Harriet L. Lampert The Reuven Merker Charitable Foundation, Robin Hood Foundation CIBC World Markets Corporation Paul Felzen Estate of Katherine Hawrylow Vivian F. Laube Inc. Estate of Sandra Sheppard Rodgers The Clark Foundation Hilary Carla Feshbach Estate of Irma Hayes Lavelle Fund for the Blind, Inc. Mesothelioma Applied Research Fund Estate of Nathan Rothstein Estate of Dorothy L. Cobb Mrs. Frederick Fialkow Hecht & Company Philanthropic Betty Reid Lawson Estate of Despina Messinesi Estate of Wilhelmina T. Rouget Trust of Joan F. Cobb Estate of Selma Fine Foundation The Iris and Junming Le Foundation Peter Michael Foundation Trust of Cecile N. Ruben Frances B. Cohen The Grace J. Fippinger Foundation, Inc. Mr. and Mrs. Charles Heimbold, Jr. Lead Annuity Trust Trust of Russell H. Michel The Selma and Lawrence Ruben Foundation Mr. and Mrs. John K. Colgate, Jr. First Quality Enterprises, Inc. Cherie Henderson and David Poppe Trust of Joseph Lebednik The Milbank Foundation for Rehabilitation Mrs. Orhan I. Sadik-Khan The Julien Collot Foundation, Inc. Jeanne Donovan Fisher Trust of Richard V. Henry, Jr. The Richard S. and Karen LeFrak Charitable Jim and Mary Jane Milton Mrs. Edmond J. Safra The Community Foundation for Northern The Jodi Spiegel Fisher Cancer Foundation Heyman-Merrin Family Foundation Foundation Mrs. Minot K. Milliken Moise Safra Family Virginia – Hanlon Family Fund Aaron I. Fleischman Foundation Brian J. Higgins In memory of Stacey Leondis Estate of Dorothea K. Money Mr. and Mrs. Herbert E. Saks Estate of Robert I. Conley The Floren Family Foundation The Catie Hoch Foundation Estate of Donald LeRoy Young Ae Lim and Joonsikk Moon Mara and Ricky Sandler Estate of Lillian Copperman Fondazione Italiana Estate of Laverne Hodges Leukemia Research Foundation Trust of Anny S. Moore Trust of Erika Saphier Carlos A. Cordeiro Foundation For the Love of Life Estate of Martha Holloway Mr. and Mrs. Allan L. Levey Ronald and Brenda Morey Sarcoma Foundation of America Estate of Leonard Cossack Trust of William Forbes Hope Funds for Cancer Research Fran and Ralph Levine Trust of Edmund L. Murray Trust of Paul C. Sawyer The Cowles Charitable Trust Foundation 14 Mr. and Mrs. D. Gregory Horrigan Trust of Leona Levy Trust of Louise F. Neely Trust of Edwin & Grace Sayers Estate of Mary O. Craft The Evan Frankel Foundation Estate of Chester S. Howard The Anne Boyd Lichtenstein Foundation Craig H. Neilsen Foundation Estate of Christine C. Scanlan Estate of Edna W. Curl Mr. and Mrs. Lewis Frankfort Estate of Karen L. Hudson Estate of Helen Lieber Estate of Ann M. Nelson Trusts of Anabel M. Scarborough and Walter Filomen M. D’Agostino Foundation Corp. Trust of Jill and Jayne Franklin The Howard Hughes Medical Institute Estate of John E. Liebmann Muriel Neumann L. Scarborough Mr. and Mrs. Rafic Dahan The Edna R. Fredel Charitable Lead Annuity Edith M. Hunter Pauline H. Lin The Newport Foundation The Milton Schamach Foundation, Inc. Estate of Thomas R. Daly Trust Syde Hurdus Foundation, Inc. Estate of Leah W. Linn Estate of Jane M. Nicholson Mr. and Mrs. Stephen Scherr Trust of DeWitt S. Davidson Estate of Frank O. Fredericks IBM International Foundation Live4Life Foundation James G. Niven Trust of Jennie C. Schneider Trust of Richard L. Davies The Fribourg Foundation Mr. and Mrs. Thomas C. Israel Estate of Marian J. Looser The Okonite Company Mrs. Silvia A. Schnur The Arthur Vining Davis Foundations Estate of Gerard M. Friedman Bruce H. Jacobs Lung Cancer Research Foundation Grace Oughton Cancer Foundation Estate of Evelyn Schrank Estate of Frederick W. Davis The Anna Fuller Fund Trust of Clyde H. Jacobs Estate of Julian Malkiel The Ovarian Cancer Research Fund Trust of Crystal Schull Estate of Leonard Davis Estate of Leonard Galasso Harry A. Jacobs, Jr. Manhasset Women’s Coalition Against Eileen and James A. Paduano Estate of Bertha Schulman Trust of Marion E. Dean Estate of Regina M. Gallichio Janssen Pharmaceutical Products LP Breast Cancer Parfums de Coeur Ltd. The Schultz Foundation Deborah A. DeCotis Estate of Norman D. Galloway Estate of Mira Jelin Estate of Albert Manning PepsiCo Foundation, Inc. Searle Scholars Program Trust of Carolyn B. Denney Mr. and Mrs. Robert M. Gardiner The JMB Hope Foundation Estate of Marvin Margolies Estate of Ann Perkins The Select Equity Group Foundation Hester Diamond Foundation Trust of Esther B. Garnsey The Robert Wood Johnson Foundation Mrs. John L. Marion Estate of Claude E. Petruzzi The Nina and Ivan Selin Family Foundation The Dickson Foundation Trust of Frances L. Gatterdam Estate of Al Jolson Trust of Sarah H. Marks Pin Down Bladder Cancer Estate of Sam Seltzer Estate of Evelyn Z. Diehl Estate of Mildred B. Gehrke Estate of Robert L. Jones The Marmot Foundation Mr. and Mrs. Jeroen Henk L. Pit Mr. Frank Senior The DiMenna Foundation, Inc. Leonardo Giambrone Max Kade Foundation, Inc. Estate of Edith Lipphardt Martens Jean D. Pitcher Seventh District Association, Inc. Elizabeth R. Miller and James G. Dinan and The Albert and Pearl Ginsberg Foundation Katzman Family Foundation Estate of Elizabeth Martin Plastic Surgery Foundation Estate of Gladys N. Severud The Dinan Family Foundation Liane Ginsberg Mr. and Mrs. Robert B. Kay Trust of Richard and Betty Martin Polo Ralph Lauren Corporation The Shanken Family Foundation Elizabeth K. Dollard Charitable Trust The Glades Foundation Estate of Helen Keena Estate of Ann L. Martinez Estate of Elizabeth Polotaye Estate of Odette Sharow William C. Dowling, Jr. Foundation Corinne and Daniel Goldman Trust of Fenton O. Keister The Lucille and Paul Maslin Foundation Trust of Helen M. Price Trust of Minnie M. Shaw The Eberstadt-Kuffner Fund Inc. Susan Wallack Goldstein Robert J. Keller Trust of Cecelia Matarazzo Estate of Seymour Price Hope Sheridan Foundation Mr. and Mrs. Thomas J. Edelman Estate of Barbara Grace The John R. Kennedy Foundation Estate of Michael Matchen Project A.L.S. Nancy Shevell Mr. and Mrs. Barclay Ehrler Granary Associates Estate of Ursula A. Kildea Prudential Financial, Inc. Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 78 Transformations 79

Donors to the Campaign for Memorial Sloan Kettering

Renee and Irwin Shishko United Hospital Fund of New York Mr. and Mrs. Robert I. Alpern Estate of Robert D. Bennett Elizabeth Bucher William Joseph Ciliberti Estate of Lillian M. Siemionko United Leukemia Fund Inc. The Amaturo Foundation, Inc. Corinne Berezuk and Michael Stieber The Peter & Carmen Lucia Buck Foundation Judith Ann Cion Revocable Trust The Grace, George, and Judith Silverburgh United Way of New York City American Federation for Aging Research Trust of Isidore Bergner Janna Bullock Estate of Piera Circiello Foundation The Lucy & Eleanor S. Upton Charitable (AFAR) Mr. Bernard S. Berkowitz Trust of Florence Bunn Amanda Styles Cirelli Foundation for Trust of Leonard & Ruth Silverman Foundation Amgen, Inc. Joan and James Berkowitz Fund Mr. and Mrs. Franz H. Burda Pediatric Cancer Research Leonard and Donna Simon The Vasey Foundation Estate of Maurice Amzalak Estate of Tony P. Bernabich Estate of Edith R. Burger The Anne L. and George H. Clapp Trust Trust of Angie S. Skinner Vital Projects Fund, Inc. Mr. and Mrs. Harold F. Anderson The Bill Bernbach Foundation Mrs. Coleman P. Burke Estate of Lyman W. Clardy The Gordon H. and Norma Smith Family Estate of Eleanor B. Vogel Richard and Peggy Anderson Steffi and Robert Berne Estate of Louise V. Burnett Cleveland Clinic Health System Foundation Walk the Walk America, Inc. Warren and Lillian Anderson Mrs. Louis Bernstein Janet Burros Memorial Foundation CLL Global Research Foundation Estate of Robert A. Smith Estate of Muriel F. Wall Anonymous Estate of Margaret L. Bingman Mr. and Mrs. Harold Busch The Coca-Cola Company Estate of Roberta A. Smith Douglas Walker Mr. and Mrs. Jerome V. Ansel Biomet Estate of John D. Bush Mr. and Mrs. Laurence W. Cohen Estate of William E. Snee The Washington Post Company Anthony Brands Trust of C. June Bisplinghoff Mr. and Mrs. Jonathan J. Bush Mr. and Mrs. Charles Payson Coleman III Ms. Beryl Snyder The Wasily Family Foundation Estate of Mark J. Anton BJ’s Charitable Foundation The Paul Nabil Bustany Foundation Clarence L. Coleman Jr. and Lillian S. Society of Interventional Radiology The Bert & Sandra Wasserman Foundation The Antonacci Family Foundation The Blackstone Charitable Foundation Gilbert and Ildiko Butler Family Coleman Foundation Foundation Marla J. Wasserman Mr. and Mrs. Rand V. Araskog Trust of Raymond Blake Foundation, Inc. James J. Coleman, Jr. Society of New York Workers’ Compensation The Scott Weingard Memorial Fund Mr. and Mrs. William J. Armfield IV Blaker Family Fund Estate of Ruth J. Butterworth Paul Jackson Coleman Bar Association Mr. and Mrs. Boaz Weinstein Kym S. Arnone Bill Blass Licensing Company, Inc. Estate of Lillian A. Byman Estate of Gertrude T. Coles Roy M. Spear Foundation Estate of Elias Weiss The Aronson Family Foundation Madeline and Alan S. Blinder Mr. and Mrs. Bruce L. Calhoun Robert and Maryann Collin The Seth Sprague Educational and In memory of Marie T. Weiss Paul Armin Family Foundation Ambassador and Mrs. Alan J. Blinken Trust of Marilyn Campbell Arthur R. Collins Charitable Foundation John A. Weissenbach and Ann Southworth Mary Kay Ash Charitable Foundation Mr. and Mrs. James A. Block Cancer Research & Treatment Fund Estate of Lila V. Collins Trust of James L. Stackhouse Effie Wells-Lonning The David R. and Patricia D. Atkinson Estate of Vivian K. Blonder Leah Rush Cann Terry Collins The Robert Steel Foundation for Pediatric Trust of Ida Wharton Foundation The Walter & Adi Blum Foundation, Inc. James A. Cannon The Colon Cancer Foundation Cancer Research Whitehall Foundation The Isaac and Carol Auerbach Family Trust of Eli Blumenfeld Estate of Edward A. Cantor Mr. and Mrs. Alexius Conroy Trust of Frederick T. Steinberg John C. Whitehead Foundation Harold and Adele Blumenkrantz Caring for Carcinoid Foundation Consolidated Edison Company of New York The Jeffrey Steiner Family Foundation Estate of Ruth Whitfield Autism Speaks Estate of Simon P. Blustone Mr. and Mrs. Edmund M. Carpenter Dudley P. Cook Mr. and Mrs. Howard Stern The Helen Hay Whitney Foundation Aviesan French National Bruce Bocina Mr. and Mrs. Warren E. Carpenter III Mr. and Mrs. Errol M. Cook Trust of Charles M. Stevenson Mr. and Mrs. Frank C. Whittelsey III B*Cured Estate of Marti A. Boden Estate of William K. Carson Mrs. William B. Cook Estate of Sonia Stolin-Moresco The Jesse R. Wike Charitable Trust Trust of Maureen E. Bacchi Estate of Marjorie R. Boselly Mr. and Mrs. William M. Carson Cooley’s Anemia Foundation The Daniel P. Sullivan Clinical Fellowship The David and Ellen Williams Foundation Dr. Joseph J. Bailey Alan F. Bovee Estate of Colon B. Carter Mr. and Mrs. E. Gerald Cooper Fund Kendrick R. Wilson III Elliot A. Baines William R. Boyle Trust of Winifred T. Carter Estate Of Morris Coppersmith Timothy P. Sullivan Charitable Lead Trust Wooden Nickel Foundation The Baird Family Fund Estate of Mary C. Brabson Estate of Elsie Cartotto Estate of G. R. Couch The Greater New York City Affiliate of Susan Trust of Vincent J. Zappolo Gail L. Baird Family Foundation Estate of Elsie L. Bradford Joan (Perkowski) Cashin Foundation Frederic R. Coudert Foundation G. Komen for the Cure Estate of Robert E. Ziegler David M. and Barbara Baldwin Foundation Brahman Capital Casual Male Corp. Courtesy Associates, Inc. The Paula Takacs Foundation for Sarcoma Nicholas B. Zoullas Inc. Brain Tumor Funders’ Collaborative The Cayuga Foundation Estate of Edith C. Cox Research Ariela and Mendel Balk Anna M. and Mark R. Brann Estate of Charlotte A. Celian Trust of Franklin C. Craig J. T. Tai & Co. Foundation Estate of David B. Ballard Mr. and Mrs. Henry R. Breck Trust of George F. Chagnot W Michael and Lois Craig James R. Tanenbaum and Elizabeth M. Estate of Harold P. Bannister Milton Brenner Trust of Henry D. Chaikin Trust of Louise Crites Scofield $100,000 — $249,999 Mr. and Mrs. Robert L. Barbanell Estate of Mae Bridewell Dr. Kalpana Chakraburtty The Crown Family Frank N. Tedesco A & P Foundation Trust of James R. Barber The Brightwater Fund, Gloria Jarecki Chanel, Inc. Bruce Crystal Estate of Ida Tepper Abbott Laboratories Trust of Margaret D. Barber Trust of Marie H. Brock Margaret Anne Chappell Cure Alzheimer’s Fund Trust of Annette M. Terdina The Louis & Anne Abrons Foundation, Inc. Barish Family Foundation Estate of Edna Brodie Mr. and Mrs. Bernard T. Chauss Cure Childhood Cancer Estate of Stella R. Thater Mr. and Mrs. Laszlo Adam Trust of Grace M. Barry Randall Brooks Estate of Camille Chericone Mr. and Mrs. James F. Curtis III Thrasher Research Fund Dr. Miriam and Sheldon G. Adelson Medical Estate of Kaethe F. Barry Ms. Betsy Levine-Brown and Mr. Marc Child Neurology Foundation Cusa Realty, LLC Mr. and Mrs. Carl W. Timpson, Jr. Research Foundation Estate of Patricia A. Barry Brown Childhood Brain Tumor Foundation Custom Design Communications, Inc. Estate of Michael Z. Toman Adenoid Cystic Carcinoma Research Trust of Eileen L. Batten Carl and Nickey Brown The Children’s Brain Tumor Foundation William J. Cwenn The Robert Mize & Isa White Trimble Foundation The Modestus Bauer Foundation David A. and Merle L. Brown Children’s Neuroblastoma Cancer Mrs. Charles A. Dana, Jr. Family Foundation The Francis X. Ahearn, Sr. Foundation Lynn B. Bayard Brown Helicopter, Inc. Foundation Estate of Richard Daniels Mr. Steven Trost Roger and Elizabeth Ailes Estate of Thelma Beatty Trust of Ruth Ann Brown The Francis and Miranda Childress The Gloria and Sidney Danziger Foundation, Thomas N. Tryforos Daniel G. Alexander Trust of John A. Beaty Estate of William A. Brown, Sr. Foundation Inc. The Tyler Foundation Robert and Elaine Allen Mr. and Mrs. Edmund Becker Mr. and Mrs. Norman Brownstein The Jane Coffin Childs Memorial Fund for Estate of Hannah Danziger Trust of Irwin C. Unger Alliance for Life Sciences & Health Estate of Charles R. Beechler The Honorable Tina Brozman Foundation Medical Research The E. S. P. Das Foundation Estate of Lori S. Alper Estate of Vernon Brunelle Estate of Selma Chyatt Estate of Hazel Davidson Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 80 Transformations 81

Donors to the Campaign for Memorial Sloan Kettering

Mr. and Mrs. Scott E. Davidson Andrew J. Entwistle Trust of Ralph W. Gaines Estate of Evelyn Gross The Hillcrest Foundation Kaleidoscope of Hope Foundation The Ellen and Gary Davis Foundation Estate of Lillian Epps Estate of Anne Gallagher Estate of J. Stanley Gross Hillenbrand Family Foundation Jane Kalmus Roxana V. Dawson Mr. and Mrs. Christopher Errico Mr. and Mrs. Julius R. Gaudio Trust of Lambert J. Gross Mrs. John S. Hilson Harry P. Kamen Family Foundation Estate of Karin D. de Chellis Esophageal Cancer Education Foundation Bruce G. Geary Foundation Estate of Anthony Grosso The Mark Hindy Charitable Foundation Mr. and Mrs. Daniel B. Kamensky Estate of Jean Decker Rafael Etzion Trust of Louis C. Geiger Allen J. Grubman Trust of Myfanwy Hinkle Trust of Mildred Kaminsky Estate of Libiro DeFilippis Estate of Eugene M. Evans, Jr. Trust of William G. Genner, Sr. Audrey and Martin Gruss Foundation Estate of Vladimir Hladik Estate of Eleanor Kane The Lawrence and Florence DeGeorge The Evslin Family Foundation Kara and Peter Georgiopoulos Estate of Wanda Grzymala James and Angela Ho Mr. and Mrs. William Kane Charitable Trust Trust of James D. Ezzell Estate of Jacques A. Gerard Mr. and Mrs. Roberto de Guardiola Estate of Edward B. Hodge Estate of William Kanter Lynn DeGregorio Family Reach Foundation Robert & Sylvia Gergen Guardsmark, LLC Estate of Marion Hoffman Estate of Bernard Kantor Estate of Katherine C. DeHaan Goff Fanconi Anemia Research Fund Estate of Charles J. Gerhart Marilyn B. Gula Mountains of Hope Estate of Ruth M. Hoffman Steve and Meghan Kanzer Anthony Del Bove Mr. and Mrs. Alfonso Fanjul, Jr. Panayotis Gerolymatos Foundation Trust of Steward B. Hoffman, Sr. Estate of Irvin L. Kaplan Estate of Helen Demitriades Mr. and Mrs. James T. Fantaci The Patrick A. Gerschel Foundation Estate of Pauline R. Gulau Hoffman-La Roche Inc. Marie H. Karger Mr. and Mrs. Steven Denning Estate of Marion E. Feigenbaum Trust of Alda Getti Trust of Elizabeth Guon Deborah H. and Sigmar K. Hofmann The Karma Foundation The De Rosa Foundation for Colon Cancer Gretchen V. and Samuel M. Feldman Estate of Theresa A. Ghiringhello Estate of Gloria E. Gurney Hope V. Hofmann Trust of Jerry Katz Research and Prevention The Corinne Feller Memorial Fund Marlene and Alan Gilbert Gurney Foundation Mrs. Carolyn T. Holden Trust of Toby Katz Ernst and Paula Deutsch Foundation Trust of Robert I. Fendrich Mrs. Bruce A. Gimbel Mimi and Peter Haas Fund Trust of Burt Holtzman Edward M. Kaufmann The DeWitt Wallace Fund Roger W. Ferguson, Jr. Mr. and Mrs. William H. Girvan Hachette Filipacchi Media U.S. Howard and Carol Holtzmann Trust of John Kaufmann, Jr. Mr. and Mrs. Anthony Diaco Trust of Thelma F. Fernandez Mr. and Mrs. Eugene J. Glaser Jayma Meyer Hack and Bruce L. Hack Estate of Herman L. Hoops Trust of Ralph W. Kaufmann The Miriam & Arthur Diamond Charitable Fetzer Institute Estate of Grace E. Glenn The Hagedorn Fund Trust of Anita S. Horbacz Mr. and Mrs. Robert M. Kavner Trust Trust of Lydia K. Fiedler Glenwood Management Corporation The Laverna Hahn Trust Alfred Samson Hou Carl Michael Kawaja and Gwendolyn N. The Ernest & Jeanette Dicker Foundation Gloria S. Fine Trust of Glenn R. Gobble Estate of Margaret S. Hahn Robert Howard Family Foundation Holcombe Estate of Richard I. Diennor First Eagle Investment Management Mr. and Mrs. Bradley Goldberg Martin and Deborah Hale Estate of Frank Huber Thomas F. Kearns Discavage Family Foundation Randee and Howard Fischer Leslie H. Goldberg Estate of Elizabeth W. Hall Nancy Hughes Charles L. Keith & Clara Miller Foundation Oliver S. & Jennie R. Donaldson Charitable Estate of James K. Fisher Trust of Marc S. Goldberg Estate of Mazie J. Hall Humanscale Corporation Mr. and Mrs. Brian G. Kelly Trust Estate of William and Frederica Fissell The Goldhirsh Foundation Estate of Helen Sue Hameetman Estate of Edna Hunt Estate of Ruth C. Kelly Estate of Maurice A. Donovan Trust of Loretta B. Fitzgerald Goldhirsh-Yellin Foundation Milton and Miriam Handler Foundation Carol Hunter Mrs. Ann Kelman and the late Dr. Charles John R. Doss Mr. and Mrs. Thomas M. Fitzgerald III Estate of Elizabeth B. Golding Trust of Robert Hanson James B. Hunter D. Kelman Michael Douglas and Catherine Zeta-Jones The Francis Florio Fund of the New York The Barbara L. Goldsmith Foundation Estate of Marion K. Hardwicke Hyundai Motor America Eleanora and Michael Kennedy Percy S. Douglas Community Trust Lawrence Goldstone, MD Dorothy Harlow I Back Jack Foundation, Inc. Peter Kenner Family Fund Susie M. Downing Steve Forbes Mr. & Mrs. Sidney Goodfriend Estate of Mary Jane Harrington Mr. and Mrs. David W. Ichel J. Kevin Kenny Mr. and Mrs. Frank P. Doyle The Mary Alice Fortin Foundation Trust of Manuel and Anne Goodman Leonard B. Hart Estate of Priscilla T. Iden Kensico Capital Management Trust of Max Drechsler Richard N. Foster The Gordon Family Foundation, Inc. Laura Hartenbaum Breast Cancer Inamed Corporation John A. Kent Jane Clausen Drorbaugh Trust of Aida A. Foti Christy and Sheldon Gordon Foundation Incyte Corporation Estate of Herman Kerner Dr. Scholl Foundation Four Seasons Hotel – New York Arthur A. Gosnell Mr. and Mrs. William R. Hartong Ingersoll Rand Company Estate of Patricia A. Kerrigan Dr. Jeffrey Duban The Fan Fox and Leslie R. Samuels Trust of Louise S. Gosse Have A Chance, Inc. Mr. and Mrs. William H. Ingram The Glenn D. Kesselhaut Children’s Trust of Patricia P. Duffy Foundation, Inc. Marietta A. Goulandris Haymakers for Hope The Interpublic Group of Companies Joy Fund Estate of Doris M. Dunham Estate of Thomas R. Foy Julie Gould Fund for Medical Research Morris A. Hazan Family Foundation Irish Society of Medical Oncology Estate of Mary F. Kessler Margaret H. Dunwiddie Claire and Meyer W. Frank and Leann Estate of Richard P. Gould HCCF Foundation It Figures LLC Mr. and Mrs. Peter A. Kessler The Durst Organization, Inc. Frank Charitable Foundation Felice M. Grad Mr. and Mrs. Andrew P. Heaney J. P. Wish Fund Coyla E. Ketchy Estate of Laura D. Eastman Trust of Irene R. Frank Graff Diamonds Trust of Lonie G. Hearn Jacobus-Iacobucci Foundation The Kettering Family Foundation The Edelman Family Charles A. Frueauff Foundation Grantham Mayo Van Otterloo & Co. Trust of Shirley S. Heiligman Estate of Harold F. Jaeger Estate of Henri Khouri Doris M. Edwards Helen Frankenthaler Foundation The Grateful Foundation, Inc. Mr. and Mrs. Robert M. Hendrickson Mr. and Mrs. Stanley R. Jaffe Doris and Floyd Kimble Foundation E. E. Cruz Company Mr. and Mrs. David Lee Frankfurt Estate of Harvey R. Graveline Mr. and Mrs. John Hennessy Thomas Jaffe The King Family Charitable Lead Trust Mr. and Mrs. Blair W. Effron Mr. Edward W. Frantel Susan Zises Green The Maxine R. and Richard L. Henry Trust James Family Foundation Mr. James W. Kinnear II Trust of Bertram Ehrlich Frazier Foundation Brigadier General and Mrs. William S. Estate of Robert Hensel, Jr. Trust of Ann E. Jennings Patricia A. Kirby Trust of Raymond Ehrlich Estate of Gloria Freed Greenberg Carolina Herrera, Ltd. Richard H. Jenrette Mr. and Mrs. James M. Klausmann Estate of Elinor Ehrman Estate of Katherine Freeman Mr. and Mrs. Peter S. Gregory Trust of Leon Hershaft The Jewish Communal Fund David L. Klein, Jr. Foundation Estate of Estelle Eisenstat Frey Family Foundation, Inc. Mr. and Mrs. Melvin W. Griffin Ms. Marlene Hess and Mr. Jim Zirin Mr. and Mrs. Peter James Johnson, Jr. Robert D. Klemme Mr. and Mrs. Frederick Elghanayan Zoltan Fried Estate of Edythe Griffinger Trust of Marie Hesselbach The Samuel C. Johnson Trust The Esther and Joseph Klingenstein Fund Martin Elk League for Cancer Research Richard M. Furlaud Trust of William C. Griffith, Jr. Heymann-Wolf Foundation J.P. Wish Fund Fernand Koch Trust of Arnold B. and Joan S. Elkind Estate of Joseph F. Fursa, Jr. Trust of Vernon H. Grigg Estate of Manny Hilfman The Kahn Charitable Foundation Estate of Gale K. Kokubu Mr. and Mrs. Richard S. Emmet Mr. and Mrs. Thomas J. Gahan Grodetsky Family Foundation Trust of Frank J. Kahn Mrs. Mitzi Koo Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 82 Transformations 83

Donors to the Campaign for Memorial Sloan Kettering

The Koppelman Family Foundation Stephanie and James Loeffler Mr. and Mrs. Jeffrey A. McDermott The Garrett and Mary Moran Trust Pediatric Brain Tumor Foundation The Beatrice Renfield Foundation The Kors Le Pere Foundation Long Island League to Abolish Cancer McDonald Financial Group Estate of Barbara B. Morgan Pells-Mayton Foundation Mr. and Mrs. Ira L. Rennert Robert A. Kotick Estate of Margaret S. Longwell Lee McDonald Yvonne & Arthur Moretti Trust of James A. Pemberton Olivier and Yosun Reza Mr. and Mrs. Robert A. Kramer Estate of Anthony Lopez Ralph McDonough Melissa and Chappy Morris Mrs. Richard T. Perkin Estate of Roland S. Rhode Mr. and Mrs. Jerome I. Kroll Milton Lowenstein The Dextra Baldwin McGonagle Foundation Alfred L. and Annette S. Morse Foundation Mort Perlroth Judy Rhulen and Family Trust of Grace E. Kruse James J. and Marianne B. Lowrey Mr. and Mrs. Edward B. McKeough Ken and Linda Mortenson Lisa and Richard Perry Martin Rich KVFF Fund The Lucerne Foundation The McKnight Endowment Fund for Mr. and Mrs. George K. Moss Pershing Square Foundation Anne S. Richardson Fund Dina Hubell and the Labkon Family Cynthia and Dan Lufkin Neuroscience Manuel and Mercedes Mosteiro Estate of Frederick D. Petrie Trust of A. Leslie Richardson Mrs. Thomas G. Labrecque Ronald S. Lux Estate of Geoffrey McLoughlin Lisa and Marcelo Mottesi The Pew Charitable Trusts Dee Dee Ricks Estate of Sidney J. Lacher Mr. and Mrs. Alexander P. Lynch Estate of Mary E. McMaster Virginia M. Mueller Mr. Donald Pfanz Estate of Harry Rinehimer Lake Road Foundation Trust of John F. Lynch Mr. and Mrs. David B. McQueary Estate of Irving Mulde Samantha and Ernst Pfenninger Estate of Elizabeth M. Ringo The Lakeside Foundation Estate of Kathleen E. Lynch The Meckler Foundation Mrs. Sandy Mulligan Trust of Peter H. Pflugk Trust of Victoria Rinius Estate of Schubert L. Lamb Estate of Charles S. Lyons Melanoma Research Foundation Mr. and Mrs. Thomas W. Murphy II Phelps Family Foundation The Fannie E. Rippel Foundation Estate of Marvadene B. LaMonica Estate of Melvin E. Lyons The Melville Foundation Ernest Muth Estate of Edmund Piasecki Estate of Norma Risman The Edward & Kinga Lampert Foundation MacDonald-Peterson Foundation Mr. and Mrs. Prakash Melwani Edith L. Nathanson Trust of Charles V. Pickup The Ritter Family Foundation Emma Landau Mr. and Mrs. Duncan MacMillan Estate of Dorris M. Mendelsohn The National Genetics Foundation, Inc. Estate of Irene Pickup Abigail Rittmeyer Mr. and Mrs. Barry Lang Josiah Macy, Jr. Foundation Estate of Irving M. Mendelson NBC Universal Mr. Alessandro Pinto The RMF Family Fund, Inc. Estate of Annie Langen The Arthur and Holly Magill Foundation Estate of Lorraine Mensing Estate of Leslie A. Nelkin Mr. and Mrs. Roy R. Plum Bernard and Elaine Roberts Estate of Anne Lanigan The Maguy Foundation Julia and Gilbert Merrill Foundation Trust of Jerome Nerenberg Estate of Beatrice Pockrass Estate of Floyd B. Roberts J. Clair and Pamela Lanning Estate of Margaret E. Maihl Estate of Amy Joan Meskin New York City District Council of Estate of John E. Polek Vivien Rock Dr. Gerald D. Laubach Estate of Margaret H. Mairs Mr. and Mrs. Frank A. Metz, Jr. Carpenters Relief and Charity Fund Mr. and Mrs. Gerard Pompilio Rodale, Inc. Laura Mercier Ovarian Cancer Fund Maite Aquino Memorial Fund Mr. Robert A. Metzler New York State Health Foundation Janis Z. Porch Estate of Maria Rolfe Mrs. Lois H. Lazaro Estate of Mariette P. C. Major Estate of Abby E. Meyer Gerald L. Nichols and Jacqueline W. Nichols Trust of Ann C. Porterfield Sheldon Rose Trust of Edwin S. Lee, Jr. Herbert J. Maletz Estate of Ursula Meyer Foundation Estate of Edna G. Potter Taryn Rose International Mr. and Mrs. Thomas V. Leeds Mr. and Mrs. Irving H. Malitson The Emanuel N. Micallef Foundation Trust of Robert F. Novak Estate of John A. Powers Estate of Sylvia Rosenberg Gary Leet Elissa Caterfino Mandel Mrs. Sidney Michael NYS Fraternal Order of Police Foundation John and Jane Powers Foundation Trust of Ilsa Rosenblum The Lefkofsky Family Foundation Karen G. Mandelbaum Trust of William M. Michaelson The Michael A. O’Bannon Foundation Trust of Ruth S. Prall Trust of Evelyn Rosenstein Lehman Brothers Inc. Estate of Harry Marder Trust of Florence B. Mickels Estate of Ernestine A. O’Connell Prevent Cancer Foundation Jeffrey Rosenzweig Foundation for Karen and James Lehrburger Estate of Ida Mae Margolis The Mike and Steve Foundation Mr. and Mrs. Jeremiah O’Connor Rita Price Pancreatic Cancer Research Mr. and Mrs. Lewis E. Lehrman Trust of Carlton G. Marie Elaine P. Miles Trust of Emily C. O’Grady The Procter & Gamble Company Leo Rosner Foundation Trust of Martha B. Leigh Edward J. Marino Eleanor F. Miley Estate of Grace O’Hare Estate of Ardys M. and Harold I. Proctor Mrs. Howard L. Ross Estate of Helen Lesniewski Susan and Morris Mark Carolyn Rosen Miller Family Foundation Dara and Tim O’Hara The William H. Prusoff Foundation Estate of Sylvia Ross The Leukemia & Lymphoma Society Jerome S. and Maria Markowitz Mr. and Mrs. Donald K. Miller The Oceanic Heritage Foundation Trust of Raymond F. Prussing Estate of Eva L. Rothberg Laurence W. Levine Foundation Zvi and Linda Markowitz Mr. and Mrs. Larry J. Miller Oki Data Americas, Inc. Dr. and Mrs. Mark Ptashne Philip and Marcia Rothblum Foundation Estate of Dina Levinsky Estate of Benjamin Marmer Mr. and Mrs. Matthew Miller Harold N. Openshaw, Jr. Richard I. Purnell Fund Mr. and Mrs. Eric A. Rothfeld Elvire Levy The Christina & Paul Martin Foundation Mr. and Mrs. Richard A. Miller Mr. and Mrs. John D. Opie Estate of Richard I. Purnell Estate of Geraldine E. Rove Estate of Erna T. Lewine Mr. and Mrs. Roman Martinez IV Mrs. Mary E. S. Milligan Optiscan Bambi Lyman Putnam Denise Rover The Bertha and Isaac Liberman Foundation, Dorothy Marx Estate of Dorothy B. Minard Estate of Elaine Orbach Roselyn Flaum Radcliffe Fran and Jeff Rowbottom Inc. Estate of Johanna Marx Melissa and Robert Mittman Otis Elevator Company Trust of Samuel J. Radcliffe, Jr. Mr. and Mrs. Charles Royce The Marvin Kay Lichtman Foundation Estate of Rita B. Masse Leslie M. Modell The William & Jane Overman Foundation Stewart Rahr Estate of Pearl Rubin Mr. and Mrs. Richard Lightburn James Mathos Estate of Catherine Mohan Mr. and Mrs. Gunnar S Overstrom III Trust of Betty Raiff Mr. and Mrs. Mitchell E. Rudin Linda Lipay The Hale Matthews Foundation Estate of Irene Mokrzycki Mr. and Mrs. Neil Padron Muriel Rains Estate of Maria Stella Ruggirello Trust of Wilhelmina I. Lipfert Trust of Walter J. Matthews Trust of Celestine Elizabeth Moloney Pam’s Pals Inc. Mary L. Ralph Philanthropic Fund Estate of Katherine L. Rummler Ira A. Lipman The Matt’s Promise Foundation Estate of William Monaghan Daniel P. and Nancy C. Paduano Family Mr. and Mrs. Edward A. Rankin Estate of Eileen B. Ruthrauff Lisa’s Heart Kids’ Cancer Research Fund Maverick Capital Charities Pauline M. Monteleone Foundation Theodore A. Rapp Foundation The Derald H. Ruttenberg Foundation The Harold I. & Faye B. Liss Foundation Mr. and Mrs. Hamish Maxwell Arthur R. Montgomery The Parnassus Foundation John H. Rassweiler Trust of Anne I. Ryan Mr. and Mrs. Martin Liss Maynard Childhood Cancer Foundation John and Hee-Jung Moon Rosalie Pataro Abigail T. Reardon Andrew Sabin Family Foundation The Litterman Family Foundation The Helen & William Mazer Foundation Estate of Pauline Moor Trust of Edith Pattison Estate of Phyllis E. Redmerski Martin Sabowitz and Muriel Goldrich The Lucius N. Littauer Foundation Mr. Michael Mazzucca Mr. and Mrs. Charles V. Moore Estate of Herman L. Paul, Jr. Elenore Reed The Saibel Foundation Estate of Santina Livolsi Estate of Ralph L. McBean Diana M. Moore Hector Payares Blanco Estate of Martha Cuneo Reed Mr. and Mrs. Francois de Saint Phalle Demarest Lloyd, Jr. Foundation Estate of Ann C. McBride Estate of Percy W. Moore Mr. and Mrs. Kenneth Pearlman Samuel P. Reed Estate of V. Edward Salamon Jeanette and Peter Loeb Estate of Donald J. McCarraher Tom & Judy Moore Foundation Richard S. Pechter Compton Rees, Jr. Mr. and Mrs. Eugene L. Salem Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 84 Transformations 85

Donors to the Campaign for Memorial Sloan Kettering

Mr. and Mrs. William R. Salomon Estate of Leo A. Shifrin, MD The Fred & Sharon Stein Foundation Mr. and Mrs. David C. Tracey Estate of Louis Weinstock Trust of Rose K. Salzwas Mr. and Mrs. Stanley B. Shopkorn Mrs. Nancy Steinfeld Jill Tracey Mr. and Mrs. Michael Weisberg Trust of Sidney Samuels Mr. and Mrs. William Shulevitz The Ernest E. Stempel Foundation Estate of Rita L. Tracey Andrew and Ronnie Weiss Henry Sanborn Mr. and Mrs. Steven J. Sidewater Estate of Irene Stern Trust of Helen A. Trahin Estate of Gertrude Weiss Estate of Andrew D. Sanders Muriel F. Siebert Foundation Estate of Winona H. Stevens Trust of Dorothy B. Traufield Trust of Gertrude Wellisch The Sandler Family Estate of Ruth Siegmann The Guy M. Stewart Cancer Fund Beatrice Travis-Cole The Nina W. Werblow Charitable Trust Nina and Julian Sandler Charitable Fund Estate of Mary Siekert J. McLain Stewart The W. James & Jane K. Truettner Estate of Robert L. Werner Mrs. Barbara Santangelo Trust of Walter Silberfarb Estate of Rebecca Stohl Foundation Virginia A. Werner The Sass Foundation for Medical Research Mr. and Mrs. Robert H. Silver Mr. and Mrs. Stuart P. Stoller Estate of Ina Tuckman Estate of E. Olga Wesner The Saw Island Foundation The Slomo & Cindy Silvian Foundation Mr. and Mrs. Norman L. Stone Estate of R. Read Tull Mrs. Elizabeth G. Weymouth Estate of Ida M. Scagliarini The Seymour Simon Charitable Trust Estate of Martha W. Stouffer Lucien L. and Shirley Turk When Everyone Survives Scalamandré Silks Marilyn M. Simpson Charitable Trust Estate of Clair B. Stough John J. Twomey Estate of Frank A. Widenski Didi and Oscar S. Schafer Simpson Thacher & Bartlett Trust Trust of May Strang Ahavas Tzedek Foundation Nancy P. Widmer Peter L. Schaffer Trust of Marie A. Sinclair Estate of Gene K. Strange David V. Uihlein, Sr. Mr. and Mrs. Gene Wilder Estate of Richard Scharff Trust of Otto K. & Harriet J. Singer Estate of Alice K. Straschil Elaine L. Ullrich The Wilf Family Foundation Estate of Sylvia Schatzman Estate of Shirley Singer Estate of Herta Strauss The Unger Family Foundation, Inc. Andrea J. Will Memorial Foundation The LeRoy Schecter Foundation Estate of Madeline Sisia Geraldine Stutz Trust Inc. Mr. and Mrs. Mark D. Unger Jacqueline and Robert Willens Estate of Josephine L. Schiff Estate of Evelyn M. Skolnick Trust of Mary R. Suchanski The Valley Foundation Barbara F. Williams Estate of Billie Schneider SL 2005 Family Trust Mr. and Mrs. Robert J. Sullivan Valley of the Sun United Way Williams Trading LLC Mr. and Mrs. Robert Schneider The Alan G. Slifka Foundation Susquehanna Foundation Estate of June A. Vanderpool Trust of Helen A. Wilson The Schneider-Kaufmann Foundation, Inc. Estate of Alvin F. Sloan David W. Sussman Jonathan and Sarah Vanica (GS Gives) Mr. and Mrs. Jon Winkelried Mr. and Mrs. Paul C. Schorr IV Dr. and Mrs. Bernard E. Small Phyllis and Bernard Sussman The Vanneck-Bailey Foundation The Winters Family Fund Trust of Lola Schug Suse Smetana Estate of Sandra Syms The Varnum DeRose Trust Estate of James B. Wittrock Estate of Harold B. Schwartz Louis and Dora Smith Foundation, Inc. Dorothy D. Taggart Trust Dr. Terry G. Vavra and Linda F. Vavra The Henry Wolf Foundation Theodore G. Schwartz Family Foundation The Randall and Kathryn Smith Foundation Trust of Andrew Taras Veejay Foundation Alice Aeschliman Wolfe Estate of Rosalind Schwartzbach Mr. Robert J. Smith Trust of Joyce A. Taras The Victoria’s Smile Foundation Trust of Toby Wolfberg Trust of Paul J. Schwarz Estate of Woodrow Q. Smith Edward Tarby Trust of Eva Vida Mrs. Barbara Wolfson Mrs. Arline Schwarzman Estate of Dorothy Smolen Target MarkeTeam, Inc. The Family of Maria Elena Villanueva Estate of Gordon Wootton Mr. and Mrs. Jeffrey E. Schwendeman Catherine M. Smolich Estate of Ruth N. Taub Estate of Dorothy Voelker Deborah C. Wright Trust of Robert E. Schwenk Trust of Robert J. Smutny Tay-bandz, Inc. Trust of Anna L. Vogel Trust of Twylia H. Wright Mr. and Mrs. John W. Scully Mr. and Mrs. Jay T. Snyder Estate of Florence G. Taylor Estate of Gertrude Vogel Estate of Bernadette Wyrough Estate of Jewel C. Seab Valerie L. Sodano Estate of Gertrude S. Taylor Voices Against Brain Cancer Foundation Estate of Arthur P. Young The Jean & Charles Segal Foundation The Harry & Estelle Soicher Foundation Team Connor Cancer Foundation Ralph W. Voit Alfred D. Youngwood Mr. David Sekiguchi Trust of Robert Solnick Team Luke vs. Neuroblastoma Trust of Beverly Wachtel The Patricia J. and Edward W. Zeh Rena Selden Professor and Mrs. C. Alan Soons Telethon Italy – US Foundation Wachtell, Lipton, Rosen & Katz Charitable Foundation The Maryam and Hervey Seley Foundation Estate of Sharon Sorok Estate of Walter G. Terwedow The Paul E. and Mary Wagner Trust The Zickler Family Foundation Rosemary Selky Soros Fund Charitable Foundation Estate of Theresa M. Thingelstad Estate of Lillie M. Waldon The Isaac Ziegler Charitable Trust R. B. Sellars Foundation Sotheby’s Think Pink Rocks Mr. and Mrs. Paul D. Walsh Stanley Shalom Zielony Foundation Dominique Senequier Mr. and Mrs. Richard A. Spelke Mr. and Mrs. Andrew S. Thomas Estate of Frances M. Wanek Martha E. Zimmer Sephardic Hospital Fund – Medstar Trust of Henry Spenadel Estate of Robert P. Thome Estate of Shirley I. Warner Larry and Anne Zimmerman The Jacqueline Seroussi Memorial Estate of Regina W. Spence Trust of Robert W. and Pauline Z. Thompson Warren/Soden/Hopkins Family Foundation Mr. and Mrs. Jeffrey A. Zucker Foundation Alvira R. Spencer Trust of Vernon Thompson Mr. and Mrs. Bruce Wasserstein L. J. Sevin Estate of DeAnne Spencer The Vernon F. & Mae E. Thompson Elizabeth T. Wassmundt Harold Shames Estate of Agnes Spillmer Charitable Foundation Estate of Shirley F. Watkins Estate of Reuben Shane The St. Giles Foundation Thrill Hill Productions Mr. and Mrs. Peter Webster Estate of Saul Shapiro Ronald Stafford Cancer Support Foundation, Mr. and Mrs. Alexander Tisch Mr. and Mrs. Bradford G. Weekes III The Sharma Foundation Inc. Estate of Margaret R. Tomas Mr. and Mrs. John G. Weiger Trust of Margaret S. Sharp Staten Island Yacht Sales, Inc. Estate of Milton Topolsky Trust of Gertrude H. Weiler Estate of Bernice Baruch Shawl Esta Eiger Stecher Estate of John J. Tormey Mrs. John L. Weinberg William R. Sheldon Mr. and Mrs. Edward C. Steele The Tortuga Foundation Marc S. Weinberger Estate of Alice Sherwin Estate of Sanford L. Steelman Estate of Virginia M. Toth Danny M. Weinheim The Shevell Family Estate of Dennis Stein Trust of Angelina Ann Tovar The Isak & Rose Weinman Foundation, Inc. Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 86 87

01 02 03 04 (From top) Singer (From left) Associates (From left) Spring (From left) Diana Krall performs Committee Fall Party Ball Co-Chairmen Courtney Arnot, at the 2013 Spring Ball; Co-Chairmen Emilia Karen LeFrak, Society President MSK President Fanjul Pfeifler and Julia Koch, and Martha Vietor Glass, Craig Thompson, Cynthia Cook Smith, Shelley Carr and Muffie Potter former Society Honorary Chairman Aston during the President Annette U. Patricia Herrera “Miracle on Madison” Rickel, and Robert Lansing, Associates event Motzer at the Spring Committee Chairman The Society of Ball; Chairman of Shoshanna Gruss, the MSK Boards and Fall Party of Overseers and Co-Chairmen Memorial Sloan Kettering Cancer Center Managers Douglas A. Hayley Bloomingdale Warner III and his wife, and Joanna Baker de Patsy Warner, enjoy Neufville the Spring Ball.

Since 1948, The Society of MSK’s Annual New York City’s Four Seasons hotel was the Founded in 1946, The Society of MSK is a Appeal has raised money to support cancer setting in November for the annual Fall volunteer organization that works to ensure research conducted by Memorial Sloan Party of the Associates Committee. Three Kettering clinicians and scientists. The hundred and sixty guests attended the the well-being and comfort of patients; raise Society partnered with MSK’s Chief of festivities, which featured a presentation Endocrinology, James A. Fagin, for its 2013 from MSK pediatric medical oncologist funds for cancer research and treatment; campaign in support of thyroid cancer and sarcoma expert Paul A. Meyers, and research, raising more than $800,000. raised funds to accelerate and support and provide public education on the prevention, 02 An estimated 56,000 new cases of thyroid the first clinical trial of a treatment with early detection, and treatment of cancer. cancer are diagnosed in the United States a monoclonal antibody called 3F8 against each year — and that number is rising. osteosarcoma, a tumor of the bone. The Appeal is a hands-on initiative of The Sponsored by Carolina Herrera, the event Society in which members write personal kicked off the Associates Committee’s letters to friends, family, and colleagues newest initiative, Harnessing the Immune urging them to support MSK research. System to Target Sarcoma. The event Four hundred guests dined and danced at Administrative Board members also make raised $532,000. The Society’s sixth annual Spring Ball, personal contributions to the campaign. held in April at the Metropolitan Museum Since The Society’s beginnings, its mission of Art’s Temple of Dendur. The evening, One of the most beloved New York City has included the funding of early-stage sponsored by Harry Winston, raised philanthropic holiday traditions is “Miracle research. The Society’s Research $1.5 million for The Society’s mission, on Madison,” organized by the Madison Grants support important clinical and and included a special funding initiative Avenue Business Improvement District. translational research projects of MSK’s to support MSK’s Targeted Therapy During the 2013 holiday season, The Society junior faculty members, many of which Translational Research Program for Kidney of MSK was the beneficiary and partner of have gone on to become permanent 03 Cancer. Led by medical oncologist Robert the shopping event for the second year, with programs and features of MSK. In 2013, J. Motzer, urologic surgeon Paul Russo, funds benefiting its pediatric initiatives. seven research proposals were funded. The and physician-scientist James J. Hsieh, the On December 7, more than 85 of the world’s projects included investigations into lung program works to develop novel and more- most prestigious brands and retailers along cancer, breast cancer, multiple myeloma, effective treatment strategies to extend Madison Avenue, from 57th Street to 86th hematologic cancers, testicular cancer, the lives of many patients and eventually Street, welcomed shoppers who wanted to ovarian clear cell carcinoma, and pancreatic eradicate the disease. join them in giving back. Twenty percent neuroendocrine tumors. of the day’s sales — a total of more than $200,000 — was donated to The Society by the participating retailers and businesses.

04

01 Transformations MEMORIAL SLOAN KETTERING CANCER CENTER 88 89

The Society of Memorial Sloan Kettering Cancer Center Administrative Board

EXECUTIVE COMMITTEE PRODUCED BY Martha Vietor Glass Mrs. Thomas S. Glover Robyn Lane Joseph Lavinia Branca Snyder The Department of Public Affairs President Vice President Vice President Vice President Memorial Sloan Kettering Cancer Center Debra Pipines Victoria Greenleaf Kempner Mrs. Thomas V. Leeds 1275 York Avenue Treasurer Assistant Treasurer Past President New York, NY 10065 t 212-639-3573 Mrs. Thomas M. Fitzgerald III Leslie Heaney f 212-639-3576 Secretary Assistant Secretary [email protected]

MEMBERS-AT-LARGE Avice A. Meehan Muffie Potter Aston Mrs. Lars Forsberg Mrs. Roman Martinez IV Mrs. Stephen C. Sherrill Senior Vice President and Mrs. James Halsey Bell Mrs. Christopher P. Fuller Mrs. S. Christopher Meigher III Mrs. Sean Smith Chief Communications Officer Mrs. Alan J. Blinken Mrs. Robert M. Gardiner Mrs. Richard A. Miller Mrs. Paul Soros Tory Burch Mrs. Mark V. Giordano Mrs. George K. Moss Amanda Anne Cox Taylor Anne B. O’Malley Mrs. Bryan J. Carey Eugenie Niven Goodman Nancy Coffey Nagler Mrs. Andrew S. Thomas Vice President, Mrs. Michael Carr Mrs. Peter S. Gregory Mrs. Gunnar S Overstrom, III Mrs. Jerome L. Villalba Creative and Digital Communications Mrs. Kevin C. Coleman Mrs. Roger P. Griswold, Jr. Mrs. Richard T. Perkin Victoria Vought Mrs. Michael J.A. Darling Grace W. Harvey Mrs. Samuel F. Pryor IV Naomi Waletzky Mrs. Marvin H. Davidson Melanie Holland Mrs. Bambi Putnam Alexis Robinson Waller WRITER Mrs. Hilary Dick Mrs. Scott C. Johnston Shafi Roepers Mrs. Douglas A. Warner III Celia Gittelson Webb Egerton Mrs. Michael Kennedy Mrs. Louis Rose Mrs. Martha Webster

Mrs. Christopher Errico Suzie Kovner Alexia Hamm Ryan Mrs. Thomas E. Zacharias CONTRIBUTORS Ruth G. Fleischmann Kamie Lightburn Mrs. Paul C. Schorr IV Fiona Begg Jennifer Castoro Wendy Crandall SUSTAINING BOARD Julie Grisham Courtney Arnot Deborah A. DeCotis Mrs. Ann F. Jeffery Evelyn Angevine Silla Eva Kiesler Mrs. Andres Bausili Antonia Paepcke DuBrul Mrs. Brian A. McCarthy Mrs. Richard J. Sterne Esther Napolitano Mrs. Andrew M. Blum Mrs. Thomas J. Fahey, Jr. Suzanne McDonnell Long Leith Rutherfurd Talamo Christina Pernambuco-Holsten Dianne G. Crary Mrs. Roberto de Guardiola Mrs. Minot K. Milliken Mrs. Michael L. Tarnopol Jim Stallard Jennifer Creel Mr. Kirk Henckels Mrs. George F. Moss Mrs. James F. Curtis III Mrs. Peter K. Hills Mrs. Charles H. Mott Mrs. James H. Dean Mrs. John S. Hilson Mrs. Benjamin M. Rosen PHOTOGRAPHY Matthew Septimus

ADDITIONAL PHOTOGRAPHY PRESIDENT’S COUNCIL Richard DeWitt Mrs. Rand V. Araskog Mrs. Charles A. Dana, Jr. Mrs. Donald B. Marron Linda Gosden Robinson Peter Ross Nina Garcia Conrod Mrs. Richard S. LeFrak Mrs. Milton Petrie Mrs. H. Virgil Sherrill

DESIGN Ideas On Purpose, NY PAST PRESIDENTS www.ideasonpurpose.com Mrs. Coleman P. Burke Mrs. Bruce A. Gimbel Mrs. Arie L. Kopelman Mrs. Frank A. Metz, Jr. Mrs. Edwin M. Burke Mrs. William O. Harbach Mrs. Derek L. Limbocker Dr. Annette U. Rickel Mrs. William M. Carson Alison Barr Howard Jean Remmel Little Mrs. Bijan Safai PRINTING Mrs. Walter B. Delafield Mrs. Peter D. Jones Mrs. M. Anthony May Allied Printing Services Mrs. Charles H. Dyson Mrs. Kerryn King Mrs. Jay H. McDowell

FOUNDER Mrs. Edward C. Delafield

© Copyright 2014 Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065

GENERAL INFORMATION 212-639-2000

PHYSICIAN REFERRAL SERVICE 800-525-2225

VISIT US ONLINE www.mskcc.org facebook.com/sloankettering twitter.com/sloan_kettering youtube.com/mskcc

www.mskcc.org/annualreport Departments of Memorial Hospital Departments of Memorial Hospital

Medical Board as of FFebruaryebruary 1, 2014 Department of Anesthesiology and Critical Care Medicine as of FFebruaryebruary 1, 2014

Medical Board PRESIDENT – ALTERNATES – MEMBERS Roger E. Padilla, MD Mohit Chawla, MD Medical Staff Medical Staff David R. Artz, MD David Amar, MD, Memorial Hospital Alisa C. Thorne, MD Cosmin Gauran, MD Martin R. Weiser, MD Colin B. Begg, PhD Maura N. Dickler, MD Jeffrey S. Groeger, MD, Memorial Amitabh Gulati, MD (July 1, 2013 - June 30, 2015) Richard Barakat, MD Nadeem Abu-Rustum, MD Hospital ASSOCIATE CLINICAL Kaye E. Hale, MD MEMBERS George J. Bosl, MD (July 1, 2013 - June 30, 2015) Neil A. Halpern, MD, Memorial Amy Lu, MD PRESIDENT-ELECT – Hospital William S. Breitbart, MD Kenneth H. Cubert, MD Jennifer Mascarenhas, MD Medical Staff ASSOCIATE MEDICAL Chairman Kevin Browne, RN CHAIR AND MEMBER Chief, Critical Care Medicine Eric R. Kelhoffer, MD STAFF REPRESENATIVE Elena Mead, MD Jedd D. Wolchok, MD Roger S. Wilson, MD Service José T. Baselga, MD, PhD Michelle Burke, RN Vivek T. Malhotra, MD Leslie S. Ojea, MD (July 1, 2013 - June 30, 2015) Katherine O’Connor Founder’s Chair Stephen M. Pastores, MD, Memorial Lisa M. DeAngelis, MD Chief, Pain Service Vinay G. Puttanniah, MD Hospital Joseph O. Deasy, PhD Louis P. Voigt, MD Nina D. Raoof, MD IMMEDIATE PAST PRESIDENT Diane E. Stover, MD, Memorial Dawn P. Desiderio, M.D Elizabeth F. Rieth, MD Paul Sabbatini, MD Hospital ASSISTANT CLINICAL Mary Dowling, RN Larisa Storozhenko, MD, DO (July 1, 2013 – June 30, 2015) Robert A. Veselis, MD, Memorial MEMBERS John R. Gunn Cindy Beng-Imm Yeoh, MD Hospital Clara Broad, MD Philip H. Gutin, MD Sanjay Chawla, MD William Hoskins, MD CLINICAL MEMBERS AT NEW YORK-PRESBYTERIAN Anahita Dabo-Trubelja, MD HOSPITAL Hedvig Hricak, MD, PhD Lisa R. Barr, MD Alessia C. Pedoto, MD Member (Affiliate) Lewis J. Kampel, MD Ruth A. Borchardt, MD Luis E. Tollinche, MD Paul M. Heerdt, MD, PhD, Memorial Aileen Killen, RN, PhD Paul H. Dalecki, MD Hallie Weiss, MD Hospital David S. Klimstra, MD Dawn P. Desiderio, MD Charles D. Lucarelli, RPH Mary Ellen Fischer, MD ASSISTANT MEMBERS Assistant Member Kathryn Martin Jamie A. Fortunoff, MD (Level I) (Affiliate) Joan Massagué, PhD Florence J. Grant, MD James R. Alberti, MD Kane O. Pryor, MBBS Mary Jane Massie, MD Anne C. Kolker, MD Vittoria Arslan-Carlon, MD Mary McCabe, RN Alan L. Kotin, MD Kara M. Barnett, MD Elizabeth N. McCormick, MSN, RN William L. Marx, MD Sarah L. Bowman, MD Larry Norton, MD Chief, Anesthesiology Service Richard J. O’Reilly, MD Melissa S. Pessin, MD, PhD David G. Pfister, MD Simon N. Powell, MD, PhD Leonard B. Saltz, MD Kent Sepkowitz, MD Rori Salvaggio, RN Charles L. Sawyers, MD Peter T. Scardino, MD Craig B. Thompson, MD Roger S. Wilson, MD Departments of Memorial Hospital Departments of Meemorialmorial HospHospitalital

Department of Epidemiology and Biostatistics as of February 1, 2014 Department of Medical Physics as of February 1, 2014

MEMBERS Chaya S. Moskowitz, PhD, Memorial Talya Salz, PhD MEMBERS James G. Mechalakos, PhD, Memorial Ruimei Ma, PhD Peter B. Bach, MD Hospital Ronglai Shen, PhD Howard I. Amols, PhD, Memorial Hospital Charles R. Schmidtlein, PhD Jonine L. Bernstein, PhD Sara H. Olson, PhD, Memorial Hospital Hospital Joseph A. O’Donoghue, PhD, Memorial Yulin Song, PhD Hospital Mithat Gonen, PhD, Memorial Hospital Katherine S. Panageas, DrPH, Memorial ASSISTANT MEMBERS Maria F. Chan, PhD, Memorial Hospital Guozhen (Jenny) Yang, PhD (Level I) Kyung K. Peck, PhD, Memorial Hospital Glenn Heller, PhD, Memorial Hospital Hospital John L. Humm, PhD, Memorial Hospital Kristen L. Zakian, PhD, Memorial Malcolm C. Pike, PhD Jaya M. Satagopan, PhD Sean M. Devlin, PhD ASSISTANT MEMBERS CHAIR AND MEMBER Margie A. Hunt, MS, Memorial Hospital Hospital (Level I) Chris Sander, PhD Howard T. Thaler, PhD, Memorial Behfar Ehdaie, MD Chair and Attending Hospital Chief, Clinical Physics Service Cesar Della Biancia, PhD Colin B. Begg, PhD Venkatraman Ennapadam Seshan, PhD, Shari Goldfarb, MD Joseph O. Deasy, PhD ASSOCIATE CLINICAL Eugene W. Kettering Chair Zhigang Zhang, PhD, Memorial Hospital Allison N. Lipitz-Snyderman, PhD Enid A. Haupt Chair of Jason A. Koutcher, MD, PhD David H. Gultekin, PhD Memorial Hospital MEMBERS Acting Chief, Biostatistics Service Andrew J. Vickers, DPhil Medical Physics Chief, Imaging and Spectroscopic Elena Kaye, PhD Yusuf E. Erdi, DSc ASSISTANT MEMBERS Physics Service Ann G. Zauber, PhD PROFESSIONAL SUPPORT Govindarajan Srimathveeravalli, PhD Doracy P. Fontenla, PhD Victoria S. Blinder, MD STAFF Gikas S. Mageras, PhD, Memorial Grace Tang, PhD Associate Laboratory Member Hospital Y.C. David Huang, PhD ASSOCIATE MEMBERS Marinela Capanu, PhD Harini Veeraraghavan, PhD Irene Orlow, PhD Chief, Computer Service Assen S. Kirov, PhD Elena B. Elkin, PhD, Memorial Hospital Anna Helena Furberg-Barnes, PhD Weijun Xiong, PhD Ellen D. Yorke, PhD, Memorial Hospital Dale M. Lovelock, PhD Alexia E. Iasonos, PhD, Memorial Irina Ostrovnaya, PhD Assistant Laboratory Members Sadek Nehmeh, PhD Hospital Sujata Patil, PhD Marco Zaider, PhD, Memorial Hospital PROFESSIONAL SUPPORT Susan A. Oliveria, ScD Ceferino H. Obcemea, PhD STAFF Yuelin Li, PhD, Memorial Hospital Li-Xuan Qin, PhD Pat B. Zanzonico, PhD, Memorial Camelia S. Sima, MD Hospital Assistant Laboratory ASSISTANT MEMBERS Members CLINICAL MEMBERS Sean L. Berry, PhD Ellen Ackerstaff, PhD Chandra M. Burman, PhD Jung Hun Oh, PhD Hongbiao Carl Lekaye, PhD Peter Kijewski, PhD Kayvan R. Keshari, PhD Thomas J. LoSasso, PhD Jazmin Schwartz, PhD AT NEW YORK-PRESBYTERIAN Department of Laboratory Medicine as of February 1, 2014 HOSPITAL Jean M. St. Germain, MS Sunitha B. Thakur, PhD Associate Member Neelam Tyagi, PhD (Affiliate) MEMBERS CLINICAL MEMBERS ASSISTANT MEMBERS ASSOCIATE MEMBERS Pengpeng Zhang, PhD Douglas J. Ballon, PhD Ahmet Dogan, MD, PhD, Memorial Lilian M. Reich, MD Maria E. Arcila, MD Lawrence T. Dauer, PhD, Memorial Hospital David L. Wuest, MD Kazunori Murata, PhD Hospital ASSISTANT CLINICAL Martin Fleisher, PhD, Memorial Chief, Blood Bank-Cytotherapy N. Esther Babady Otete, PhD Amita Dave, PhD, Memorial Hospital MEMBERS Hospital Laboratory Service Christopher Y. Park, MD, PhD Andrew Jackson, PhD, Memorial Ase M. Ballangrud-Popovic, PhD Hans G. Lilja, MD, Memorial Hospital David C. Park, MD Hospital Paul Frisch, PhD Chair and Attending Peter G. Maslak, MD, Memorial ASSOCIATE MEMBERS Mikhail Roshal, MD, PhD Yousef Mazaheri, PhD, Memorial Guang (George) Li, PhD Melissa S. Pessin-Minsley, MD, PhD Hospital Renier J. Brentjens, MD, PhD Hospital Jingdong Li, DrPH Chief, Hematology April Chiu, MD, Memorial Hospital ASSISTANT MEMBER (LEVEL I) Laboratory Service Christine Gi-Yun Moung, MD Eric G. Pamer, MD ASSOCIATE CLINICAL MEMBERS Enid A. Haupt Chair in Clinical PROFESSIONAL SUPPORT Investigation Dean C. Carlow, MD, PhD STAFF Ellinor I.B. Peerschke, PhD, Memorial Richard C. Meagher, PhD Assistant Laboratory Member Hospital Chief, Cellular Therapy Service Larry J. Smith, PhD Gerald A. Soff, MD, Memorial Hospital Lakshmi V. Ramanathan, PhD Yi-Wei Tang, MB, PhD, Memorial Chief, Clinical Chemistry Service Hospital Filiz Sen, MD Chief, Microbiology Service Departments of Memorial Hospital Departments of Memorial Hospital

Department of Medicine as of February 1, 2014 Department of Medicine as of February 1, 2014

MEMBERS Jose G. Guillem, MD, Memorial Larry Norton, MD Howard I. Scher, MD CLINICAL MEMBERS Chau T. Dang, MD, Memorial Hospital ASSOCIATE CLINICAL Carol Aghajanian, MD Hospital Norna S. Sarofim Chair in Clinical D. Wayne Calloway Chair Michael S. Baum, MD Gary E. Deng, MD, PhD, Memorial MEMBERS Chief, Gynecologic Medical Allan C. Halpern, MD Oncology Chief, Genitourinary Oncology Arthur E. Brown, MD Hospital David R. Artz, MD Oncology Service Chief, Dermatology Service Kevin C. Oeffinger, MD, Memorial Service Chief, Employee Health and Maura N. Dickler, MD, Memorial Alan C. Carver, MD Scott A. Armstrong, MD, PhD Neil A. Halpern, MD, Memorial Hospital Andrew D. Seidman, MD, Memorial Wellness Service Hospital Kathleen N.S. Cathcart, MD Hospital Kenneth Offit, MD Hospital Monica N. Fornier, MD, Memorial Carol L. Chen, MD Grayer Family Chair Philip C. Caron, MD, PhD Hospital Chair and Attending Peter B. Bach, MD Martee L. Hensley, MD, Memorial Chief, Clinical Genetics Service Kent A. Sepkowitz, MD, Memorial Albert R. Casazza, MD Chih-Shan Jason Chen, MD, PhD George J. Bosl, MD Dean F. Bajorin, MD, Memorial Hospital Hospital Richard J. O’Reilly, MD Hospital Hugo R. Castro-Malaspina, MD Hani Hassoun, MD, Memorial Hospital Gabriella M. D’Andrea, MD Patrick M. Byrne Chair in José Baselga, MD, PhD Alan N. Houghton, MD Claire L. Tow Chair in Pediatric Moshe Shike, MD, Memorial Hospital Michael P. Fanucchi, MD Steven M. Horwitz, MD Pamela R. Drullinsky, MD Clinical Oncology Ellin Berman, MD, Memorial Hospital Clifford A. Hudis, MD Oncology Research Stewart Shuman, MD, PhD John J. Fiore, MD James Hsieh, MD, PhD Alan L. Engelberg, MD William S. Breitbart, MD Chief, Breast Cancer Medicine Eric G. Pamer, MD Simon H. Rifkind Chair Carlos D. Flombaum, MD Katharine C. Hsu, MD, PhD Marc B. Feinstein, MD Service Murray F. Brennan, MD Enid A. Haupt Chair in Clinical Susan F. Slovin, MD, PhD, Memorial Chief, Renal Service Noah D. Kauff, MD, Memorial Hospital Stephanie A. Fish, MD David H. Ilson, MD, PhD, Memorial Investigation Hospital Benno C. Schmidt Chair in Clinical Hans Gerdes, MD Jason A. Konner, MD, Memorial Maya Gambarin-Gelwan, MD Hospital Chief, Infectious Disease Service Gerald A. Soff, MD, Hospital Oncology Teresa Ann Gilewski, MD Ilya G. Glezerman, MD Ann A. Jakubowski, MD, PhD, Head, Division of General Medicine Memorial Hospital Lee M. Krug, MD, Memorial Hospital Ephraim S. Casper, MD, Memorial Audrey M. Hamilton, MD Venera Grasso, MD Memorial Hospital Esperanza B. Papadopoulos, MD, Chief, Hematology Service Mario E. Lacouture, MD, Memorial Hospital Lewis J. Kampel, MD Yvona Griffo, MD Suresh C. Jhanwar, PhD, Memorial Hospital Head, Division of Network David R. Spriggs, MD Hospital Memorial Hospital Beatriz Korc-Grodzicki, MD, PhD Michelle N. Johnson, MD Medicine Services Gavril W. Pasternak, MD, PhD Winthrop Rockefeller Chair in Ross L. Levine, MD David Paul Kelsen, MD Chief, Geriatrics Service Marcia F. Kalin, MD Barrie R. Cassileth, PhD, Memorial Anne Burnett Tandy Chair of Medical Oncology Laurence Joseph Dineen Chair in Diana E. Lake, MD Mary L. Keohan, MD Hospital Edward S. Gordon Chair in Neurology Head, Division of Solid Tumor Leukemia Medical Oncology Arnold J. Markowitz, MD Sheron Latcha, MD Laurance S. Rockefeller Chair in Stephen M. Pastores, MD, Memorial Oncology Ashfaq A. Marghoob, MD, Memorial Steven C. Martin, MD Jennifer E. Liu, MD Integrative Medicine Nancy E. Kemeny, MD, Memorial Hospital Richard M. Steingart, MD, Memorial Hospital Hospital Chief, General Internal Vivek T. Malhotra, MD Chief, Integrative Medicine Service David G. Pfister, MD Hospital Michael J. Morris, MD Richard N. Kolesnick, MD Medicine Service Simon Mantha, MD Raju S.K. Chaganti, PhD Chief, Head and Neck Oncology Chief, Cardiology Service Mary E. Moynahan, MD, Memorial Jason A. Koutcher, MD, PhD Service Michael J. Mauro, MD Richard C. Meagher, PhD William E. Snee Chair Diane E. Stover, MD, Hospital Mark G. Kris, MD Carol S. Portlock, MD, Memorial Memorial Hospital Nancy E. Mills, MD Natalie Moryl, MD Paul B. Chapman, MD Ariela Noy, MD, Memorial Hospital William and Joy Ruane Chair in Hospital Chief, Pulmonary Service Patricia L. Myskowski, MD Rekha Parameswaran, MBBS Bayard D. Clarkson, MD Eileen M. O’Reilly, MB, BCh, BAO, Thoracic Oncology Mark E. Robson, MD David J. Straus, MD, Kenneth K. Ng, MD Memorial Hospital Mona Sabra, MD Enid A. Haupt Chair of Therapeutic Robert C. Kurtz, MD, Memorial Neal Rosen, MD, PhD Memorial Hospital Lilian M. Reich, MD Research Genovefa A. Papanicolaou, MD, Mark A. Schattner, MD Hospital Enid A. Haupt Chair in Medical Martin S. Tallman, MD Nancy Roistacher, MD Memorial Hospital Dan Douer, MD, Memorial Hospital Susan K. Seo, MD Chief, Gastroenterology and Oncology Chief, Leukemia Service Jean T. Santamauro, MD Miguel-Angel Perales, MD, Memorial James A. Fagin, MD Monika Shah, MD Nutrition Service Charles M. Rudin, MD, PhD Yi-Wei Tang, M.B., PhD, Memorial William J. Schneider, MD Hospital Chief, Endocrinology Service Philip S. Spencer, MD Steven M. Larson, MD Chief, Thoracic Oncology Service Hospital Nancy T. Sklarin, MD Milind Rajadhyaksha, PhD, Memorial Kathleen M. Foley, MD Tiffany Troso-Sandoval, MD Donna and Benjamin M. Rosen Chair Paul J. Sabbatini, MD, Memorial Craig B. Thompson, MD Steven M. Sugarman, MD Hospital Gina M. Villani, MD Society of Memorial Sloan Kettering in Radiology Hospital Robert M. Tuttle, MD, Memorial Naiyer A. Rizvi, MD, Memorial Hospital Cancer Center Chair Maria Theodoulou, MD Louis P. Voigt, MD Stuart M. Lichtman, MD, Memorial Michel Sadelain, MD, PhD Hospital Nicholas Jon Vander Els, MD Jonathan E. Rosenberg, MD, Memorial Howard Weinstein, MD Francesca M. Gany, MD Hospital Stephen and Barbara Friedman Marcel R.M. van den Brink, MD, PhD Hospital Sergio A. Giralt, MD Stephen R. Veach, MD Hans G. Lilja, MD, Memorial Hospital Chair David B. Solit, MD Alan N. Houghton Chair Carolyn Wasserheit-Lieblich, MD ASSISTANT MEMBERS Chief, Bone Marrow Transplant Paul A. Marks, MD Leonard B. Saltz, MD Head, Division of Hematologic Geoffrey Beene Chair Service David L. Wuest, MD Omar I. Abdel-Wahab, MD Peter G. Maslak, MD, Chief, Gastrointestinal Oncology Oncology William D. Tap, MD, Memorial Hospital Han Xiao, MD Katherine M. Bell-McGuinn, MD, PhD Acting Chief, Myeloma Service Memorial Hospital Service Andrew J. Vickers, DPhil Chief, Sarcoma Medical Oncology Victoria S. Blinder, MD Paul A. Glare, MBBS, Malcolm A.S. Moore, DPhil Charles L. Sawyers, MD Sidney J. Winawer, MD Service Memorial Hospital ASSOCIATE MEMBERS Laura Boucai, MD Enid A. Haupt Chair of Cell Biology Marie-Josée and Henry R. Kravis Paul Sherlock Chair William P. Tew, MD, Memorial Hospital Chief, Palliative Medicine Service Ghassan K. Abou-Alfa, MD, Memorial Richard D. Carvajal, MD Craig H. Moskowitz, MD Chair in Human Oncology and Anas Younes, MD Jedd D. Wolchok, MD, PhD Michael S. Glickman, MD Hospital Elizabeth and Felix Rohatyn Chair Robert J. Motzer, MD Pathogenesis Chief, Lymphoma Service Lloyd J. Old Chair for Clinical Alfred P. Sloan Chair Juliet N. Barker, MBBS for Junior Faculty Kishwer S. Nehal, MD, Memorial Howard Hughes Medical Institute James W. Young, MD Investigation Jeffrey S. Groeger, MD, Memorial Renier J. Brentjens, MD, PhD Sarat Chandarlapaty, MD, PhD Hospital Investigator Chief, Melanoma and Hospital Ann G. Zauber, PhD Jacqueline F. Bromberg, MD, PhD Yu Chen, MD, PhD David A. Scheinberg, MD, PhD Immunotherapeutics Service Andrew D. Zelenetz, MD, PhD Chief, Urgent Care Service Vincent Astor Chair Gabriela Chiosis, PhD Ping Chi, MD, PhD Geoffrey Beene Junior Faculty Chair Departments of Memorial Hospital Departments of Memorial Hospital

Department of Medicine as of February 1, 2014 Department of Medicine as of February 1, 2014

Liang Deng, MD, PhD Erik K. Johnson, MD Alexander Geyer, MD Anna M. Varghese, MD Assistant Members Assistant Clinical Associate Clinical Members Assistant Member Darren R. Feldman, MD Rana Kaplan, MD Jenna Goldberg, MD Martin H. Voss, MD (Affiliate) Members (Affiliate) (Affiliate) (Affiliate) Matthew G. Fury, MD, PhD Amsale Ketema, MD Shari Goldfarb, MD Rona D. Yaeger, MD Juliet B. Aizer, MD Kyriakos A. Kirou, DSc, MD Deena J. Nelson, MD Joseph P. Yoe, MBBS John F. Gerecitano, MD, PhD Adam D. Klotz, MD Mrinal M. Gounder, MD Helena A. Yu, MD Dalit Ashany, MD Edward J. Parrish, MD Richard Stern, MD AT ROCKEFELLER UNIVERSITY Boglarka Gyurkocza, MD Douglas Junwoo Koo, MD Rachel N. Grisham, MD Marjorie G. Zauderer, MD Jessica R. Berman, MD Linda A. Russell, MD Assistant Members (Affiliate) Paul A. Hamlin, MD Chhavi Kumar, MD Ayca Gucalp, MD Vivian P. Bykerk, MD Assistant Member (Affiliate) Madhuri Devabhaktuni, MBBS Tobias M. Hohl, MD, PhD Michelle K. Logozzo, MD Rebecca D.S. Guest, MD PROFESSIONAL SUPPORT Stephen J. Di Martino, MD, PhD AT NEW YORK-PRESBYTERIAN STAFF HOSPITAL Muthukumar Thangamani, MBBS Barbara O’Sullivan, MD Yelena Y. Janjigian, MD Emmy Ludwig Miller, MD Dipti Gupta, MBBS Doruk Erkan, MD Laboratory Members Member (Affiliate) Sohail F. Tavazoie, MD, PhD Robert Jenq, MD Debra Mangino, DO Kaye E. Hale, MD Susan M. Goodman, MD Neil H. Bander, MD AT THE RALPH LAUREN Govindaswami Ragupathi, PhD Lisa A. Mandl, MD Virginia M. Klimek, MD Anna R. Marcelli, MD Alan M. Hanash, MD, PhD CENTER FOR CANCER CARE Isabelle Riviere, PhD Richard D. Granstein, MD Guenther Koehne, MD, PhD Eileen P. McAleer, MD James J. Harding, MD Charis Fan-Hui Meng, MD AND PREVENTION Geoffrey Y. Ku, MD Peter A. Mead, MD Alan Loh Ho, MD, PhD Lisa C. Vasanth, MD Associate Clinical Member Associate Laboratory Members Associate Member Hendricks H. Whitman, III, MD (Affiliate) Heather J. Landau, MD Elizabeth A. Quigley, MD David M. Hyman, MD (Affiliate) Jeffrey A. Knauf, PhD Arthur M.F. Yee, MD, PhD Franklin Marsh, Jr., MD Heather L. McArthur, MD Dragos Rancea, MD Gopakumar V. Iyer, MD Jonathan W. Weinsaft, MD Michael R. McDevitt, PhD Shanu Modi, MD Marina Rozenberg, MD Anna Kaltsas, MD Taha Merghoub, PhD Alison J. Moskowitz, MD Cori Salvit, MD Mini Kamboj, MBBS Dionysios Neofytos, MD Nelson F. Sanchez, MD Asma Latif, MD Assistant Laboratory Members Maria Lia A.P. Palomba, MD Wendy L. Schaffer, MD, PhD Erica H. Lee, MD Vijai Joseph, PhD Department of Neurology as of February 1, 2014 Maria C. Pietanza, MD Marisa Siebel, MD Robert P. Lee, MD Robert J. Klein, PhD Dana E. Rathkopf, MD Stephanie Smith-Marrone, MD Nikoletta Lendvai, MD, PhD Susan A. Oliveria, ScD Diane L. Reidy, MD Robin E. Stutman, MD Jennifer C.F. Leng, MD MEMBERS ASSOCIATE CLINICAL Katarzyna Ibanez, MD John T. Poirier, PhD MEMBERS Gregory J. Riely, MD, PhD Sung Wu Sun, MD Alexander M. Lesokhin, MD Ronald G. Blasberg, MD Lisa M. Ruppert, MD Dharmarao Thapi, PhD Alan C. Carver, MD Eric J. Sherman, MD Adrienne Vincenzino, MD Maeve A. Lowery, MBB, Ch, BAO Kathleen M. Foley, MD Roma Tickoo, MD Society of Memorial Sloan Kettering Igor T. Gavrilovic, MD Efstathia Tzatha, MD Zsofia K. Stadler, MD George K. Wang, MD, PhD Vicky Makker, MD AT HOSPITAL FOR SPECIAL Cancer Center Chair Yvona Griffo, MD Emily S. Tonorezos, MD Steven Q. Wang, MD Matthew J. Matasar, MD SURGERY Paul A. Glare, MBBS, Memorial Hospital Yasmin Khakoo, MD PROFESSIONAL SUPPORT Tiffany A. Traina, MD Robin B. Mendelsohn, MD Members (Affiliate) Chair and Attending Ying-Xian Pan, PhD, Memorial Hospital Natalie Moryl, MD STAFF Kathleen M. Wesa, MD ASSISTANT MEMBERS Ana M. Molina, MD Michael D. Lockshin, MD Lisa M. DeAngelis, MD Assistant Laboratory Member (Level I) Gavril W. Pasternak, MD, PhD Craig P. Nolan, MD Richard M. White, MD, PhD Tanya M. Nikolova, MD Steven K. Magid, MD Lillian Rojtman Berkman Chair Susruta Majumdar, PhD Abraham Aragones, MD Anne Burnett Tandy Chair of Michael D. Stubblefield, MD Kenneth Ho-Ming Yu, MD Roisin E. O’Cearbhaill, MB, BCh, BAO Stephen A. Paget, MD in Honor of Jerome B. Posner Neurology Chief, Rehabilitation Service Karen A. Autio, MD Chief, Neurology Service Paul K. Paik, MD AT NEW YORK-PRESBYTERIAN Shrujal Baxi, MD Jerome B. Posner, MD ASSISTANT CLINICAL Jae Hong Park, MD Clinical Member HOSPITAL MEMBERS (Affiliate) American Cancer Society Clinical ASSISTANT MEMBERS Margaret K. Callahan, MD, PhD Doris Ponce, MD Clinical Member (Affiliate) Joseph A. Markenson, MD Research Professor Thomas Kaley, MD Arlyn Apollo, MD Andrea Cercek Hanjis, MD Michael A. Postow, MD Jonathan D. Victor, MD, PhD George C. Cotzias Chair of Neuro- Stefan Berger, MD Jamie E. Chaft, MD Antonio M.P. Omuro, MD Christine Querfeld, MD Oncology Associate Member Elena Pentsova, MD Michelle S. Boyar, MD Mohit Chawla, MD Raajit K. Rampal, MD, PhD Assistant Members (Affiliate) (Affiliate) Neal Rosen, MD, PhD Sree Bhavani Chalasani, MBBS David J. Chung, MD, PhD Nina D. Raoof, MD Marc J. Dinkin, MD Theodore R. Fields, MD Enid A. Haupt Chair in Medical ASSISTANT CLINICAL Sanjay Chawla, MD Elizabeth A. Comen, MD Craig S. Sauter, MD Oncology MEMBERS Babak Navi, MD Helen H. Chung, MD Parastoo B. Dahi, MD Neil H. Segal, MD, PhD Associate Clinical Edward K. Avila, DO Jennifer L. DeFazio, MD Sandra P. D’Angelo, MD Assistant Clinical Member Brian Shaffer, MD Members (Affiliate) ASSOCIATE MEMBERS Christian M. Custodio, MD Barbara C. Egan, MD Daniel C. Danila, MD (Affiliate) Pari M. Shah, MD Anne R. Bass, MD Xi Chen, MD, PhD, Memorial Hospital Sonia K. Sandhu, DO Azeez Farooki, MD Bahar Dasgeb, MD Kaleb H. Yohay, MD Armin Shahrokni, MD C. Ronald MacKenzie, MD Denise D. Correa, PhD, Memorial Jonas M. Sokolof, DO Julie Fasano, MD Avni M. Desai, MD Stacy M. Stabler, MD, PhD Lisa R. Sammaritano, MD Hospital Monica Girotra, MD Mark A. Dickson, MD AT ROCKEFELLER UNIVERSITY Eytan M. Stein, MD Sergio Schwartzman, MD Ingo K. Mellinghoff, MD ASSISTANT MEMBERS Member (Affiliate) Zoe Goldberg, MD Lisa C. Diamond, MD Roni Tamari, MD Robert F. Spiera, MD Evnin Family Chair in Neuro- (Level I) Robert B. Darnell, MD, PhD Tabitha N. Goring, MD Alexander E. Drilon, MD Ying Taur, MD Oncology Eli L. Diamond, MD Mila Gorsky, MD Andrew S. Epstein, MD Roma Tickoo, MD Christian Grommes, MD Shellie Gumbs, MD Devika Gajria, MD Departments of Memorial Hospital Departments of Memorial Hospital

Department of Neurosurgery as of February 1, 2014 Department of Pediatrics as of February 1, 2014

MEMBERS AT NEW YORK-PRESBYTERIAN Associate Clinical Member MEMBERS ASSOCIATE CLINICAL Associate Clinical HOSPITAL MEMBERS Members (Affiliate) Mark H. Bilsky, MD, Memorial Hospital (Affiliate) David H. Abramson, MD Members (Affiliate) Lorenz P. Studer, MD Mark M. Souweidane, MD Scott A. Armstrong, MD, PhD Abraham S. Bartell, MD Patrick A. Flynn, MD Samuel H. Selesnick, MD, Memorial Viviane S. Tabar, MD Grayer Family Chair Richard C. Meagher, PhD Bruce M. Greenwald, MD Hospital Assistant Members Farid Boulad, MD, Memorial Hospital Yasmin Khakoo, MD Jeffrey Kern, MD Philip E. Stieg, MD, PhD (Affiliate) ASSISTANT MEMBERS Nai-Kong V. Cheung, MD, PhD Joshua P. Needleman, MD Marc A. Cohen, MD ASSISTANT MEMBERS Chair and Attending Cameron W. Brennan, MD Chair and Attending Enid A. Haupt Chair in Pediatric Maria G. Vogiatzi, MD Associate Member Philip H. Gutin, MD Jeffrey P. Greenfield, MD, PhD Richard J. O’Reilly, MD Oncology Jennifer S. Ford, PhD Stefan Worgall, MD, PhD Ilya Laufer, MD (Affiliate) Fred Lebow Chair in Neuro-Oncology Claire L. Tow Chair in Pediatric Ira J. Dunkel, MD, Memorial Hospital Todd E. Heaton, MD Michael Kaplitt, MD, PhD Oncology Research Nancy A. Kernan, MD, Memorial Alex Kentsis, MD, PhD Assistant Members (Affiliate) Chief, Bone Marrow Transplant Service Hospital Christine A. Pratilas, MD Brian H. Kushner, MD, Memorial Stephen S. Roberts, MD Naomi B. Bishop, MD Department of Pathology as of February 1, 2014 Hospital Deyin Doreen Hsing, MD Michael P. LaQuaglia, MD, Memorial ASSISTANT MEMBERS David C. Lyden, MD, PhD (Level I) MEMBERS William D. Travis, MD, Memorial Jason T. Huse, MD, PhD Hospital Chani Traube, MD Alexander Ja-Ho Chou, MD Cristina Antonescu, MD Hospital Nora Katabi, MD Joseph H. Burchenal Chair in Stephen W. Gilheeney, MD Edi Brogi, MD, PhD, Memorial Hospital Maureen F. Zakowski, MD, Memorial Melissa Murray, DO Pediatrics Assistant Clinical Hospital Aisha N. Hasan, MBBS Members (Affiliate) Klaus J. Busam, MD, Memorial Hospital Christopher Y. Park, MD, PhD Paul A. Meyers, MD, Memorial Hospital Julia A. Kearney, MD Seena S. Abraham, MBBS Ahmet Dogan, MD, PhD, Memorial Kay J. Park, MD Robbins Family Chair in Pediatrics CLINCIAL MEMBERS Zoltan Antal, MD Hospital Melissa P. Pulitzer, MD Kevin C. Oeffinger, MD, Memorial Susan E. Prockop, MD Dilip D. Giri, MBBS, MD Hospital Sheila J. Carroll, MD Chair and Attending Chief, Hematopathology Service Natasha Rekhtman, MD, PhD Neerav N. Shukla, MD Khedoudja Nafa, PhD Michel Sadelain, MD, PhD Jeffrey Dayton, MD David S. Klimstra, MD Ronald A. Ghossein, MD Mikhail Roshal, MD, PhD Johannes L. Zakrzewski, MD Lee K. Tan, MD Stephen and Barbara Friedman Steven Pon, MD Memorial Hospital Meera R. Hameed, MBBS, Memorial Sahussapont J. Sirintrapun, MD Christina E. Vallejo, MD Chair PROFESSIONAL SUPPORT Leonard G. Steinberg, MD James Ewing Chair Hospital Efsevia Vakiani, MD, PhD Charles A. Sklar, MD, Memorial STAFF Anne E. Stone, MD Acting Chief, Surgical Pathology Yong Hannah Wen, MD, PhD Associate Laboratory Member Service ASSOCIATE MEMBERS Hospital Kaleb H. Yohay, MD Emily Cheng, MD, PhD Laurel J. Steinherz, MD, Memorial Irene Y. Cheung, ScD Suresh C. Jhanwar, PhD, Memorial ASSISTANT CLINICAL MEMBER Hospital April Chiu, MD, Memorial Hospital Hospital Assistant Member Laetitia A. Borsu-Valente, PhD Assistant Laboratory Member (Level 1) (Affiliate) Achim Jungbluth, MD, PhD, Memorial Samson W. Fine, MD, Memorial Peter G. Steinherz, MD, Memorial Hospital Hospital Hospital Ekaterina Doubrovina, MD, PhD Joy D. Howell, MD ASSISTANT MEMBERS Leonard H. Wexler, MD, Memorial Marc Ladanyi, MD André L. Moreira, MD, PhD, Memorial (Level I) Hospital AT NEW YORK-PRESBYTERIAN William J. Ruane Chair in Molecular Hospital Donavan Cheng, PhD HOSPITAL Oncology Laura H. Tang, MD, PhD, Memorial Sarah Chiang, MD ASSOCIATE MEMBERS Clinical Member (Affiliate) Oscar Lin, MD, Memorial Hospital Hospital Deborah F. DeLair, MD Kim Kramer, MD, Memorial Hospital Patricia J. Giardina, MD Acting Chief, Cytology Service Snjezana Dogan, MD Shakeel Modak, MBBS, Jorge S. Reis-Filho, MD, PhD ASSOCIATE CLINICAL MEMBER David C. Park, MD Memorial Hospital Associate Member (Affiliate) Victor E. Reuter, MD Filiz Sen, MD Dara S. Ross, MD Andromachi. Scaradavou, MD, James B. Bussel, MD, Memorial Hospital Marc K. Rosenblum, MD, Memorial Carlie S. Sigel, MD Memorial Hospital Hospital ASSISTANT MEMBERS Britta Weigelt, PhD Tanya M. Trippett, MD, Narasimhan Agaram, MBBS Founder’s Chair Memorial Hospital Hikmat A. Al-Ahmadie, MD Chief, Neuropathology and Autopsy PROFESSIONAL SUPPORT Service Maria E. Arcila, MD STAFF Jinru Shia, MD, Memorial Hospital Olca Basturk, MD Associate Laboratory Members Robert A. Soslow, MD, Memorial Michael F. Berger, PhD Marija Drobnjak, MD Hospital Yingbei Chen, MD, PhD Liying Zhang, MD, PhD Julie Teruya-Feldstein, MD, Memorial Adriana Dionigi Corben, MD Hospital Marcia Edelweiss, MD Assistant Laboratory Member Satish K. Tickoo, MD, Memorial Anuradha Gopalan, MBBS Lu Wang, MD, PhD Hospital Travis J. Hollmann, MD, PhD Departments of Memorial Hospital Departments of Memorial Hospital

Department of Psychiatry and Behavioral Sciences as of February 1, 2014 Department of Radiology as of February 1, 2014

MEMBERS ASSOCIATE MEMBERS James C. Root, PhD MEMBERS H. William Strauss, MD ASSOCIATE CLINICAL Timothy A. Ahles, PhD Jeanne Carter, PhD, Memorial Hospital Elizabeth L. Ryan, PhD Ronald G. Blasberg, MD Wolfgang A. Weber, MD MEMBERS Katherine N. DuHamel, PhD, Memorial Jennifer L. Hay, PhD Karen T. Brown, MD, Memorial Chief, Molecular Imaging and Linda R. Aboody, MD Hospital Tomer T. Levin, MBBS, Memorial ASSISTANT MEMBERS Hospital Therapy Service William Alago, Jr., MD Francesca M. Gany, MD Hospital (Level I) Jorge A. Carrasquillo, MD Pat B. Zanzonico, PhD, Memorial Lynn A. Brody, MD Chief, Immigrant Health and Cancer Yuelin Li, PhD, Memorial Hospital Allison J. Applebaum, PhD D. David Dershaw, MD, Memorial Hospital Betty A. Caravella, MD Acting Chair and Disparities Service Abraham Aragones, MD Chair and Attending Hospital Kimberly N. Feigin, MD Attending Jimmie C. Holland, MD ASSOCIATE CLINICAL MEMBER Lisa C. Diamond, MD Hedvig Hricak, MD, PhD Yuman Fong, MD CLINICAL MEMBERS Arthur A. Fruauff, MD William S. Breitbart, MD Wayne E. Chapman Chair of Abraham S. Bartell, MD Jada G. Hamilton, PhD Carroll and Milton Petrie Chair Murray F. Brennan Chair in Surgery Andrea F. Abramson, MD Scott R. Gerst, MD Chief, Psychiatry Service Psychiatric Oncology Julia A. Kearney, MD Michelle S. Ginsberg, MD, Memorial Sara J. Abramson, MD Sofia S. Haque, MD Mary Jane Massie, MD, Memorial ASSISTANT MEMBERS Jennifer C.F. Leng, MD Hospital Ariadne M. Bach, MD Tammy Huang, MD Hospital Yesne Alici, MD Talia I. Zaider, PhD Marc J. Gollub, MD, Memorial Hospital Michael S. Baum, MD Tunc A. Iyriboz, MD Jamie S. Ostroff, PhD Smita Banerjee, PhD Andrei I. Holodny, MD, Memorial Mark J. Bluth, MD Stefanie S. Jacobs, MD Chief, Behavioral Sciences Service John (Jack) E. Burkhalter, PhD PROFESSIONAL SUPPORT Hospital James F. Caravelli, MD Maxine S. Jochelson, MD STAFF Jennifer S. Ford, PhD Chief, Neuroradiology Service Christopher E. Comstock, MD Jennifer B. Kaplan, MD CLINICAL MEMBERS Assistant Laboratory Member Wendy G. Lichtenthal, PhD John L. Humm, PhD, Memorial Otilia-Liana Dumitrescu, MD Delia M. Keating, MD Philip A. Bialer, MD Thomas M. Atkinson, PhD Hospital Christian J. Nelson, PhD George I. Getrajdman, MD Robert A. Lefkowitz, MD Andrew J. Roth, MD Jason A. Koutcher, MD, PhD Peter Kijewski, PhD Svetlana Mironov, MD Steven M. Larson, MD George Krol, MD Sadek Nehmeh, PhD Donna and Benjamin M. Rosen Chair Anita P. Friedman Price, MD Debra M. Sarasohn, MD in Radiology Hilda E. Stambuk, MD Marc Z. Simmons, MD Carol H. Lee, MD, Memorial Hospital Jerrold B. Teitcher, MD Barbara Wajsbrot-Kandel, MD Department of Radiation Oncology as of February 1, 2014 Jason S. Lewis, PhD Jean M. Torrisi, MD Corinne B. Winston, MD Emily Tow Jackson Chair in Oncology MEMBERS ASSOCIATE MEMBERS ASSISTANT CLINICAL ASSOCIATE MEMBERS ASSISTANT MEMBERS Chief, Radiochemistry and Imaging David H. Abramson, MD Timothy A. Chan, MD, PhD MEMBERS Oguz Akin, MD, Memorial Hospital Sciences Service Omer Aras, MD Kaled M. Alektiar, MD, Memorial Frederick R. Adler, Chair for Junior Karen Borofsky, MD Michelle S. Bradbury, MD, PhD Laura Liberman, MD, Memorial Kinh Gian (Richard) Do, MD, PhD Hospital Faculty James E. Lee, MD Anne M. Covey, MD, Memorial Hospital Hospital Mark Phillip S. Dunphy, DO Zvi Fuks, MD Karyn A. Goodman, MD, Memorial Melissa R. Remis, MD Amita Dave, PhD, Memorial Hospital Elizabeth A. Morris, MD, Memorial Joseph P. Erinjeri, MD, PhD Hospital Alfred P. Sloan Chair Hospital Jeremy C. Durack, MD, Memorial Ravinder K. Grewal, MD Chair and Attending Yoshiya Yamada, MD, Memorial ASSISTANT MEMBERS Hospital Nancy Lee, MD Chief, Breast Imaging Service Jan Grimm, MD, PhD Simon N. Powell, MBBS, PhD Hospital (Level I) Sasan Karimi, MD, Memorial Hospital Beryl McCormick, MD, Memorial David M. Panicek, MD, Memorial Vaios Hatzoglou, MD Enid A. Haupt Chair in Hospital Christopher A. Barker, MD Eric Lis, MD, Memorial Hospital Hospital Kayvan R. Keshari, PhD ASSOCIATE CLINICAL Pinaki R. Dutta, MD, PhD Radiation Oncology Chief, External Beam Radiotherapy Evis Sala, MD, PhD, Memorial Hospital Yousef Mazaheri, PhD, Memorial MEMBERS Moritz F. Kircher, MD Service Gaorav Gupta, MD, PhD Hospital Chief, Body Imaging Service John K. Lyo, MD Suzanne L. Wolden, MD Daphna Y. Gelblum, MD Sean M. McBride, MD Neeta Pandit-Taskar, MBBS, Memorial Heiko Schoder, MD, Memorial Hospital Majid Maybody, MD Joachim Yahalom, MD Richard M. Gewanter, MD Preeti K. Parhar, MD Hospital Constantinos T. Sofocleous, MD, PhD, Joseph R. Osborne, MD, PhD Michael J. Zelefsky, MD Boris Mueller, MD William R. Polkinghorn, MD Harpreet K. Pannu, MD, Memorial Memorial Hospital Vladimir Ponomarev, MD, PhD Borys R. Mychalczak, MD Andreas Rimner, MD Hospital Chief, Brachytherapy Service Stephen B. Solomon, MD, Memorial Kyung K. Peck, PhD, Memorial Hospital Thomas Reiner, PhD Abraham Jing-Ching Wu, MD Hospital ASSISTANT MEMBERS Jurgen Rademaker, MD, Memorial Elmer B. Santos, MD, PhD CLINICAL MEMBER Chief, Interventional Radiology Kathryn F. Beal, MD Hospital Janice S. Sung, MD Karen D. Schupak, MD PROFESSIONAL SUPPORT Service Oren Cahlon, MD STAFF Raymond H. Thornton, MD, Memorial Elizabeth J. Sutton, MDCM Richard M. Steingart, MD, Memorial Laboratory Member Hospital Sunitha B. Thakur, PhD Alice Yoosun Ho, MD Hospital Marisa A. Kollmeier, MD Adriana Haimovitz-Friedman, PhD Kristen L. Zakian, PhD, Memorial Gary A. Ulaner, MD, PhD Helen L. Sidebotham, MD Hospital Hebert A. Vargas Alvarez, MD Hooman Yarmohammadi, MD Robert J. Young, MD Departments of Memorial Hospital Departments of Memorial Hospital

Department of Radiology as of February 1, 2014 Department of Surgery as of February 1, 2014

ASSISTANT CLINICAL Weining Ma, MD PROFESSIONAL SUPPORT AT NEW YORK-PRESBYTERIAN Virgilio Sacchini, MD, Memorial Jeanne Carter, PhD, David J. Finley, MD Assistant Clinical Member MEMBERS Robert H. Siegelbaum, MD STAFF HOSPITAL Hospital Memorial Hospital Jasmine H. Francis, MD (Affiliate) Associate Laboratory Members Member (Affiliate) Sandra Brennan, MB, BCh, BAO Jatin P. Shah, MD, Memorial Hospital Brett S. Carver, MD Todd E. Heaton, MD John P. Lyden, MD Joshua L. Chaim, DO ASSISTANT MEMBERS Michael R. McDevitt, PhD Robert D. Zimmerman, M.D., Elliot W. Strong Chair in Head and Jonathan A. Coleman, MD, Memorial James Huang, MD (Level I) Memorial Hospital AT NEW YORK-PRESBYTERIAN Donna D. D’Alessio, MD Nagavarakishore Pillarsetty, PhD Neck Oncology Hospital Elizabeth L. Jewell, MD HOSPITAL Stephen E. Fleming, Jr., MD Allison S. Aguado, MD Chief, Head and Neck Service Ian Ganly, MB, ChB, PhD, Memorial T. Peter Kingham, MD Member (Affiliate) Assistant Laboratory Members Associate Member (Affiliate) Hospital James L. Fuqua, III, MD Josef J. Fox, MD Ashok R. Shaha, MD, Memorial Hospital Evan Matros, MD Neil H. Bander, MD Miriam Benezra, PhD Douglas J. Ballon, PhD Ginger J. Gardner, MD, Memorial Jeffrey Girshman, MD Jill S. Gluskin, MD Jatin P. Shah Chair in Head and Neck Luc G.T. Morris, MD Sean D. Carlin, PhD Surgery and Oncology Hospital Mary C. Hughes, MD David H. Gultekin, PhD Catherine and Frederick R. Adler Associate Clinical Member Clinical Member (Affiliate) Sinchun Hwang, MD Sara A. Hayes, MB, BCh, BAO Darren R. Veach, PhD Joel Sheinfeld, MD, Memorial Hospital Mary L. Gemignani, MD, Memorial (Affiliate) Chair for Junior Faculty Vijay K. Anand, MBBS Hospital Yuliya Lakhman, MD Seth S. Katz, MD, PhD William G. Cahan Chair in Surgery Garrett M. Nash, MD Linda A. Heier, MD Noah D. Kauff, MD, Memorial Hospital Andrew J. Plodkowski, MD Samuel Singer, MD Jonathan Landa, DO Inderpal Singh Sarkaria, MD Associate Member (Affiliate) Tari King, MD, Memorial Hospital Govindarajan Srimathveeravalli, PhD Vincent Astor Chair of Clinical Duan Li, MD Assistant Member (Affiliate) Oliver Zivanovic, MD Mark I. Rosenblatt, MD, PhD Research Jeanne A. Petrek Junior Faculty Muthukumar Thangamani, MBBS Chief, Gastric and Mixed Tumor Chair ASSISTANT CLINICAL Associate Clinical Service Mario M. Leitao, Jr., MD, MEMBERS Members (Affiliate) Bhuvanesh Singh, MD, PhD Memorial Memorial Hospital Jerry L. Halpern, DDS Murk-Hein Heinemann, MD Hospital Douglas A. Levine, MD, Memorial Sae Hee Kim, DDS Glenn L. Schattman, MD Department of Surgery as of February 1, 2014 Pramod C. Sogani, MD, Memorial Hospital Debra Mangino, DO Darren B. Schneider, MD Hospital Colleen M. McCarthy, MD, Steven J. Tunick, DMD Diane E. Stover, MD, Memorial Hospital Memorial Hospital MEMBERS Ronald P. DeMatteo, MD Harry W. Herr, MD, Memorial Hospital Assistant Members Kimberly J. Van Zee, MD, Memorial Snehal G. Patel, MBBS, Memorial David H. Abramson, MD Leslie H. Blumgart Chair in Surgery William J. Hoskins, MD ASSISTANT MEMBERS (Affiliate) Hospital Hospital Chief, Ophthalmic Oncology Service Joseph J. Disa, MD, Memorial Hospital William R. Jarnagin, MD, (Level 1) Peter H. Connolly, MD Martin R. Weiser, MD, Memorial Andrea L. Pusic, MD Nadeem R. Abu-Rustum, MD, Memorial S. Machele Donat, MD, Memorial Memorial Hospital Mohit Chawla, MD Nabil Rizk, MD, Memorial Hospital Marc J. Dinkin, MD Enid A. Haupt Chair in Surgery Hospital Hospital Hospital Behfar Ehdaie, MD Leonard N. Girardi, MD Richard J. Wong, MD Jaspreet S. Sandhu, MD, Memorial Peter J. Allen, MD, Memorial Hospital Robert J. Downey, MD, Memorial Chief, Hepatopancreatobiliary Melissa L. Pilewskie, MD Hospital Charles A. Mack, III, MD Hospital Service Chair and MEMBER Richard R. Barakat, MD, Memorial George Plitas, MD Andrew J. Meltzer, MD CLINICAL MEMBERS Yukio Sonoda, MD, Memorial Hospital Hospital James A. Eastham, MD, Memorial David R. Jones, MD Peter T. Scardino, MD Anton Orlin, MD Manjit S. Bains, MD Vivian E. Mack Strong, MD, Memorial Ronald O. Perelman Chair in Hospital Chief, Thoracic Service PROFESSIONAL SUPPORT David H. Koch Chair Hospital Nitsana A. Spigland, MD Gynecologic Surgery Florence and Theodore Baumritter/ Michael P. LaQuaglia, MD, Memorial Patrick J. Boland, MD STAFF Larissa K.F. Temple, MD, Memorial Chief, Gynecology Service Enid Ancell Chair of Urologic Hospital Mercedes Castiel, MD Assistant Laboratory Members Hospital AT THE RALPH LAUREN Leslie H. Blumgart, MD Oncology Joseph H. Burchenal Chair in Cherry L. Estilo, DMD Yuan Liu, MD, PhD Karim A. Touijer, MD, Memorial CENTER FOR CANCER CARE Chief, Urology Service Pediatrics Alexandra S. Heerdt, MD Zhaoshi Zeng, MD AND PREVENTION Bernard H. Bochner, MD, Memorial Hospital Hospital Mahmoud El-Tamer, MD, Memorial Chief, Pediatric Surgical Service Joseph M. Huryn, DDS Member (Affiliate) Sam S. Yoon, MD, Memorial Hospital Murray F. Brennan, MD Hospital Hans G. Lilja, MD, Memorial Hospital Chief, Dental Service AT COLUMBIA UNIVERSITY Harold P. Freeman, MD, Memorial Nicola Fabbri, MD, Memorial Hospital Babak Mehrara, MD Maureen Killackey, MD Assistant Member (Level 1) Hospital Benno C. Schmidt Chair in Clinical ASSOCIATE CLINICAL Yuman Fong, MD (Affiliate) Oncology Monica Morrow, MD Raul O. Parra, MD MEMBERS Murray F. Brennan Chair in Surgery Allan D. Greenberg, DMD, PhD Associate Clinical Member Dennis S. Chi, MD, Memorial Hospital Anne Burnett Windfohr Chair of Lisa M. Sclafani, MD Deborah M. Capko, MD Julio Garcia-Aguilar, MD, PhD Clinical Oncology (Affiliate) Hiram S. Cody, III, MD, Memorial Deborah J. Goldfrank, MD AT HOSPITAL FOR SPECIAL Hospital Stuart H.Q. Quan Chair in Colorectal Chief, Breast Service ASSOCIATE MEMBERS Henry G. Godfrey, MD Vincent Laudone, MD SURGERY Daniel G. Coit, MD, Memorial Hospital Surgery John P. Mulhall, MB, BCh, BAO, Prasad S. Adusumilli, MBBS, Brian P. Marr, M.D Associate Member (Affiliate) Peter G. Cordeiro, MD, Memorial Chief, Colorectal Service Memorial Hospital Memorial Hospital Edward A. Athanasian, MD, Hospital Jose G. Guillem, MD, Memorial Hospital Philip B. Paty, MD, Memorial Hospital Jay O. Boyle, MD, Memorial Hospital ASSISTANT MEMBERS Memorial Hospital Chief, Plastic and Reconstructive John H. Healey, MD Valerie W. Rusch, MD Mary S. Brady, MD, Memorial Hospital Charlotte Eielson Ariyan, MD, PhD Surgical Service Stephen McDermott Chair in Miner Family Chair in Intrathoracic Carol L. Brown, MD, Aimee M. Crago, MD, PhD Guido Dalbagni, MD, Memorial Hospital Surgery Cancers Memorial Hospital Michael D’Angelica, MD, Memorial Chief, Orthopedic Service Paul Russo, MD, Memorial Hospital Hospital Departments of Memorial Hospital Departments of Meemorialmorial HospHospitalital

Human Oncology and Pathogenesis Program as of February 1, 2014 Department of Nursing as of February 1, 2014

MEMBER James Hsieh, MD, PhD Yu Chen, MD, PhD Kathleen Choo, RN Nurse Practitioners/NP Naomi Cazeau, ANP RN Jane Duffy-Weisser, ANP, RN, NP Scott A. Armstrong, MD, PhD Ross L. Levine, MD Ping Chi, MD, PhD Amanda Copeland, RN Coordinators Jessica Cerulli, NP, RN Coordinator Grayer Family Chair Laurence Joseph Dineen Chair in Geoffrey Beene Junior Faculty Chair Maureen F. Cunningham, RN Megan P. Abate, ANP, RN Mei Ling Chan, ANP, RN Dorothy Dulko, CRNP, RN José Baselga, MD, PhD Leukemia Jason T. Huse, MD, PhD Mary Elizabeth Davis, RN Lynn Adams, ANP, RN, NP Coordinator Ewa Chauvin, ANP, RN Megan Dunne, ANP, RN James A. Fagin, MD Ingo K. Mellinghoff, MD Christopher Y. Park, MD, PhD Kristyn DiFortuna, RN Melanie Albano, CRNP, RN Leon Chen, ANP, RN Christina Durney, CPNP, RN Marc Ladanyi, MD Evnin Family Chair in Neuro- Christine Dorman, RN Rose Ali, ANP, RN Kimberly Chow, ANP, RN Nancy E. Edmonds, ANP, RN Chair and Attending Oncology William J. Ruane Chair in Molecular PROFESSIONAL SUPPORT Nkechi Fearon, RN Karen V. Allison, CPNP, RN Cynthia Ciaschi, AOCNP, RN Carlene Edwards-Robb, FNP, RN Charles L. Sawyers, MD David B. Solit, MD STAFF Oncology Erica A. Fischer-Cartlidge, RN Sharon Alvarezi, GNP, RN Laura Ciavolino, ANP, RN Milagros Elia, ANP, RN Marie-Josée and Henry R. Kravis Geoffrey Beene Chair Assistant Laboratory Members Jorge S. Reis-Filho, MD, PhD Elizabeth R. Grahn, RN Shannon Andersen, ANP, RN Keith A. Clement, ANP, RN Glenda Espinosa, ANP, RN Chair in Human Oncology Andrei V. Krivtsov, PhD Cathyann M. Hanson-Heath, RN Christine Anderson, NP, RN Gloria Coffey, ANP, RN Catherine Ann Featherstone, FNP, RN, and Pathogenesis ASSOCIATE MEMBER ASSISTANT MEMBERS Maurizio Scaltriti, PhD Catherine Hydzik, RN Holly Anderson, NP, RN Kristen Cognetti, ACNP, RN NP Coordinator Howard Hughes Medical Omar I. Abdel-Wahab, MD Timothy A. Chan, MD, PhD Sandra E. James, RN Lorraine E. Anderson, ANP, RN Abigail Cohen, ANP, RN Zulay E. Fernandez, ANP, RN Institute Investigator Michael F. Berger, PhD Frederick R. Adler Chair for Noelene A. Johnson, RN Latasha Anderson-Dunkley, ANP, RN Nancy Collado, ANP, RN Christine Ferrari, ANP, RN Junior Faculty Cameron W. Brennan, MD Joyce E. Kane, RN Latasha Andre-Jones, PNP, RN Mercedes M. Condy, CRNP, RN Cheryl M. Fischer, CPNP, RN Emily Cheng, MD, PhD Sarat Chandarlapaty, MD, PhD Nancy Karo, RN Ramadevi Arcot, ANP, RN Erin Ann Conlon, FNP, RN Cristy B. Fitzpatrick, ANP, RN Joanne F. Kelvin, RN Nadine Auguste, ACNP, RN Lenny Coraci, ANP, RN Deborah A. Fleischer, ACNP, RN Janine Kennedy, RN Jennifer Aviado-Langer, FNP, RN Zana Correa, ANP, RN Idania Flete-Olmeda, ANP, RN Christina Kiss, RN Cheryl D. Barnes, FNP, RN Marissa Corti, ANP, RN Jennifer A. Flood, ANP, RN Elizabeth Barry, FNP, RN Alison Costalos, ACNP, RN Karen A. Flynn, ACNP, RN Department of Nursing as of February 1, 2014 Robina Kitzler, RN Rebecca Kolenik, RN Melissa Barzola, ACNP, RN Margaret Courtney, AOCNP, RN Anna Ford, ACNP, RN Beth Dee Licht, RN Desiree Bascombe, ANP, RN Joanne Cregg, ANP, RN Christine Freise, ACNP, RN Directors Michele Kranz, RN Clinical/ Nurse Jamie Fritts, ANP, RN Supervisors Vashti Livingston, RN Raffi Artine Bashlian, ANP, RN Nancy Cruz-Sitner, ANP, RN Kevin P. Browne, RN, MS, CCRN Catherine T. Licitra, RN Diane M. Llerandi, RN Melissa Bassis, ACNP, RN Bernadette M. Cuello, ANP, RN Erin Fusco, FNP, RN, NP Coordinator Michelle Burke, RN, MSA, CNOR Sulin Low, RN Nancy M. Borzain, RN Nora A. Love, RN Rana Bazzi, ACNP, RN Laryn M. Cullen, ANP, RN Patricia Gabriel, ANP, RN MaryAnn Connor, RN, MSN, CPHIMS Annmarie Mazzella-Ebstein, RN Marie E. Cox, RN Nancy McEntee, RN Anna Bodyziak, ANP, RN Rhonda D’Agostino, ACNP, RN, NP Giuseppina Gaglio, AGPCNP-BC, RN Mary E. Dowling, RN, MSN, OCN Lorraine K. McEvoy, DNP, RN Barbara K. Hutton, RN Linda Muller, RN Christine Bray, ANP, RN Coordinator Ruth Gargan-Klinger, ANP, RN Dennis Graham, DNSc, ANP, RN Shelley W. McKay, RN Christine E. Lantier, RN Maureen G. O’Brien, RN Laurie Brusco, ANP, RN Linda D’Andrea, PNP, RN Lincy George, PNP, RN Senior Vice President, Josephine Nappi, MA, RN Patricia A. McTague-Allen, RN Kathleen Maher, RN Chief Nursing Officer Debra O’Shea, RN Jamila N. Brutus, ANP, RN Dorothea A. Dashiell, CPNP, RN Alison Gilgan, FNP, RN Rori Salvaggio, MS, RN, NEA-BC Kim Mertens, RN Jennifer Ogilvie, RN Elizabeth Nelkin McCormick, Natasha Pinheiro, RN Tara Buchholz, ACNP, RN Denise Dasti, ANP, RN Zlata Golubitskaya, AAHNP, RN Donna Schick, MA, RN, FNP-BC Donna Miale-Mayer, RN Esther M. Ruiz, RN MSN, RN Wayne Alec Quashie, RN Bernice E. Burford, ANP, RN Deeann M. Davidson, ACNP, RN Joan Gorham, NP, RN Annlouise Moran, BSN, MPH, RN, Regina Byrne, CRNP, RN Janine Davis, ACNP, RN Winsome L. Grant, WHCNP, RN, NP Enid A. Haupt Chair of Nursing Nurse Leaders/Managers/ NE-BC Nurse Educators Natasha Ramrup, RN Maura Byrnes-Casey, CPNP, RN Nancy J. DeGuzman, ANP, RN Coordinator Coordinators Altagracia I. Mota, RN Suzanne Chanel, RN Piera Robson, RN Maureen Caban, ANP, RN Anthony De La Cruz, CRNP, RN Randolph E. Gross, WHCNP, RN Abigail Baldwin, RN Maryellen O’Sullivan, RN Kristy Dunleavy, RN Debra Rodrigue, RN Jennifer M. Cagney, ANP, RN Meghan Decker, ANP, RN Maureen Guiney, ANP-BC, RN Patricia Brosnan, RN Diane Paolilli, RN Wendella Facey, RN Wanda Rodriguez, RN Amparo Camacho, ANP, RN Anna Dee, ANP, RN Michele Hall, ANP, RN Jacquelyn Burns, RN Elizabeth S. Rodriguez, DNP, RN Lisa Kennedy, RN Patricia Schaindlin, RN Maryann Canavan, ANP-BC, RN Joanne Delaleu, NP, RN Joshua Halpert, NP, RN Carole M. Cass, RN Carol Rossetto, CPNP, RN Joan McKerrow, RN Rosemary Semler, RN Joanne Candela, ANP, RN Suhana DeLeon-Sanchez, NP, RN Elizabeth F. Halton, ANP, RN Kristin Cawley, RN Corey Russell, MSN, OCN Jaime Louise McNally, RN Beth Sferrazza, RN Lisa Canecchia, ACNP, RN Amy Rose Devigne, FNP, RN Joan M. Hartnett, ANP, RN Stacie Corcoran, RN Jane A. Sallustro, RN Marjorie E. Mosley, RN Kathleen Short, RN Margaret Canjura, NP, RN Kleoniki Diamantis, FNP, RN Rebeca Hass, CPNP/CPHON, RN Susan L. Dosil-Loiacono, RN Robert Schley, RN Annette V. Pineiro, RN Margaret Simon, RN Maria Elena C. Cantos, ANP, ACNP, RN Deborah Diotallevi, CPNP, RN Kelly Haviland, NP, RN Mary M. Eagan, RN Anna M. Schloms, RN Annette Roman, RN Nicole Ventura, RN Maryann Carousso, FNP, AOCNP, RN Patricia Donoghue, NP, RN Megan Heavey, NP, RN Susan Filshie, RN Lenore Smykowski, RN Hrafn Oli Sigurdsson, RN Elisabeth M. Wall, PhD, RN Erin K. Carr, FNP, RN Maria Donzelli, CPNP, RN Courtney E. Hennelly, ANP, RN Jeanine Gordon, RN Patricia Spellman, RN Shaneka D. Storey, RN Eileen M. Walsh, RN Shirley Carrenard-McDowell, FNP, RN Karen Dougherty, ANP, RN Alison Hergianto, CRNP, RN Judy M. Graham, RN Lystra M. Swift, RN Inderani M. Walia, RN Cecilia Watson, RN Roseann Caruso, NP, RN Karen Drucker, ANP, RN Evlyn L. Hinds, FNP, RN Barbara G. Hennessey, RN Blanca M. Vasquez-Clarfield, RN Donna J. Wilson, RN Clinical Nurse Specialists Anne Regan Casson, CPNP, RN Lauren Drysdale, ANP, RN Ashley Hole, FNP, RN Nancy G. Houlihan, RN Keri Jean Wagner, RN Jean Adelhardt, RN Karen E. Holritz, ANP, RN Matthew Kennedy, RN Marianne Wallace, RN Roberta H. Baron, RN Stephanie Kennedy, RN Maribeth Woodridge-King, RN Christopher Brooks, RN Departments of Memorial Hospital Departments of Memorial Hospital

Department of Nursing as of February 1, 2014 Division of Pharmacy Services as of February 1, 2014

Mi Young Hong, ACNP, RN Suzanne Maier, CPNP-PNP-PC, RN Maria Pacis, ANP, RN Rebecca Steed, WHCNP, RN Associate Directors Rachel Choi, RPh Clinical Specialists Adults Aletha R. Huckins, FNP, RN Jibran Majeed, ACNP, RN Brima Padlan, ANP, RN Christine Stefanski, FNP, RN Stella Lee Eng, RPh Florina Chuy, RPh Manpreet Boparai, RPh Lauren Hughes, NP, RN Michelle A. Mallamud, ANP, RN Meighan Palazzo, NP, RN Deborah E. Stein, ACNP, RN Scott Freeswick, RPh Douglas Deritis, RPh Nina Cohen, RPh Brigit Huwyler, FNP, RN Jennifer L. Maloney, ACNP, RN Lauren Panico, NP, RN Karen Stellato, ANP, RN Raymond J. Muller, RPh Joseph Galgano, RPh Thu Dang, RPh Solange D. Inglis, ANP, RN Nina Maresca, FNP, RN Taylor Pecora-Saipe, PNP, RN Dyana K. Sumner, CRNP, RN Priti Patel, RPh Dennis Grossano, RPh Andrew Lin, RPh Shani Irby, ANP, RN Denise Margiotta, ACNP, RN Jennifer Pedulla, ANP, RN Marie Tait, FNP, RN Peter Ho, RPh Director Angela Michael, RPh Lorraine Jackson, ACNP, RN Kathryn Mariano, FNP, RN Purnima Persaud, NP, RN Yekaterina D. Tayban, ACNP, RN Supervisors Alan Huang, RPh Charles D. Lucarelli, RPh Alla Paskovaty, RPh Mindy Jaffe, CPNP, RN Mariel Marrano, FNP, RN Jenny Persson, ACNP, RN Jennifer Tempesta, ANP, RN Barbara Beck-Camacho, RPh Ellie Kashani-Massoumi, RPh Valkal Bhatt, RPh Laura A. James, ANP, RN Marie Kathlyn Marte, ANP, RN Mary C. Petriccione, CPNP, RN Janice Terlizzi, NP, RN Jerry Chow, RPh Michael Kellick, RPh Ryan Daley, RPh Jeanine Jerro-Doody, ANP, RN Alison Massey, ANP, RN Katherine Picconi, FNP, RN Amanda Thomas, NP, RN Jacqueline Gomes, RPh Mark Klang, RPh Kristen Beyer, RPh Christine Kasper, PNP, RN Leslie V. Matthews, ANP, RN Bobbi Pino-y-Torres, ANP, RN Ursula McPeak Tomlinson, CPNP, RN Susan Murillo, RPh Caroline Lau, RPh Anthony Proli, RPh Stacey L. Kaufman, ANP, RN Shirley Mauzoul, ANP, RN Joan M. Pope, ANP, RN Joanne E. Torok-Castanza, CPNP, RN Gerald O’Neill, RPh Diane Leone, RPh Mabel Rodriguez, RPh Stefanie Keating, ACNP, RN Joanne Maynard, ANP, RN Elaine M. Pottenger, CPNP, RN Kathleen A. Trotta, ANP, RN Melissa Lee-Teh, RPh Donna McGuffy, RPh Salma Afifi, RPh Sheila Keaveney, ANP, RN Susan McCall, CRNP, RN Nana Prempeh-Kete Ku, ANP, RN Roseann Tucci, CPNP, RN Marie Ryan, RPh Thomas Monahan, RPh Mahshid Azimi, RPh Kathleen J. Keenan, ANP, RN Janet Mc Kiernan, NP, RN Erin Punturieri, ANP, RN Leslie Tyson, CRNP, RN Dolores Sleiman, RPh Vivian Park, RPh Kevin Dai, RPh Elizabeth Kelliher, ANP, GNP, RN Emily J. McCullagh, FNP, RN Hilda Quintanilla, ANP, AOCNP, RN Idongesit Mfon Udoh, ACNP, RN John Timoney, RPh Donald Murphy, RPh Joshua Pecoraro, RPh Paulette M. Kelly, FNP, RN Courtney McElrath, AGACNP, RN Carey Ramirez, ANP, RN Yelena Ustoyev, CRNP, RN Jodi Wald, RPh Dena Rahman, RPh Rachel Garonce, RPh Sheila A. Kenny, ANP, RN Christine McGrade, FNP, RN Coleen Ranaghan, NP, RN Jennifer Valdellon, ANP, RN Elaine Yam, RPh Barbara Simon, RPh Meagan Barbee, RPh Denise M. Kessel, ANP, RN Kateri McGuire, CPNP, RN Robin Rawlins-Duell, ANP, RN Jill M. Vanak, ACNP, RN Karen Yeung, RPh Pofan Sin, RPh Lauren Koranteng, RPh Kathleen Kilroy, ANP, RN Julie Ellen Mcmahon, CPNP, RN Sarah Rebal, ACNP, RN Amy P.Y. Vatanapradit, AACNP, RN Yat Ling So, RPh Clinical Managers Nicole Kowalewski, ACNP, RN Julianne McNamara, FNP, RN Vanessa Reed, CRNP, RN Stephanie Vitolano, CPNP, RN Gregory Stelzer, RPh Nelly Adel, RPh Clinical Specialists Kelly Vuksanaj, ANP, RN James Sumka, RPh David R. Kraft, ANP, RN Margaret McSweeney, ACNP, RN, NP Tara A. Reilly, ACNP, RN Pediatrics Sherry Mathew, RPh Nicole L. Kurtis, PNP, RN Coordinator Rebecca W. Repetti, ANP, RN Emily Walther, ACNP, RN Frank Surita, RPh Melissa Pozotrigo, RPh Richard Tizon, RPh Lauren Kushner, PNP, RN Carol Ann Milazzo-Kiedaisch, FNP, RN Rosetta Richards, ANP, RN Christine D. Waters-Clayton, FNP, RN Edward Tyler, RPh Jennifer Thackray, RPh Stephen Harnicar, RPh Kenny M. Lacossiere, ANP, RN Aida Milcetic, FNP, RN Martha Rodriguez, ANP, RN Joanne Weiner, FNP, RN Frank Zappa, RPh Brian Seyboth, RPh Liza Lee Lagdamen, FNP, RN Grace Monger, CRNP, RN Rose Ann Ruddy, ACNP, RN Richard Weiner, ANP, RN Anthony Zinga, RPh Clinical Coordinators Michelle Kussin, RPh Michelle Lange, NP, RN Mary Montefusco, ACNP, RN Mary Rudzewick, ANP, RN Alyona Weinstein, CRNP, RN Stern Bereth, RPh Catherine Lapsanski, AGPCNP, RN Clare Moran, CRNP, RN Julianne Ruggiero, CPNP, RN Joanne M. Wells, ANP, RN Operations Coordinator Zenia Bunyi, RPh Ethel B. Law, ANP, RN Kara Mosesso, NP, RN Tara Russo, FNP, RN Elizabeth H. Whittam, FNP, RN Brian Del Corral, RPh Amelia Chan, RPh Alexis Leitenberger, ANP, RN Carolyn Mulryan, ANP, RN Jean Rutigliano, CPNP, RN Charles Wikle, NP, RN Angela Lentini-Rivera, CPNP, RN Yvette Murillo, FNP, RN Erin Ryan, ACNP, RN Kerry Williams, ANP, RN Nicole R. Leonhart, ANP, RN Eibhlis Murray, FNP, RN Lina Saab, FNP, RN Nadia Aziz Wilson, FNP, RN Nicole LeStrange, ANP, RN Joseph B. Narus, GNP, RN Harpinderjit Sandhu, FNP, RN Tara Wolff, NP, RN Erica G. Levinson, ANP, RN Rachel O. Nebab, ACNP, RN Anita Schabel, ANP, RN Gloria Y. Wong, ACNP, RN Isobel M. Lewis, FNP, RN Tracy Neilan, FNP, RN Mary A. Schoen, ANP, RN Christina M. Wray-Asaro, ACNP, RN Division of Social Work as of February 1, 2014 Christine A. Liebertz, ANP, RN Teresa Nguyentran, NP, RN Nadia Schwenk, ANP, RN Fengxin Wu, ACNP, RN Olivia Nicastro, ACNP, RN Yi-Chih Lin, CPNP, RN Barbara Seidel, ANP, RN Jane Yoffe, FNP, RN Senior Clinical Staff Resources for Life After Katherine G. O’Connor, ANP, RN Camille L. Lineberry, ACNP, RN Gaelle Senatus, ANP, RN Joanna Yohannes-Tomicich, ANP, RN Margery Davis, LCSW Cancer Mary Ann P. O’Connor, FNP, RN Ashley Linington, ACNP-BC, RN Yelena Shames, ACNP, RN Heidi M. Yulico, GNP, RN Rosalind Kleban, LCSW Annamma Abraham–Kaba, LCSW Siobhan O’Donnell, FNP, RN Marie-Helene Lofland, ANP, RN Rosanne Sharp, ANP, RN Nicole Zakak, CPNP, RN Anne Martin, LCSW Kristen Ohagan, ANP, RN Helen M. Loumeau, ANP, RN Caroline Shirzadi, NP, RN Joan M. Zatcky, ACNP, RN Nadine Lugo, NP, RN Shannon O’Keeffe, ACNP, RN Kara Ann Singer, ANP, RN Rebecca Zeuren, ANP, RN Andria D. Lyn, ACNP, RN Robert U. Okolie, NP, RN Ana Sjoberg, ANP, RN Joanna Zizzo, ACNP, RN Director Peggy Lynch, CRNP, RN Adriana Olivo, ANP, RN Zeta Smikle-Hamilton, ANP, RN Nicole Zoller, AGACNP, RN Penny Damaskos, PhD, Noelia Maamouri, ACNP, RN Marykate O’Rourke, ACNP, RN Letitia Smith, FNP, RN LCSW, OSW-C Kelly M. Magee, FNP, RN, NP Claudia M. Ortiz, WHCNP, RN Tammy Son, ACNP, RN Coordinator Rosemary Ortiz, FNP, RN Celeste M. Springer, ANP, RN Programs of the sloan kettering institute Programs of the sloan kettering institute

Steering Committee as of February 1, 2014 Cell Biology Program as of February 1, 2014

Kathryn Anderson, PhD Alexander Rudensky, PhD MEMBERS ASSOCIATE MEMBER AT ROCKEFELLER UNIVERSITY Eric Cottington, PhD Chris Sander, PhD Raju S.K. Chaganti, PhD Meng-Fu Bryan Tsou, PhD Assistant Member (Affiliate) John Gunn David Scheinberg, MD, PhD William E. Snee Chair Hironori Funabiki, PhD Alan Hall, PhD Craig Thompson, MD (ex officio) Filippo G. Giancotti, MD, PhD ASSISTANT MEMBERS Kenneth Marians, PhD Xuejun Jiang, PhD Emily A. Foley, PhD AT WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY Nikola Pavletich, PhD Paul A. Marks, MD Cole M. Haynes, PhD Member (Affiliate) Director, SKI Chair and Member Malcolm A.S. Moore, DPhil Philipp M. Niethammer, PhD Joan Massagué, PhD Timothy A. Ryan, PhD Alan Hall, PhD Enid A. Haupt Chair of Cell Biology Michael H. Overholtzer, PhD Alfred P. Sloan Chair Alfred P. Sloan Chair Marilyn D. Resh, PhD Howard Hughes Medical Urs Rutishauser, PhD PROFESSIONAL SUPPORT Institute Investigator STAFF Assistant Laboratory Member Gouri Nanjangud, PhD

Cancer Biology and Genetics Program as of February 1, 2014 Computational Biology Program as of February 1, 2014

MEMBERS PROFESSIONAL SUPPORT JOINT APPOINTMENT ASSOCIATE MEMBERS PROFESSIONAL SUPPORT AT WEILL MEDICAL COLLEGE STAFF STAFF OF CORNELL UNIVERSITY Robert Benezra, PhD Kenneth Offit, MD Gregoire Altan-Bonnet, PhD Laboratory Members Associate Laboratory Members Member (Affiliate) Scott W. Lowe, PhD Bristol-Myers Squibb/James D. Ralph J. Garippa, PhD Raya Khanin, PhD Harel Weinstein, DSc Geoffrey Beene Senior Faculty Chair Robinson, III Junior Faculty Chair Neil S. Lipman, VMD Nikolaus Schultz, PhD Craig B. Thompson, MD Christina S. Leslie, PhD Felix R. Wolf, DVM, PhD Gunnar Raetsch, PhD Nicholas D. Socci, PhD Chair and Member ASSOCIATE MEMBERS Chair and Member Associate Laboratory Member Joan Massagué, PhD Johanna A. Joyce, PhD Chris Sander, PhD ASSISTANT MEMBERS Andrew C. Nicholson, DVM, PhD Alfred P. Sloan Chair Hans G. Wendel, MD Tri-Institutional Professor John D. Chodera, PhD Howard Hughes Medical Joao de Bivar Xavier, PhD Assistant Laboratory Members Institute Investigator ASSISTANT MEMBERS Justin R. Cross, PhD Kitai Kim, PhD Christine Lieggi, DVM Geoffrey Beene Junior Faculty Chair Kerith R. Luchins, DVM Developmental Biology Program as of February 1, 2014 Christine Mayr, MD Sebastien Monette, DVM Andrea Ventura, MD, PhD Rodolfo J. Ricart-Arbona, DVM MEMBERS ASSOCIATE MEMBERS PROFESSIONAL SUPPORT Richard M. White, MD, PhD Julie White, DVM Mary K. Baylies, PhD Anna-Katerina Hadjantonakis, PhD STAFF Peter Besmer, PhD Song-Hai Shi, PhD Laboratory Members Maria Jasin, PhD Bristol-Myers Squibb/James D. Katia O. Manova-Todorova, PhD William E. Snee Chair Robinson, III Junior Faculty Chair Willie H. Mark, PhD Alexandra L. Joyner, PhD Jennifer A. Zallen, PhD Chair and Member Courtney Steel Chair in Pediatric Howard Hughes Medical Institute Associate Laboratory Member Kathryn V. Anderson, PhD Cancer Research Investigator Mark J. Tomishima, PhD Enid A. Haupt Chair in Elizabeth H. Lacy, PhD Developmental Biology Eric C. Lai, PhD ASSISTANT MEMBERS Assistant Laboratory Member Lorenz P. Studer, MD Zhirong Bao, PhD Peter J. Romanienko, PhD Mary G. Goll, PhD Danwei Huangfu, PhD Julia A. Kaltschmidt, PhD Programs of the sloan kettering institute Programs of the sloan kettering institute

Immunology Program as of February 1, 2014 Molecular Pharmacology and Chemistry Program as of February 1, 2014

MEMBERS ASSISTANT MEMBER JOINT APPOINTMENTS MEMBERS Neal Rosen, MD, PhD Associate Laboratory Members Michael S. Glickman, MD Joseph C. Sun, PhD Ronald P. DeMatteo, MD Colin B. Begg, PhD Enid A. Haupt Chair in Medical Elisa de Stanchina, PhD Alfred P. Sloan Chair Leslie H. Blumgart Chair in Surgery Eugene W. Kettering Chair Oncology Lee J. McDonald, PhD Alan N. Houghton, MD PROFESSIONAL SUPPORT Katharine C. Hsu, MD, PhD Ronald G. Blasberg, MD Charles M. Rudin, MD, PhD George D. Sukenick, PhD STAFF Richard J. O’Reilly, MD Jedd D. Wolchok, MD, PhD Murray F. Brennan, MD Michel Sadelain, MD, PhD Laboratory Member Claire L. Tow Chair in Pediatric Lloyd J. Old Chair for Clinical Benno C. Schmidt Chair in Clinical Stephen and Barbara Friedman Assistant Laboratory Members Tullia Lindsten, MD, PhD Chair and Member Oncology Research Investigation Chair and Member Oncology Chair Ying-Xian Pan, PhD Alexander Y. Rudensky, PhD Eric G. Pamer, MD James W. Young, MD David A. Scheinberg, MD, PhD Bayard D. Clarkson, MD Peter T. Scardino, MD Xiuyan Wang, PhD Associate Laboratory Members Howard Hughes Medical Enid A. Haupt Chair in Clinical Vincent Astor Chair Enid A. Haupt Chair of Therapeutic David H. Koch Chair P. Jan Hendrikx, PhD Institute Investigator Investigation Research Derek S. Tan, PhD AT CORNELL UNIVERSITY Frances Weis-Garcia, PhD Marcel R.M. van den Brink, MD, PhD Samuel J. Danishefsky, PhD Wolfgang A. Weber, MD Assistant Member (Affiliate) Phillip Wong, PhD Alan N. Houghton Chair Eugene W. Kettering Chair Chief, Molecular Imaging and Hening Lin, PhD Zvi Fuks, MD Therapy Service Assistant Laboratory Members ASSOCIATE MEMBERS Alfred P. Sloan Chair AT ROCKEFELLER UNIVERSITY Annamalai Selvakumar, PhD Jayanta Chaudhuri, PhD Hedvig Hricak, MD, PhD ASSOCIATE MEMBERS Assistant Member (Affiliate) Jianda Yuan, MD, PhD Morgan Huse, PhD Carroll and Milton Petrie Chair Gabriela Chiosis, PhD Sean Brady, PhD Ming Li, PhD Richard N. Kolesnick, MD Renier J. Brentjens, MD, PhD Jason A. Koutcher, MD, PhD JOINT APPOINTMENTS Steven M. Larson, MD ASSISTANT MEMBERS Michelle S. Bradbury, MD, PhD Donna and Benjamin M. Rosen Chair Jan Grimm, MD, PhD Renier J. Brentjens, MD, PhD in Radiology Daniel A. Heller, PhD Kayvan R. Keshari, PhD Jason S. Lewis, PhD Alex Kentsis, MD, PhD Jason A. Koutcher, MD, PhD Emily Tow Jackson Chair in Michael G. Kharas, PhD Jason S. Lewis, PhD Molecular Biology Program as of February 1, 2014 Oncology Minkui Luo, PhD Emily Tow Jackson Chair in Yueming Li, PhD Oncology MEMBERS ASSOCIATE MEMBER JOINT APPOINTMENT Gavril W. Pasternak, MD, PhD PROFESSIONAL SUPPORT Vladimir Ponomarev, MD, PhD Jerard Hurwitz, PhD Xiaolan Zhao, PhD Simon N. Powell, MBBS, PhD Anne Burnett Tandy Chair of STAFF Charles M. Rudin, MD, PhD Prasad V. Jallepalli, MD, PhD Enid A. Haupt Chair in Radiation Neurology Laboratory Members Wolfgang A. Weber, MD Scott N. Keeney, PhD ASSISTANT MEMBERS Oncology Jerome B. Posner, MD Hakim Djaballah, PhD Howard Hughes Medical Institute Xiaohui Qu, PhD American Cancer Society Clinical Ronald C. Hendrickson, PhD Investigator Dirk Remus, PhD Research Professor Ouathek Ouerfelli, PhD Chair and Member Thomas J. Kelly, MD, PhD Iestyn Whitehouse, PhD George C. Cotzias Chair of Isabelle Riviere, PhD Kenneth J. Marians, PhD Benno C. Schmidt Chair of Cancer Neuro-Oncology William E. Snee Chair Research PROFESSIONAL SUPPORT Andrew Koff, PhD STAFF John H.J. Petrini, PhD Laboratory Members as of February 1, 2014 Paul A. Marks Chair in Molecular Hediye Erdjument Bromage, PhD Structural Biology Program Cell Biology Agnes Viale, PhD

Simon N. Powell, MBBS, PhD MEMBERS ASSOCIATE MEMBER PROFESSIONAL SUPPORT Associate Laboratory Member Enid A. Haupt Chair in Radiation Jonathan D. Goldberg, PhD Stephen B. Long, PhD STAFF Oncology Ricardo Toledo-Crow, PhD Associate Laboratory Stephen and Barbara Friedman Member Mark S. Ptashne, PhD Chair ASSISTANT MEMBER Virginia and Daniel K. Ludwig Chair AT ROCKEFELLER UNIVERSITY Yehuda Goldgur, PhD Howard Hughes Medical Institute Alexandros Pertsinidis, PhD Member (Affiliate) Stewart Shuman, MD, PhD Investigator C. David Allis, PhD Chair and Member Simon H. Rifkind Chair Christopher D. Lima, PhD Nikola P. Pavletich, PhD Paul Tempst, PhD Dimitar B. Nikolov, PhD Stephen and Barbara Dinshaw Patel, PhD Friedman Chair Abby Rockefeller Mauze Chair of Howard Hughes Medical Experimental Therapeutics Institute Investigator MEMBERS EMERITI MEMORIAL SLOAN KETTERING

as of February 1, 2014

Lowell L. Anderson, PhD Walter B. Jones, MD Herbert F. Oettgen, MD Elliot W. Strong, MD Donald Armstrong, MD Susan E. Krown, MD Stuart H.Q. Quan, MD Osias Stutman, MD Ronald A. Castellino, MD Marguerite S. Lederberg, MD Richard A. Rifkind, MD Alan D. Turnbull, MD Eugene Covington, MD Gloria C. Li, PhD Lawrence N. Rothenberg, PhD Robert E. Wittes, MD Bo Dupont, MD, D.Sc. Philip H. Lieberman, MD F. Kingsley Sanders, D.Phil. Norma Wollner, MD Thomas J. Fahey, Jr., MD C. Clifton Ling, PhD Morton K. Schwartz, PhD James M. Woodruff, MD Joseph H. Galicich, Jr., MD Kenneth O. Lloyd, PhD Maurice E. Shils, MD, ScD Samuel D.J. Yeh, MD, ScD Robert B. Golbey, MD Klaus Mayer, MD Francis M. Sirotnak, PhD Ulrich Hammerling, PhD Myron R. Melamed, MD Maus W. Stearns, MD Robert T. Heelan, MD Manuel Ochoa, Jr., MD Stephen S. Sternberg, MD